<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        150-276-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XYZAL 5MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOCETIRIZINE DIHYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="U.C.B." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            U.C.B.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AE09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Xyzal is levocetirizine. Levocetirizine belongs to a group of antiallergic medicines called antihistamines.</p><p>&nbsp;</p><p>Xyzal is used to treat symptoms such as sneezing, a runny nose and watery eyes associated with allergic rhinitis (including persistent allergic rhinitis).</p><p>&nbsp;</p><p>Xyzal is also used to relieve the rashes and itching of chronic urticaria (<em>hives</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Xyzal</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6d750518-c0a7-44ec-9ec0-94ebeeac0718 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (<em>hypersensitive</em>) to levocetirizine, cetirizine, hydroxyzine, any piperazine derivatives (closely related active substances of other medicines) or any other ingredients of Xyzal (listed in Section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>severe kidney disease</strong> (severe impairment of kidney function with creatinine clearance below 10 ml/min)<strong> </strong></p><p>➔ If you think any of these apply to you, <strong>don&rsquo;t</strong> <strong>take </strong>Xyzal until you have checked with your doctor.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Take special care with Xyzal</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Tahoma;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8f4b5e3c-7d61-49c8-99a2-f89fa02aec0a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Tahoma;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Before you take Xyzal </strong>your doctor needs to know:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>difficulty passing urine</strong> or you have conditions that make you more likely to be unable to empty your bladder, such as <strong>spinal cord injury</strong> or <strong>enlarged prostate</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>kidney problems</strong> (your doctor may lower your dose of Xyzal)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>epilepsy </strong>or you are at risk of convulsions (fits)</p><p>➔ <strong>Check with your doctor </strong>if you think any of these may apply to you<strong>. </strong>&nbsp;</p><p><strong>Children</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_35c7cdb3-2c6c-4386-8a1c-9641c5de6aa9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Xyzal film-coated tablets are not recommended for children under 6 years</strong>, as this formulation does not allow for appropriate dose adaptation.<strong><em>&nbsp; </em></strong></p><p><strong>While you are taking Xyzal</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5eb4d8dd-e928-428b-9c78-1474a72ba9d4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid alcohol while you are taking Xyzal (see &lsquo;Food and drink with Xyzal&rsquo; in Section 2).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Xyzal may affect your allergy test result. If you are scheduled for allergy testing ask your doctor if you should stop taking Xyzal for several days before testing.</p><p><strong>Conditions you need to look out for</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f7658d55-7358-4ead-9659-79c2d317f60d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Xyzal can make some existing conditions worse, or cause <strong>severe allergic reactions</strong> <strong>or urinary retention</strong>. Some people may have suicidal thoughts when taking Xyzal. You must look out for certain symptoms while you are taking Xyzal, to reduce the risk of any problems. See &lsquo;Conditions you need to look out for&rsquo;<em> </em>in Section 4.</p><p>&nbsp;</p><p><strong>Other medicines and Xyzal</strong><!--[if supportFields]><span style='font-size:12.0pt;
line-height:107%;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f8902c5a-fef7-41b6-88be-5385f38a737b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes medicines bought without a prescription.&nbsp;</p><p>Some medicines may affect how Xyzal works, or make it more likely that you&rsquo;ll have side effects. Xyzal can also affect how some other medicines work. These include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>theophylline</strong> (used to treat respiratory diseases such as <strong>asthma</strong>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ritonavir</strong> (used to treat <strong>HIV/AIDS</strong>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines acting on the brain, for example<strong> other antihistamines </strong>such as hydroxizine, clemastine, <strong>medicines used to treat anxiety</strong> such as diazepam or <strong>sleeping pills</strong> such as zolpidem (concurrent administration of Xyzal with other agents acting on the brain may cause additional reductions in alertness and impairment of performance, <em>see &lsquo;Food and drink with Xyzal&rsquo; later in Section 2</em>).</p><p>➔ &nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist </strong>if you are taking any of these.</p><p><strong>Food and drink with Xyzal</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6d92532e-7f00-4db0-8c22-4f866dddb1da \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Caution is advised if you take Xyzal at the same time as alcohol. In sensitive patients, the concurrent administration of Xyzal and alcohol may cause additional reductions in alertness and impairment of performance.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3180f72b-85f4-44b4-98c4-407caca31958 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>There is only limited information about the safety of Xyzal in pregnant women. <strong>Xyzal should therefore be avoided in pregnant women</strong>. It can only be administered if necessary and after medical advice.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor if you are pregnant</strong> or planning to become pregnant.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you do become pregnant during treatment</strong> with Xyzal, tell your doctor.&nbsp;</p><p>The ingredients in Xyzal can pass into breast milk. <strong>If you are breast-feeding, you must check with your doctor</strong> before you take Xyzal.&nbsp;</p><p><strong>Effects on ability to drive and use machines</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0d8853f4-7c2b-43f5-a47b-b344e1806185 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Xyzal at the recommended dose is unlikely to affect your ability to drive or use machines. However, some patients being treated with <strong>Xyzal</strong> <strong>may feel drowsy, tired or weak</strong> (see &lsquo;Possible side effects&rsquo; in Section 4).</p><p>➔ <strong>Don&rsquo;t drive or use machines</strong> unless you are sure you&rsquo;re not affected.</p><p><strong>Xyzal contains lactose</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_98b68c2a-bd21-4aa6-8766-cc18515a11de \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>These tablets contain lactose, if you have been told by your doctor that you have an intolerance to some sugars you should contact your doctor before taking them.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>➔ <strong>Contact your doctor</strong> if your symptoms worsen or do not improve after 3 days.</p><p><strong><u>Adults and adolescents 12 years and above</u></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ec26748d-b87d-4e14-8ec4-cf961ef2630a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Xyzal 5 mg film-coated tablet</p><p>The usual dose of Xyzal is one 5 mg tablet taken once a day.</p><p>&nbsp;</p><p><strong><u>Children</u></strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_174bbc0b-d2c0-48d7-a2ef-a1e42023e117 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Your doctor will prescribe the most appropriate pharmaceutical form of Xyzal according to the age of your child.</p><p>&nbsp;</p><p>&minus; <strong><u>Children</u></strong><u> <strong>aged 2 to 6 years</strong></u><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2bec9d7e-c03a-478e-a441-395e0eba7610 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong><em>Xyzal 5 mg film-coated tablet </em></strong></p><p>Xyzal film-coated tablets are not recommended for children under 6 years, as this formulation does not allow for appropriate dose adaptation.</p><p>&nbsp;</p><p>&minus; <strong><u>Children aged 6 to 12 years</u></strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6d7dc90e-eabc-40ef-8b72-0594b3d135fc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong><em>Xyzal 5 mg film-coated tablet </em></strong></p><p>The usual dose of Xyzal is one 5 mg tablet, <strong><em>taken </em></strong>once a day.</p><p><strong>&nbsp;</strong></p><p><strong>Patients with kidney and liver disease </strong></p><p>Your doctor will decide on the correct dose of Xyzal depending on the illness and the results of blood tests carried out before treatment. Patients who have severe impairment of kidney function must not take Xyzal (see &lsquo;Don&rsquo;t take Xyzal&rsquo;, in section 2).</p><p><strong>How to take</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Tahoma;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7be932fa-d750-4e01-8359-d0b9717f02c2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Tahoma;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Xyzal film-coated tablet</strong><strong> </strong></p><p>Swallow the tablet whole, with some water.</p><p>Take Xyzal as one daily dose, with or without food.&nbsp;</p><p>It is best to take Xyzal at bedtime as it can make you feel drowsy.<strong> </strong></p><p><strong>If you forget to take Xyzal</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_729711cb-1138-4c0a-a43f-d6bfcdea0109 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Don&#39;t take an extra dose to make up for a missed dose</strong>. Just take your next dose at the usual time.<strong>&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p><strong>If you take too much Xyzal </strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_2382bdc7-ad18-4b07-a390-5b528864cde3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take<em> </em>more Xyzal than you should <strong>contact your doctor or pharmacist for advice.</strong> If possible, show them the Xyzal pack.&nbsp;</p><p>Symptoms of overdose may include <strong>drowsiness</strong> in adults. Children may initially show <strong>agitation</strong> and <strong>restlessness</strong>, followed by <strong>drowsiness</strong>.</p><p><strong>If you stop taking Xyzal</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d14fd502-1249-489e-888c-4ced6b75ef23 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Take Xyzal for as long as your doctor recommends.&nbsp;</p><p>Rarely pruritus (intense itching) may occur if you stop taking Xyzal, even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. If the symptoms are intense please consult your doctor as treatment may need to be restarted. The symptoms should resolve when the treatment is restarted.</p><p>➔ Ask your doctor or pharmacist if you have any questions on the use of this product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Xyzal can cause side effects, but not everybody gets them.</p><p><strong>Conditions you need to look out for</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fa4f9b96-2316-4816-bc2e-cdc263b43abf \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Severe allergic reactions. </strong>These have occurred in a small number of people, but their exact frequency is unknown. Signs include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised and itchy rash (<em>hives</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (<em>angioedema</em>), causing difficulty in swallowing or breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse or loss of consciousness</p><p><strong>Suicidal thoughts.</strong> Some people had suicidal thoughts when taking Xyzal.</p><p><strong>Urinary retention. </strong>Signs include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when passing urine or inability to pass urine</p><p>➔ <strong>Contact a doctor immediately</strong> if you get any of these symptoms<strong>. Stop taking Xyzal. </strong></p><p><strong>Common side effects</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_664d2013-7f3a-4679-89fd-f800a17dd374 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 10 </strong>people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, feeling drowsy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of energy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disorders, diarrhoea, constipation (in children)</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b5606e3b-f174-4556-9de0-066f3bbca50f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 100</strong> people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting, headache (in children)</p><p><strong>Other side effects</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e06a26b0-5d2e-4cfd-a9d4-5fd6a8f4a3be \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Other side effects have occurred in a very small number of people but their exact frequency is unknown:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (<em>hypersensitivity</em>) including severe allergic reactions (see &lsquo;Severe allergic reactions&rsquo; earlier in Section 4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased weight, increased appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggression, agitation, seeing or hearing things that are not really there, depression, difficulty in sleeping, <strong><em>nightmares, </em></strong>suicidal thoughts</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures), tingling or numbness of the hands or feet, dizziness, fainting, tremor, taste disturbance</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbances, blurred vision, oculogyration (eyes having uncontrolled circular movements)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast or irregular heart beats, heart beating faster</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>), vomiting, diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; small patches of swelling and redness of the skin, which may blister</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy, bumpy rash (<em>hives) </em>(see &lsquo;Severe allergic reactions&rsquo; earlier in Section 4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle and joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when passing urine, inability to pass urine (see &lsquo;Urinary retention&rsquo; earlier in Section 4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling caused by fluid</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intense itching (pruritus) upon discontinuation.</p><p>Other side effects that may show up in blood tests:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function test (increased amounts of liver enzymes in the blood)</p><p>➔ &nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet. <strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong><!--[if supportFields]><span style='font-size:12.0pt;
line-height:107%;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0ea1b107-42cc-484f-ba2d-cbdf6fdde5e4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p><strong><em>Kingdom of Saudi Arabia </em></strong></p><p><strong>-National Pharmacovigilance centre (NPC) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa</u></p><p><strong>&nbsp;-GSK - Head Office, Jeddah </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/ &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-indent:-.25in"><!--[if !supportLists]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep this medicine out of the sight and reach of children. </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Xyzal after the expiry date which is stated on the label and carton after Exp.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Xyzal at below 30&deg;C in dry place.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Xyzal 5 mg film coated tablet contains</strong></p><p>-&nbsp; The active substance is 5 mg levocetirizine dihydrochloride</p><p>Each film-coated tablet contains 5 mg levocetirizine dihydrochloride.</p><p>-&nbsp; The other ingredients are microcrystalline cellulose, lactose monohydrate, colloidal anhydrous silica, magnesium stearate, Opadry Y-1-7000.</p><p>&nbsp;</p><p><strong>What Xyzal looks like and contents of the pack</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_90281c05-d4ae-4ab2-93b0-58fe6f165964 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif;mso-fareast-font-family:Arial;
color:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>The film-coated tablets are white to off-white, oval, with a Y logo on one side.</p><p>Xyzal film-coated tablets are packed in aluminium blisters placed into cardboard boxes containing 20 film-coated tablets.</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p><p>Xyzal is a registered trademark of the GlaxoSmithKline group of companies</p><p>&nbsp;&copy; 2022 GlaxoSmithKline, all rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Xyzal looks like and contents of the pack
The film-coated tablets are white to off-white, oval, with a Y logo on one side.
Xyzal film-coated tablets are packed in aluminium blisters placed into cardboard boxes containing 20 film-coated tablets.
Not all presentations are available in every country.

Xyzal  is a registered trademark of the GlaxoSmithKline group of companies 
© 2016 GlaxoSmithKline, all rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Version No.: NCDS08 </strong></p><p><strong>Date of issue: 4 September 2022</strong></p><p><strong>Manufactured by: </strong></p><p>UCB Farchim SA, Ch. De Croix Blanche 10, 1630 Bulle, Switzerland&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Packed by: </strong></p><p>Aesica Pharmaceuticals S.r.I, Via Praglia, 15 10044 PIANEZZA, Torino, Italy, Pianezza.</p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorization Holder: </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia&nbsp;</p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact: </strong></p><p><strong>GSK - Head Office, Jeddah </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O Box 55850, Jeddah 21544, Saudi Arabia.</p><p><img alt="" width="722" height="646" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAkACQAAD/4REARXhpZgAATU0AKgAAAAgABAE7AAIAAAASAAAISodpAAQAAAABAAAIXJydAAEAAAAkAAAQ1OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEh1c2FhaW4gQWxtYWtyYW1pAAAFkAMAAgAAABQAABCqkAQAAgAAABQAABC+kpEAAgAAAAM3NQAAkpIAAgAAAAM3NQAA6hwABwAACAwAAAieAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowMjowNCAxMTo0MDowMgAyMDIxOjAyOjA0IDExOjQwOjAyAAAASAB1AHMAYQBhAGkAbgAgAEEAbABtAGEAawByAGEAbQBpAAAA/+ELJGh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDItMDRUMTE6NDA6MDIuNzUyPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPkh1c2FhaW4gQWxtYWtyYW1pPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAoYC0gMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiigAooooAKKKKACiiorm6gs7dp7ueOCFBlpJXCqv1J4oAlorgtY+N3w70SRo7nxNbTyL/DZq9xk/wC8gK/rXLz/ALUXgOEkR2+sz46GO1QZ/wC+nFAHstFeJf8ADVfgj/oFeIP/AAHg/wDj1H/DVfgj/oFeIP8AwHg/+PUAe20V4l/w1X4I/wCgV4g/8B4P/j1H/DVfgj/oFeIP/AeD/wCPUAe20V4l/wANV+CP+gV4g/8AAeD/AOPUf8NV+CP+gV4g/wDAeD/49QB7bRXiX/DVfgj/AKBXiD/wHg/+PUf8NV+CP+gV4g/8B4P/AI9QB7bRXiX/AA1X4I/6BXiD/wAB4P8A49R/w1X4I/6BXiD/AMB4P/j1AHttFeJf8NV+CP8AoFeIP/AeD/49R/w1X4I/6BXiD/wHg/8Aj1AHttFeJf8ADVfgj/oFeIP/AAHg/wDj1H/DVfgj/oFeIP8AwHg/+PUAe20V4l/w1X4I/wCgV4g/8B4P/j1H/DVfgj/oFeIP/AeD/wCPUAe20V4l/wANV+CP+gV4g/8AAeD/AOPUf8NV+CP+gV4g/wDAeD/49QB7bRXiX/DVfgj/AKBXiD/wHg/+PUf8NV+CP+gV4g/8B4P/AI9QB7bRXiX/AA1X4I/6BXiD/wAB4P8A49R/w1X4I/6BXiD/AMB4P/j1AHttFeJf8NV+CP8AoFeIP/AeD/49R/w1X4I/6BXiD/wHg/8Aj1AHttFeJf8ADVfgj/oFeIP/AAHg/wDj1H/DVfgj/oFeIP8AwHg/+PUAe20V4l/w1X4I/wCgV4g/8B4P/j1H/DVfgj/oFeIP/AeD/wCPUAe20V4l/wANV+CP+gV4g/8AAeD/AOPUf8NV+CP+gV4g/wDAeD/49QB7bRXiX/DVfgj/AKBXiD/wHg/+PUf8NV+CP+gV4g/8B4P/AI9QB7bRXiX/AA1X4I/6BXiD/wAB4P8A49R/w1X4I/6BXiD/AMB4P/j1AHttFeJf8NV+CP8AoFeIP/AeD/49R/w1X4I/6BXiD/wHg/8Aj1AHttFeJf8ADVfgj/oFeIP/AAHg/wDj1H/DVfgj/oFeIP8AwHg/+PUAe20V4l/w1X4I/wCgV4g/8B4P/j1H/DVfgj/oFeIP/AeD/wCPUAe20V4l/wANV+CP+gV4g/8AAeD/AOPUf8NV+CP+gV4g/wDAeD/49QB7bRXiX/DVfgj/AKBXiD/wHg/+PUf8NV+CP+gV4g/8B4P/AI9QB7bRXiX/AA1X4I/6BXiD/wAB4P8A49R/w1X4I/6BXiD/AMB4P/j1AHttFeJf8NV+CP8AoFeIP/AeD/49R/w1X4I/6BXiD/wHg/8Aj1AHttFeJf8ADVfgj/oFeIP/AAHg/wDj1H/DVfgj/oFeIP8AwHg/+PUAe20V4l/w1X4I/wCgV4g/8B4P/j1H/DVfgj/oFeIP/AeD/wCPUAe20V4l/wANV+CP+gV4g/8AAeD/AOPUf8NV+CP+gV4g/wDAeD/49QB7bRXiX/DVfgj/AKBXiD/wHg/+PUf8NV+CP+gV4g/8B4P/AI9QB7bRXiX/AA1X4I/6BXiD/wAB4P8A49R/w1X4I/6BXiD/AMB4P/j1AHttFeJf8NV+CP8AoFeIP/AeD/49R/w1X4I/6BXiD/wHg/8Aj1AHttFeJf8ADVfgj/oFeIP/AAHg/wDj1H/DVfgj/oFeIP8AwHg/+PUAe20V4l/w1X4I/wCgV4g/8B4P/j1H/DVfgj/oFeIP/AeD/wCPUAe20V4l/wANV+CP+gV4g/8AAeD/AOPUf8NV+CP+gV4g/wDAeD/49QB7bRXiX/DVfgj/AKBXiD/wHg/+PUf8NV+CP+gV4g/8B4P/AI9QB7bRXiX/AA1X4I/6BXiD/wAB4P8A49R/w1X4I/6BXiD/AMB4P/j1AHttFeNQftReA5iBJb6zBnvJaocf98yGun0f43/DvWpFjtvE1tBI38N4r2+P+BOAv60Ad9RUVtdQXlus9nPHPC4yskThlb6EcVLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVV1PVLHRtOmv9Wu4bO0hXdJNO4VVH1NZPjXxto/gLw7Lq+vT7I1+WKFOZJ37Ig7n9AOTXzvYaT42/aP17+0dXnfSPCltKfLRclF/wBmMceZJjgueBz/ALtAHR+Kv2jNQ1jVDofwn0abULl8qt5JAzs3vHEOcf7TfitZ1n8CPiD49njv/iZ4nktkJ3C2Mn2iRPYKCI0/An6V7t4Q8DeH/A2liy8OafHbAgebMfmlmPq7nk/ToOwFdBQB5Pov7Nvw90uNftlnd6tIOd93dMOf92PaPzzXV2/wq8BWqgR+ENHYL082zST/ANCBzXW0UAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TXSUUAc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNdJRQBzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E10lFAHJXHwq8BXSkSeENHUN18qzSP/ANBAxXK6z+zd8PdURvsdld6VIf47O6Y8/wC7JuH5Yr1eigD5pvPgP4/8B3EmofDPxRJcKPmNsJDbyP7FSTG//AsfStHwt+0ZqWi6oND+LGjTWFyhCtexwMjL7vF3H+0n4LX0LXP+LvA/h/xzpZsfEmnx3KgHyph8ssJPdHHI+nQ9waANXS9VsNa02HUNIu4by0nXdHNC4ZWH1H8u1W6+V9R0fxt+zjr39p6LcPq3hW4lAkRs7Gz/AAyL/A/YOOD/AOO19DeCfG+j+PvDser6FMWQnbNC/EkD45Rh6+/Q9RQB0VFFFABRRRQAUUUUAFFFFABVHW9ZsfD2iXeravOtvZ2cZklkPYDsPUk4AHckCr1fOPx78Q6h418d6X8L/DTbi0yPeEHgykZUNj+FE+c/X/ZoAxtA0nWP2jPiRPrevGW18LabJsSANgBc5EKn++wwXbsMf7Ir6gsbG10ywgstPt47a1t0EcUMS7VRR0AFZvhLwvYeDfC1loekoFgtYwpfGGlf+J29ycmtmgAorB1jVPEFvrNvY6DoNtfRPA0st3d37W0URDABPlikLMck9OAOe1cL4L+L3iDx14bvNb0XwZbNb2VwIJYDq7GduFJKKLfDYDZxuBOCB2oA9YooooAKKKKACiiigAoopHdY42eRgiKCWZjgAepoAWiszw/4h07xRpC6nos/2izeWSJJgOHKOUJHqMqcHuK06ACiiigAooooAKKxvF2t3vh3wteappejXGuXVuFMdhbEiSXLAHGATwCTwCeOlX4ri5n0dLmO08u7kgEi21xJs2uVzsZgDjngkA49DQBaorivhr8QpPiBa6tJNpS6bJpl81m6JdeeHIHLA7FwPwrtaACiiuW+Ifjq1+HvhRtZu7Z7tmmW3ggRwnmSNnALc7RwSTg9OhoA6mivK7v4xapZXtro914LuYdfur65tYLSW6ZIZkgUMZUlMW51fICYjwcHkYr0Dw3q1zrnhqx1O+0y40m5uYg8tjcjEkDd1OQD+YBxjgdKANSiisu98SaZp/iHTdDuLlf7R1Pebe3XliqIzM5HZflxnuT9cAGpRWBL4qhk8ZL4b0u3a9vIY1n1Bw+2Oyib7m44OXb+FB1AJJAxnXv5bmDT5pbC1F3cIhaOAyiPzCP4dxBAJ7Z4z1x1oAsUVk+GvElh4q0VNS0wyBC7RSwzLtlt5VOHjkXJwykYI6dCCQQTrUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQXtlbalYzWd/bx3NtOhSWGVQyup6gg9a+X/EWj6x+zp8RoNe8PmW58L6lJskgZsgr1MLH+8Bko316/Nn6nrH8V+GbDxh4XvdD1aMNb3cZXdjJjb+F19wcEfSgCzoet2HiPQ7TV9InE9neRiSKQdx6H0IOQR2IIq/Xzh8B/EGoeB/iBqnww8SsB++drQk8CUDJC5/hdMMPp6tX0fQAUUUUAFFFFABRRRQBn69rFv4f8PX+r3pxBY27zvz1CqTge5xivAv2a9En8QeJPEHxA1kebcyzNDDI3P7xzvlYfQFQPZiK7P8AaU1ptK+D89tG219Tu4rXjrt5kP6R4/Gt74KaIug/B3w/BjD3FsLyQ9yZTvGforAfhQB3lFFFABXhP7KP/JP9Y/7Ch/8ARSV7df6fZarYyWWqWcF7aS4EkFzEskb4ORlWBB5AP4VQ0rwl4b0K7N1onh/S9OuGQoZrSyjicqSCV3KAcZA49qAPANZDal/wt/VvE4U6zotxCmlTzNiWwiWRzAYW6x5+U5XG4nPc17v4Jn1DUPh9oc/iBWN/Pp8LXQlXDMxQZLDsT3HqTVy/8NaFqmpQ6jqei6deX1uFEN1cWiSSxhSWXa5BIwSSMdCc1pMqupVwGVhggjIIoA+dPhT4B0XxXeeObHUVnht7LxAHtI7STyltykrEFVA25wuzJBKqWC7dxzR0aDxJ4q8R+KNThl0618RaL4gWYX99dyrcW1uhZVt440iYmNgWXaG+bOCp4r6F0nwr4e0G4efQtC0zTZpF2PJZ2ccLMuc4JUDIyOlOl8NaFPrS6xNounSaohBW+e0QzrgYGJMbuBx1oA8Bi0Lw9efGr4pWeq2VmbaPS3uI4XUBUby1LSqvQMCxO8DILE5GTVOy1HXtW8AfCaw8QyTTaJqWrtDffaGytyiTr5EcufvKQGwpyDtB7CvRdM+F2oSfFvX/ABF4o0rw/qejawVAtppWneDYoCPseHazHGCMjaGOCcc+mXekabf6UdMv9PtbnTyqqbSaBXiIUgqNhGMAgEccYFAHgkUTHRvjPocdvG/hrTY5HsLcoDBaz7JHZYh0XDANgfdIBAGaseDPh7ourfAvTvEd4lxPqNtot8iB5cxurbwqlTxtUrkAYG4ljkkmvax4Y0EaGdFGiad/ZROTYfZI/Izu3Z8vG373PTrzU+laNpehWhtdE020063Zy5htIFiQsQAW2qAM4A59qAPMv2cLPTIfhJYXFrb2keozmU3UsaKJpFE8oTeRyQMMBn0OK5P40T2V74s8S2hnGsXNn4dMhsbuFVh0rLp+/ikO5vNbdGNqqMhhuf5QB7xpWh6ToUMkWiaXZadHK++RLO3SIO3qQoGT71Fd+GtCv9S/tG+0XTrm+8sxfaprRHl2EFSu8jOCGIx6E+tAHzt44zqvwf8AhVe6izT3kl5DE10zHzipHI8wfMPujv1APWuj8F+HdL1P4ufEzwldWcX9hTxw7rJFCxq2Bh1HZgTncOc89a9bk8CeEZrWG2l8K6I9vbljDE2nQlIy2C20bcDOBnHXFU9T8FWdlpV/ceBNK0XRPEMkDra6gunxKUc/3iEJwe/B+h6UAeWfCjw8ks+ofDjxHodtcJ4U1Y3rXclsm2dHBMOe+5vv57ooU8cV6Z8VdKk1z4eXul2+rw6RPeSRRQz3H+qdzIu2J+D8rnCng9eh6HZ8O6be2ltJd639mOrXmw3bWxJTKoFAViqkjgnkDljWldWltfW7QXtvFcwtw0cyB1P1B4oA+ZfFd4mo/AvxdZ6p4fj0jV9I1a2W4to3ElvBIdiD7PyfLXaCNgJADcHDYHTzqNZ+MvgDQvEUKXGh/wDCOrPbWlwoaGa48pwWKnhmAAxnkYBGM16+3gzwu+lJpb+G9IbT45TMlobGIxLJjG8JtwGwcZxmn3PhLw5eabb6deaBpc9ja829rLZRtFD/ALqEYX8KAPmbw7rl1pPwT+I7+GL5hdLq6nzYJ98qW7uqmQNktggEb/qc5Ga9W+EuiX+la2t9Z/2RZeHdV0aCWHTtOupJ/wB6gRfPbMSKrMpIbuxX+LBI9Pt9K060sZLK0sLWC1lLmSCKFVRy/LEqBg5yc+uai0nw/o2gRyR6FpNjpiSkNItnbJCHI6EhQM0AeS/F69vJvi54H0O7tbW80W881vsWoTmG1u7jBVVdgj5Kkx4G08sBxnNcd8T/AA/e6N8A9FtfE89jqOpaZrYs476LdJsgxIfKEjqrEDAUgcfIB1Xj6N1XRdK161W11zTLPUrdHEixXlusyKwBAYBgRnBIz7mql54P8M6jbWtvqHh3SbqCzTy7aKexjdYF4+VAVwo4HA9KAPI/iH4d0OD49fDu1j0fT47aZZY5IVtUCOqKAilcYIXgAdu1c/qFt4g8Y/En4hWqS6fa61pc1vJpt/qN48T6ZbRSFt8CrG/DLt3HK/fB5ya92l8BeD53R5/CmhyNGiojPp0JKqowoGV4AHQdquXvhnQdS1SHUtR0TTru/g2+TdT2kbyx7TldrkZGCcjB4NAHi0unw+O/jxr/AIZ8fliraLGNJUfL5OVieSSDePlk3Andt3YUg8Aiq+u6RoEv7TXhEXYs9U0u58PedJdXpSdbvZHPtmdj8rnaiHd6AEdK9x1fw1oWvtE2vaLp2ptCCIje2iTFAeuNwOM4HT0qS/0LSNVurW61TS7K9uLNt9tLcW6SPA2QcoWBKnIByPQUAeYfCKSWXxH8Tri+kaK6Ouyo8uPmRF3hMewHSsb4Ui48M+PrDw/q1vb332yxuLrTdf02Y+XqUTsrmSdO8nAXzDhuAvzAhq9OXwi+neOrnxBorwrDq0aRavZTLhZtgISZCAcOASpUjDA9QRk6B8P2Wlre3vhnR9JtNWuUI8/7OsXmN28xkXcwB5x3x1HWgDyHQP7Ol1j4zWHiC8msvDRuQ1xcRMVMbOriUqQDluBxg54GDnB9X8Bw6Nb+AtHh8L3st9pEdsq2txMxZ5EHc5AIPUYwMYxgYxUfhjwTYeH/AA7dabd7NUl1KWW41Se4iGL2WQ/OWQ5AXsF5AAA5OSd+0tLews4rWxt4ra2hUJFDCgRI1HQBRwB7CgCWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5z/AGltCn0PXvD/AMQNGHlXUMywTSKOkiHfEx/JgT6BRXvfh/WbfxF4c0/WLL/UX1uk6DP3Qyg4PuOn4Vy/xn0Ndf8Ag/4gttuZILU3cZ7gxHzOPqFI/Guc/Zp1ptU+EMVrI2W0y8ltRnrtOJB/6MI/CgD1yiiigAooooAKKKKAPnn9rS4ZdF8NWwb5JLieQr6lVQA/+Pn86960e2Wy0OwtY12pBbRxqPQKoH9K+ev2uSceERnj/TeP+/FfSIAAAAwB0AoAKKKKAOZ+IPi1/A3gy61+OyhvhasgaCS5MJcMwUBSEfLZI4wO/PFZum+OdWuY2vdT0fS9O0i3i3Xmoy6wwjikyR5SF4FWQg7QzbggYldxKkVn/E3R9a8Va14d0aHw7dX3h6DUEu9VmFxbqkqqPljCNIGZcklgQOAMbj05jSvD/jvT/glrvg6Dw5dQzec9vpryXlszNZzSHdnEpAdULcFgORgnmgD0fQvHel3+j2c+tXulaTqE9q149j/asM5jhG4mQOpwybVLbhwBn0NaV74r8O6bY2t7qOvaZaWt4u62nnvI0jnGAcoxOGGCDx615J4s+HviTWV1aey0Eoum6Bb6ToNgbuEo5YgyyZJABjAXBbHzICvIU1jeKIoLW4EUFjqFnpOn6RF4Wv7+ztV1AWqttaRCPMQxOEZQ0gEoPmbeq8gHuN54s0K00SLVDrWli1ucraTy3qLDcPzhVcZzyD90E8Hg1l+HfiBYah4E0zxL4mex8Nx6kCYo7y+UKRk7cO4TJZRuxjoa8/8AGfgnxWL7V7bw9oT6laroEGiaNM13CFtYWG25JV3U+aVwA2BkD73GC/VfAPim+1TVtPttKjt7S/0i00fTr5riN4dKtAn+koVyHZyRhdq4OVyQAaAPVrrxPoFjeXFne65ptvc2sXnTwS3caPFHx87KTlV5HJ45FWbbVdOvbuW1s7+1uLiFEkkhimVnRXGUYqDkAjkHvXi/jH4Wa74l1TU1Fg5tCun6JprtcRbobFGDz3LDdycggLjPfbkAjq/hz4MvPDnjbxTfXWlfZLa5kigsZmnRvMgjXCkKuSCzbmbdt5K4BycAHdalrmk6M9uur6pZWDXL7IBdXCRGVuOF3EbjyOB61zfiX4h2+k+JrPwvocFvq/iK6V3Fi16tuIlVN/zuQxDMPurtJPU4HNcP4w8Ja1qOr+LjrnkafpusS2sDeILq7hSGz02PazRIC24SNISCCoUk53dM9R4Ht21f4keLvFDc2kckei6ccf8ALOAfviD3BlJGfVT1oA0vEfji40XVvDei22lRS6zr5k2QXV75EMAjj3OGlVHJOSFAVTnnkd9Kw8V2kmhnVNdVNAh+1SWoXUZ0Ql0cxnnO3llbbgnIwe9ch8SdC1vxPpWrafL4Zk1IrIJfD97ZXcMUtlMsa/PIXdCo8zJGwuSM5C4XOP4r8M+PpJbNk05fEV1aeGDZQXH2qKOOPUJPkmnIcqSfLyFOOckHGTgA9RTxRoEj2KR65prNqIzZAXcZN1zj93z8/Ppmlk8S6FDpDarLrWnR6crmM3jXSCEMG2ld+cZzxjPXivKta8K+M4Lrw2PD2gZi8P8AhyaLT2a7hxFeuvljzAWGWEaA5G5d743Yy1VI/B3jPSNO8NJY+HDef2NoE62tub2HbDqkhwZpQzgN8pYjbuwzY3YJagDrtI+KkmrW9kY9M09bi81ttOhg/tmNWltkco93GJFRpAGBARQWNehySJDE0krqkaKWZ2OAoHUk9hXkfhfwbr+neIPAtvdaAYNK8PaTJl/tcRCXkp2uzqDknYCRtDDdIRuwC1df4gttZ8SXlzpZtdT0rSrVBOt3avaNJqEqtkRKshcKnGTvUbiQCVUEOAWfCvjrTPFemaxqdqfs2naZfS2hubhggdY0VnkOcbFyx69hk4zgaLeKNAXS5tSbXNNFhBII5bo3cflRuQCFZ84BIZTgn+IeteR6X4G8UzfCbXPDOpeH5Be6zrxmea7ltXEcEsil7g7HxuVVPCgHcRtBA42PGHg7WNP1ywfwX4Ygu7Gx066ktoYpYYEGpSBUWeZWZd52A4bBOT1XO4AHT+L/AIiWfhzRtJ1PTfsGq22pagtkJhfiONB82+TzArLtTY27JAGDznirureM7S1utCt9Ik0/U5NYuY1RRqkMTC3YHdPGGOZgMD5U5OevFedHwl4qs7bwjZ2nhczxaHoskcHmXUBiiv5CIxJMC+cKgLnYHwXIUt1qUeA/FGi6hoNjpFkLy28O+HriKwvnnjjjOoSqQWKklgAAAPl/i5IxQB6nH4j0SbVzpMOsafJqKsymzW6QzAqMsNmd2QCCeOBWlXkXw48J+IdL8XaZcat4bbT7PT9EFos813DI8lw7b7iRtjMS7SAY7bSxLBvkPrtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdUtlvdHvLWQbkngeNh6hlI/rXgP7JVwzaV4ntifljnt5APQssgP/AKAK+iK+bf2Rv+Zu/wC3L/2vQB9JUUUUAFFFFABRRRQB82/tc/8AMo/9vv8A7Qr6Sr5t/a5/5lH/ALff/aFfSVABRRRQAUVmalr9npN1Db3UOoyPMMqbXTLi5Qc4+Z40ZV/Ej1rxfXdAm+HOo3/jbw3pqXfh26uJ7PxHoUUS+U9uJHUSrH935VJBGMDJzwzkAHvdZU/hXw9dayur3OhaZNqasrreyWcbTBlxtIcjdkYGDnjFeW6z4yn8CfD/AEN/AkGhw28uinUzZvayNNN8iNv2I0aomCSzsxJJACkjBsWHinxFr3xmsRZ31pa2Mng8anDbSWzyqvmvHuBxIuW3KuG6BQRtBJagD1+ivBfAHxB1FfBHhTRfDWnaXpc99b6jeuZIpp4IkhlkOxVM28s7ZJJfC9gc4Gi/xh8R6jHodzolppcFvqmhXWpOl5DI7wyW+7cAVcB1JXA4U4Oc9qAPaaK8b174t6/b+A9E13SV0Vbq70d9QuLKWKWaV2TbkqodBHEPmyzOSeAoYjldIvo9W/aP0XV4oEgOpeCY7t1X1eYnk4GSBgZPYCgD1y9sbTUrKWz1G1hu7WYbZIJ4w6OPQqeDTrS0t7CzitbG3itraFQkUMKBEjUdAFHAHsK8T8e6Ppsv7QumhvCUOvtd6FNJNZpHADPIGKq7NKyjIAA3ZLAYx0rnrbw94j8GeJPhhBfvaNr0FnqpU3BMy28QgLJCzAguI1ZsKGxkkA45oA+kqK8YvvjBr7/DTQ/EWmJosd9e6fc3U9lLHLK8jQZ3GNAyBIxsYlnfgYVQ7YDaTfETxTqmueFLHw/baQv/AAkehHUALxJT9nmCBsFlb5lyQMbQeOvPAB6rRXiPiX4teM/DmoeMInttCnj8LpYSS4hmBm+0bAyD95xgyHDn+7907vl1h8T9chPji01FtBs7rw6LR7e5nE62+2ddxVwu53ZfujaAXJHyrmgD1iivGrf4x60PDt4L6xs4tYj8TJ4fhd4WSJS/IlkjEjEYAbKiQ845rb1fxj4v0rVtK8NzjRF1q6t7y8mvEgmktjDCCYwsRdWDtxnLkLg43Z4APSqK8isvixrN5N4S1KSKxs9D8R2dwRutZJJoLqJG/d7vMVSrMMr8oJAxxncM/V/FWu+HPibrNxd6Ppuq65Y+DhcLJZQzxs3+kJmPaZXUorM75ChiBjIoA9tor59174h6/wCIPh543mvk0DWNF0uGzjWW3s7hIL15vLaSMSLcZBj3AEKc5xnGcG3a6ufDvxK8e6zYtpdjLFoNjcB74ulurFF5bYC7deAMsxwOpzQB7vRXiF78YvFFn8P/ABXqptNNGpeHdShttstpIqTxSFVGYxMSjZbP3zwMEA1fvfi7rWkW3iu21G1019R0nUrWxtXjEiw5uBkGTLEkJhskFd2Oi5oA9gorzLxN468UeFJ9E0XVE0yTVtYu7oQ3dlYXNzELeFAyk2yN5nmNuUFVZgvJyRWvq3j250b4OyeMtR0ea1vI7NJZNOuFZGjmYhNjZAIG4+mcUAdtRXmOu+OvFPhXQNOk1kaPc3Ws6lb2thdWFpcSJHHIgZ2e3DF3YYYKqP8ANlenQ5tz8TfGA1TwtYx6dZWM2sQX4nTUbCeJke2VmEqqXDBHUKwRhkdN3OQAewUV4fpnjvxL4x8UfDG5iurKwh1W3vLi4t1t3dGliV0Yn5wcEbgoz8pOSX4A2NP+I3iyWPxXqN1a6NJpfhXUbqC68tZY5riGKNmGwFmVX3BckkghjwNvzAHrFFcF8NfG2s+LY3bWNPZIpLK3vLe8i064toW8wEtCDLnzCnynep2sGyAMc4MkVr47t/iNeeIbVbuPS5LnSbK2nG5LdIogxkQdA7Od2/72FQA8CgD1uivA7LR28JeJLP4b+M9Oj17Qrq9jn8NX13AsvlASKZbd85HCZ/XswC4lz4PGseLviZo3hvwjDdX32yzWwvIjBbppbY3GQMWDr03YjU7tuD1oA+l6K8T8NWMviv4w6voXxCKauvhvTbVLOzuk3QTO0YEtyY2GHYknBI4D+wxtePtP0/4d+E7vxZ4eeaK50u+t5TF9oZ1ETvDFJbAEnbEU2kR9FIUqBgYAPUqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5t/ZG/5m7/ALcv/a9fSVfNv7I3/M3f9uX/ALXoA+kqKKKACiiigAooooA+bf2uf+ZR/wC33/2hX0lXzb+1z/zKP/b7/wC0K+kqACiiigArL0rw7p2jWtzbWi3MkN07PKl5eTXW4t97/Ws2AcnIHBrUooA5XVPhp4S1hLRL/Sty2dj/AGdCsVzLEFtsY8ohHG5eB1zjGakj+HfhiK6s7mPT5FnsbH+z4JRdzblt+oQnfltp5UnJUgEEEAjpqKAORh+FvhC20W00q202aC1snle28q/uEkh80YkVZBJvCt3TO09SM0+++GfhPULi2ln02WNrWzNjAttezwJHAQQyBY3VQCCc8c966uigDjJPhJ4LmsrW0k0mUw2lq9nCv2+4yIHJZoyfMyy5OQDnHGMYFX9O+H/hvSdcstXsbOdL6xsxY28rX077LcAgR7WcgqM5wQeeetdJRQBz1x4G0K68WxeJp4bs6vCAsc41G4UIo/gCCTZtOOVxg85ByaXXfA+g+JNXtdT1e2uJL2zieG3lhvp4DErgh8CN1ALAkE9SMDPAroKiurlLO0luZVkZIkLsIomlcgDPCKCzH2AJNAHIf8Ki8E/2faWQ0iQW9lFNBAgv7gbY5TmRM+ZkqTng5HJx1q7ZfDvwzp+paTf2llcJc6Nb/ZrBzf3DCGLn5Npcgj5iOQeMDoBh2l+P9B1iS2WwbUmS6fy4ZpNHu4oWbkY8x4gg5BHJ68V0tAHIap8K/CGtXmqXWp6dcTS6uUN//wATG5VbjYQUDKJAMLtGBjAxxTJPhP4NnTU1uNMuJ/7VWJb1ptRuXaby2BjJZpCQVKjBGDjI6EiuyooA5EfC3wf/AGZqWnvpLS22qSpPdrNeTyGSVeku5nJVznl1IZu5NWrzwB4dv7O2t7u0uHNs0jR3H2+4FxmRdr5nD+YwZcAhmIIVR0UY6BLiGTzfLlRvJbbJtYHYcA4PocEH8RWTo3i7Rdfu2ttLu3klEXnIJLeSITxZx5kTOoEqZI+dCy/MvPzDIA+bwpoVxY6XZyaZB9m0ieO4sIlG1beSMEIygemTWB4x+HFhryavqemxtD4h1CwNiLt76eNfKOMphWKqOM/cI3ckNyD0Vl4j0vUdYudN0+4a5uLUss7Qwu8MTrjdG0oXyxIMjKbtwznFLp3iLS9W1G5s9MuGuntSVmlihcwqwIBQTY8suCeVDFh3AxQB5/4f+FN/NBqNj461fVNW0i8iRG0671+a9Durhg/mCKFkxjG0ZDZBP3RXRT/CjwddfbvtemT3H9oW0VpdedqFy/mxxlSgOZOqmNSG68Hnk53td8R6R4as4rnXb+KzimmSCLfktJIxAVVUZLHnsOBkngE0a14j0jw7HbNrV/Fafa50trdXyWlkZgoVVGSeSM8cDk4FAHPy/CTwZPYX9lNplw9vqUkct4jaldH7Q8f3Wc+ZknnJPc4JyQDU3/CrvCDQ6vFNpclymtbft/2m9nmM5U5ViXckMOzDBHY11tY1p4t0W91waRBdP9sZXaISW8kaThCA/lSMoSXbuGdhOO9AFO4+Hvhu60+1tLizuHFpcfaoLg39x9oSXbt3Cff5n3QB97oqjoBjVk0HTJvD76JPaJNp0kRikglJfzFPXcScsxJJLE5J5znmoNP8U6PqmqS6fY3ZkuI94GYXVJdjbZPLkKhZNrfK2wnaeDg1JaeILG+1abTrYXjTQlg8hsZ1gypwwExTy2IPGAxOQfQ0AZP/AArbwqfD66LJp0stlG8TxCW9neSExf6oRys5eMLztVWAG5sD5jlLz4a+F7+6s7m6tLx7iyjkjgnGp3SyKJARISwkyzMDgsSWIwM4AxuatrNpotuk16Llw7bVS1tJbmRjjPCRKzY9TjAqpa+LtEutCudYN4bWwtJGjnmvoZLXymUgEMJVUjkgdOvFAGbZ/DLwjYQ6TFa6UyJo7yNYg3UzeT5hy65Lncp7q2V5PHJq9o/gvQdBbVTp1kwGsSGW/We4knWdjncSsjMBncQcAZ4z0FTnxPpMfh9tbu7h7HT16yX1vJbMOcAbJFVsk4AGPmyMZyKgvfGWj6dpcF/eNfRxTq7pH/ZlyZgiffdoRH5iKMjLMoA3Lz8wyAO8OeENF8KW4g0O3mhiVBGizXc04iQc7U8xm2LnnC4B49KzH8CwnWtZHmMdF14ie9tormW3kS4ChSyPGQSrqAGUkcrnJDEDqbW6gvrOG7s5o57eeNZIpY2DLIjDIYEdQQc5qWgCjJo1hNa2MFzB9oWwdJLZ53aSSN0GFfexLFsEgsSScnOcms3RPA2heHtavNW0qG7jvb7/AI+pJdQuJhMR0LK7kEjoDjIBIGM10FFAGJrPg7Q9e1K31HULSRdQt0McV7aXMttOqHPyebEysV5Pyk45PFZus+CItTs7DRIfLg0FLhbu/V3eWe8dHV0RmYkkFgGd2LMdoHfcOtooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5t/ZG/5m7/ty/8Aa9fSVfNv7I3/ADN3/bl/7XoA+kqKKKACiiigAooooA+bf2uf+ZR/7ff/AGhX0lXzb+1z/wAyj/2+/wDtCvpKgAooooAKKKKACiiigAooooA5j4jWXiPUfh9qtr4Kufs2tSRAW7h9jEbhuVXP3WK7gG4wSOR94Znwf0vxlpHgNLb4hXUlxqX2iRoxNOJ5Y4iRhXkBO453EcnAZRnjA7qigAqK6urextJbq9njt7eFC8s0rhEjUDJYseAAO5qWigDzb4QQreeHrPVLPxTNqNrElxbvpyvC0Nu7TBwcxqG3BR0cscScYzzyWmeMdDuPEs6XXijUbPQ73RrqSZ7jX3e7WdJoiHMaE/ZnCtIRGhGVHzIuCte7UUAeSfD3VbaLVNR0vxb4huG1aPTozCJNXfy5bExgrPgTMqzkDMjA5BG5Dtbc3pYgS98PxQ6Tqc8MUkKfZ763lWd9mAQweUOHyP4mDZznrzWhRQBw+keFr6OfXP7V8T6zJZyXLiSOeK0jS4Q26KXLLArDHIypUfJ9c8vpNt4g1KeNtB1q11rTvD+i3MGnanbWZhFxcsgSOPzPMZZtoQFnQKobA5OQvsFFAHiWniaLRJ7X4aareXjDwzdC9spLh5TZ3gC+SNhOIZyxlGwBclSWGRmt7wc8VtrZi+HeoHVtHTRl82zvL6Qw290JB5a7tr+QxQy7okUBdifIvFen0UAeefE7VHtfhbI/iVtP0y6mvLVRFHe+ZGxFzG2Fd0jLHYpYjbwAewzUvxX1jTIPAtlPPqNpHDcapp8kMjzqFkUXUTllJOCAgLZHYE9K76igDLnu9YfULX+y7LTrrS5VVpbqTUHSRQTyUjWFlcbcEEuuc446nlbLxT4T8UeMLAaZrmmSvpjSw6fBb3CSSzTMhV3WNTny0QMM4wcseFVWbvqKAPJ/CzrLD4B0SCVf7U8P+a2sQq2WtQttJE3mD+HfI6ld2Nwyy5AJra8NT20WvyQ+BddTXdHa1mluIH1D7VFbXOU8vE+XZA/z5T5gMbgo53d9RQBhyaxqGl+HL7VfEmn2ltLaI7pDY3b3PmKACAGaKMhmbgDB7c84rjNf0iHSdJ8IW3im8a10uG4ln1S9imaBEvHVnEjSA5jVpHlw2QQzJghsGvT6KAPGQVnj8NS+L9Zuv+EXjudQaz1SW6eBmw4Fm8lxkMuYvNCyblL5HJ34O3pfjG28PeB9OtvEOu2cerXwlhsrnVZljeW2WRxDPNvIJHl7WOeWJx1Jr0uigDJ8LQ6VbeFNNtvDswn0u3gWC1lDbg6J8oYN/EDjO4cHqODWtRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfNv7I3/M3f9uX/tevpKvm39kb/mbv+3L/ANr0AfSVFFFABRRRQAUUUUAfNv7XP/Mo/wDb7/7Qr6Sr5t/a5/5lH/t9/wDaFfSVABRRRQAUUUUAFFFFABRRRQBT1bVrHQtJudT1e5S1srWMyTTSHhVH6k9gByTgDmqHhbxjoHjXTXv/AAxqUd/bxv5blVZGRvQqwDD8RzUfjjwla+OfBmoeHr6Z4I7xBtmjGTG6sGVsdwGAyO4yMjrWB8KPhVafC7Sr23h1GTUrq+kV552i8pcLnaAmTjG485Oc0Ad9TZJEhiaSV1SNFLM7HAUDqSewp1V9Qs01HTbmymJEdzC8LleoDAg/zoA5G18b63qehv4g0bwq17orxtJa4vdt7coBw4gKbQpPI/ebtvIUsQldK/iHRY9bTRpNXsE1RxlLFrlBOwxniPO48Anp0Fct4WbxV4f8N2Phi48PNNcadClnBq0dxD9jkjRQqSMpkEwOByoQ/MOGwdwyfEemeK7vxjFJb+H3exs9Zt76JrIWkcd0BEqvLM7yeaZAcqAqqAq4Jk+XABcfx5r6WbSvY6arx+LItFlAkkISB5Y03Dgbn+fvtA64OMHpvF2t6p4f0f7fpGkRasUdVktzdmGRtzBVEY8tgzEt0JUe9cFc6R4lbTr1U8K6g7v4vg1dEFzaZa3SWNyeZsZxGRg45Ye5Hf8Aix71dJhGnaVdapL9st5GitXhVlVJVkYkyug6Jjg5yR2yQAUE8Yz6pFoN34Ys7PUNO1hivn3F68DwlVZmGwRPkgIwIJBDDB7kY8HxJ1aAQ3WteHLW301tYbR5riz1Np5IZhIYg5jaFMxlwBkNkA529qsp4SvtM8fWus6Ou3R7uSW8v9OYqGhuzEy+YnO3592HGfvBW7sRS8G+C4rq/vNS8UeH9RtbuHWZ9Sso77UBLApkdyjrBHM8QkVW+8VBBOQSeaANqDxfqWsX9/8A8IvocWoafptw1tPdTX3kNPKn+sWBNjB9v3cu0aluM4Bauh02/e80W2v721k095IFlmt7ggNAcZZWPTjkZ6cVx3h611/wQ+o6RH4fn1nT5r2a8sbyyuIE2LNIztHMsroQVYn5kDgqRwCMV1GppqUnhG9QWdlf6k9nIBaSf8e80hQ4jbd1Qng5xkenYAz774h+E7Hw/NrX/CQadc2MMqwtLbXccgMjdEyGxuxzjPQE9BXQ21zBeWsV1ZzRz28yCSKWJwySKRkMpHBBByCK8ek8NeLtRg8Tvd6LeedqUWnSxmZ7OLL2029oo0jlYKuD8u9icDDOTXqtzptnr+kR2/iDSba4ikCvJZ3caTojdcEEFSR6/lQBVvvFFlYeFtQ16ZJfs1gbhXTADu0UjRkDnHLJxkjqM4qlaeLpbW4vrbxfZW2jTWdl/aDPDeG5ha3GQzbiiMGUjkbccrgnJAp2Hw98O6LoeoD/AIRPS7meY3YMdlaQpJNDJK7LCGbYB8jKuCwAxjOADWDD8Nr250fXbrbLaXl/axW+n2F9qU14LaKNxIEkldnx5jABlTKqAAN3JIB0ug+PLbWNJ1LWbhbOz0qxBJZb5Z7iPAJYTRRgiNuhCB2bnBCnirPg7xUfF1ncX0MFnDaK4SJYdQS5mU87lmWMFImA2naHc4bnaRiuV1HwlqfiaPWdRTQ/7Dmms7K2h0+6niIuWtp/P+fyi6BDxEDknG7IAxnW0zQNS1HXtY1rZf8AhNr63tbZYomtpJmMJkJkYYliwRIqDqcR9sgUAbHiTxNL4f1DRLddLlu49Uvls3uRKiJblgSCQTuYnHAAxwckcAniDxNLoet6DYjTJbiLV7z7IbsSoqQN5buMjlmJCHgDHXLA4ByfGdhrBt/DMOn2Goa89jqcV3c3Akto32RgglgzRqWbfwFXHBzjjMvjm11S61Xws+l6NdahHYasL25khlhQRoIZY8fvJFJOZQeAeAe+AQDrpZPKheQqz7FLbUGWOOwHc1zFr4uu7fXbjTvE2lR6WF099Shniu/tCGFGCyCT5F2Ou5DgbwcnDHFalxYX0WqSapHq2pzwxoWGkRJbCKQhMbQzRh8k88yAZ6kLxXN2lvq3iWHVbXxB4bv9Ll1WzltZbqee2eO3hKsqxxiOVmY5csSQuSTyAEUAF7SPGV1eSxR6joj2kt7YPqOmwRXAlkuIk25RgQqpL+8j+Xcy/N9/g0628X3UFj4il13S44JtBh86ZNOujdJIvlGTarMkZEmByhXoyHOGrO0yy12XVdN1PVdFmgbQNLmtVginhdr+d/KBaI7wAmIePMKE7+QuKj0vw5qdp/wk2o+GNNHheXUrIJZ6fcGIot6ok/0lkiZ413bogcZJ2ZYeoBoaF4x1DVFu47nRIluorS3u4BYXv2mGdJ92weaUTaw25PBAUhgSDU+neKNTuZdYsL3Q1i1bTDDiC2uvNhnWYfIyylEIAIYNlMrtJAbjPO+EdJ1bwlaapcaL4VvrSxNtE0Ogy3tuzy3mSJJEfzGREI2ZJbJIYhM/e1tM1HX7LRtSu/8AhDtRm1VwJmjmurSI3k5GAq7ZnVI0CqMscgYwHbNAFvT/ABRql4uq2c2hKmtadNHD9miuy9vJ5ihkcTFFIQAksSmRtICsSoNzwz4guNb/ALSt9RsBp+oaXdm1uYY5vOjJKJIrJJtUspSRTyqkHIx0JyLDUNf0/Qr6eDwhqE2pyOsriae0ja7mYbS+FnZVjVVRQC+7AUc4LU+x1yXw9oMt1q2g6habrhA5uJ7Xz7qaRsM4VZipGdoVQxY8Kq8LkA0PGfiC/wDDOhDUdP0631DE8UMkc921vjzJFjUgiN8/M4yOOM9elMt/EV9Ym7l8YQaNo9nbRqzXcWr+aiFm2hZPMii2ZyMHkHp6ZqfEuwvdX8GyaZp2izau1zcW5khjeFVEaTJI27zXUEFUIwM5JGeOazbSCfTbPU4fD/wx+wWU1o7S2LtZRi+mOESMLHMyBSpYuzdgAAx4oA3dS+IHhTS9Mvb2fX9OkSytlupY4LqN5PLZQyEKGyd4Zdv97cuOorTsNe0nVDANO1OzunuIPtMSQ3COzxZ27wATld3GRxnivMYfCHiOy8HeK/B8Ok3F1Be6a32DVZ54gXkMOPszBpnfah+RCcgDgkgB29M0u8vJY7aK80m5sy1v5jO8kTLG2cCNtrk78cnAK9RuPcAzPFnibUvDljdaja6GL7TtOg+0X0rXXkuEHLeSmw+YyqCx3FB0AYndtfr3iS/0iS3mttJjutPeWGKSZ7vypWMrhQIoth8wjOSCye2TnFbxNeatLqcWnxeFtS1LSVAkuJbWa1AnYEERbZJkO3PLZHONuCCaoeMtJuvFdrBYHwzPFqUapJaa350GzTZTtZmRxIJsgqB8qYfAB4JIANjVfE00PiaDQdFTS7rUWg+0TQXmpG2dYycAoqxuX6NngAYGTyKNV8RajpevWVudIjfTrq7jsxcG82zvIylt0cIQh0UD5iXVgFkO3CgtU8X2E/iELoq+H7l/30VxBrLPAIrOVSCJl/eeaJFGcYTk8EhSSK3ijRpfEevWS2/h64tL7T7uGW38QtJAojjVw0iIVkMpDpvTYUCncc9jQB2F3O1tZyzRwSXLopKQxY3SN2UZIAyeMkgDqSBzXPaZ4n1OfUtV0nVNESDVLC3iuY4rO78+K5jlLqpWRkj2ndG4IZRjAIJ5xduLTUtNnvNUgv8AVNXGxjDo4FqkeTjAViiNx/tSHv14rL0G+1mOG9vNR8J6lHfSr5s++e0LTOMBIYgsxG1Vzy7J3OCXOAC1p3ix/wCz9bufEVrb6d/YrkXMlvdm4gKiNZCVcohyA2CpUYPrml0/xRN/wjM+va7FptvYJEJoZdMv2vhKvsREmWzgALuyTge+Z4W0WTw7/bepaf4duNPsrwwvbeH4XgDJIgId1USeShf5eA+PkBJycDOv/B13quh65cWWjrpz6hqFrqC6NdPHsuJIJUkkMvllow02zacFh8qMxySAAdP4P8Tnxbpsuowx2KWnmbIDbail0/qRL5Y2I+Cp2q79etReLPE2peHLG61G10MX2nadB9ovpWuvJcIOW8lNh8xlUFjuKDoAxO7bQ0vQNSv9Z17WidQ8LyaqbZRHG1tJOfJVgZGBEsYLbwvBJ2xryOgfrk2tJcWuknQNX1zTYkV7m9jlsla8YYIRlaWIBc8thQDjbjBNAF/XvEl/pElvNbaTHdae8sMUkz3flSsZXCgRRbD5hGckFk9snOF8XeLofCtrasbV7ye5uoIBEjhdiyTJEZGPOAC44xknA4GSMbxlpN14rtYLA+GZ4tSjVJLTW/Og2abKdrMyOJBNkFQPlTD4APBJFfx74E1TWIZ7nRta1Np7q/spXtB9l8uNIpoySrPFvAQBnC7yNxbg7iCAa2q+N20/UdR8nT1n0vR3ij1S8NxsaFpArfIm0hwiujvllwDxuPFdZXneteFtXeHxJoNraS3ll4nmSSTUDLEq2oMMcM3mLkMSVi3LsUglsHYBmvRKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+bf2Rv+Zu/7cv8A2vX0lXzb+yN/zN3/AG5f+16APpKiiigAooooAKKKKAPm39rn/mUf+33/ANoV9JV82/tc/wDMo/8Ab7/7Qr6SoAKKKKACiiigAooooAKKKKACisrxP4k07wj4avNc1qRo7OzTc+xcsxJwqqO5JIA7c8kDmsj4f/EjQfiRpdxeeHzcRm1kCT291GEkjznaSASMHBxgnoaAOsooqK6he4tJYYriS1eRCqzxBS8ZI+8AwK5HuCPY0AS0V4bp/jbxBJ4YtLzSvGE2veKBqb28nh37PayeZEty8eXWGJZIQIwHMhYKDj+8BXqPiDxhbeH5J0/s+/1FrS2+13gskRvssPzYdt7rnOx8Ku5jtPFAHQ0Vxk/xO0w6jdWWk6VrOsS2tlFfsbK0AR4ZASGR5GRW4HQHnOF3EMFnm+IenSW0M2g2GoeIPMsF1Fk01I90UDZ2MwldOW2sAgy3ynigDrKK4e4+LGhfaLeDSLLV9bku9OOo2w06yLefEGVSFLlcsN2SO20g/MQpyYPiQZ/CnifUvFWiazZWFjqMtmotHQyKqkR7A8Mm5GBBZmJCgtgOeKAPTqK4vVPiZpmlalrWnppOtXs2hQJc3hgtQFWEqxLhpGUMAE7HLZ+UNhsW9Y8f6ZpNwY0tL7UI4bNb+8ms41ZbO2YkLLJuZSQQrnagZsITt6ZAOporC1PUF1fwHe3+kXd3aLNZSSQXAhMMqYUkMFlXI6d16cjsa5z4f+OYrzw94Y07VIdSS5u9EjuF1G9UCO7aKOPzjuLb8gvncygNyQWGCQD0CiuPtviPYXNxYr/ZOqRQaqjtpN1KkSxaiVXeqxnzMoXX5l80R5HeuQbxhrviPwX4b1mUahozyeKbeB1jliEd1C16U8vKEsVVQFOdu4g8MDQB6/RXD6l8Q9A0GfxPfXEGss2jNbxXoEUjIdwYqY0Ztqjk5fCqePmbitG28e6bJPqUV/aahph0+2jvG+2W+Gmt3LBJERSz8lCNjKrg4BUHigDp6K5vT/Ga6hcahY/2Jqdtq1jClw2mTmATSxvkK6MJTGQSrDlxgjnHGehRmkhVihidlztfBKn0ODjj2NAD6K4Hwz4k12Lw942utcuI9Xu9D1G5SBbe2ECsiW8cixqoLHqxHLMeepqnYeKNV0x/DN7c602v2/iS1lk+zrBEghlS3M48jYobZ8rIQ5dhlfm4OQD0qivMtE8V6sln4O1261r+1bbxRJ5M9isMQS1keF5R5BVQ+EaMxsJGcnOcgjmPRPF+ry6R4W8U3OsfarfxBfLZXOk+TGI7VpCwURMqiTfGyANvZgRvOF4wAeo0V5bb+MdXbQ7bxe2rl4JdcGnXGiGGPy4Izc/Z9oO0S+cPlkJZip+YBQCuPUqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvm39kb/AJm7/ty/9r19JV82/sjf8zd/25f+16APpKiiigAooooAKKKKAPm39rn/AJlH/t9/9oV9JV82/tc/8yj/ANvv/tCvpKgAooooAKKKKACiiigAooooAyvE/hvTvF3hq80PWo2ks7xNr7GwykHKsp7EEAjtxyCOKyPh/wDDfQfhvpdxZ+HxcSG6kDz3F1IHkkxnaCQAMDJxgDqa6yigAqK6a4S0layijmuAhMUcshjRmxwCwVioz3CnHoalooA8v0z4feIrbwfaxbtLsfEmj3dxdaXewXEk0T+dM8jwzAxoRGwfYQM9AwwQBVnUfA+o6n4gPiDVfDHhXWLq6tEt7mx1CZpI4GjZikkMzW7HDK5DIUHIX5jjn0eigDyyytNd0r4napY+G4tLnmt/Dun27G5LWsaYacK6JGjDAI/1YwMEAMMc3tE8Baz4EuoZPB8tjqEMmlwWN3DqUzwZkh3bJkZEfg+Y+UIHbDV2kPh7RbfWZdXt9IsItTmBEl6lsizODjguBuPQd+1aNAHnnhrwJq3hjxdos1ubG50vT9Hl06Wd7h0nkkklWZ5RF5ZUDehAXf0brxg1NX8CeJ5/CvivQdPOkvBrOoy3dvLPcyowErh23ARkKVK4AG7duzlduG9OooA82vfCvi+9vPGNy1nokZ8RaTDYxINTmPkuiyIST9nGRiZiMDPyAY+Ylcafw1rur6pNplhJp8dxZaLbaXrEVnq5gaQEOQjlrSQlShUqyiNhvcZbHHsVZWreFfD2vXCT67oWmalNGuxJLyzjmZVznALA4GT0oApRefqvw78rR7S1ilnsTBBC90TABt2ArKFJaPHKtt+ZdpwM8cla+BfEjxeDbPUINJ+yaJpMumXrw6hKXkEkawlowYMcLGGwSOWI/h3H08AKoCjAHAA7UUAef6R4N8QG18OaT4gm059P8NXCzW91aSP5175SPHCHjKBYsKwLYd8leMA1mf8ACC+LbbwlpmiWqaLOml64moQvJeSxmWNLppwGxC21mDBcAELtJy2do9TooA8s8SeCPF2sSeM0trfRUi8QrbpC8moyhohCMZZRAeSOcA8dMnrVrXvAuveKvEWqXGpxaVaWWo6LBYZjunuGjljkaYMY2hVXTe23G4ZVc8bto9JooA4vw54avdDW4vLTwt4W0i9+z+UsGlPsjumyDmSUW6sgGDhQrdTnPGOyjLmJTKqrIVG5VbcAe4BwMj3wKdRQBxvg3RvEeiy+JJtVtNLD6pfvqFultfySAO0SJ5bFoVwP3YO4A/e+7xzX8OfD+Kw8TSeKL3SdEsNTELxW1npUASKLccs7zbFaV2wBuKqFGQF5LN3VFAHC6F8P4k8ZnxVrGk6HYXsQcWttpMAIR3/1k0s5RGlduQPlUKGbhid1JpngBLnxpF4p17SNC0+8tpHkgg0uIOzyuuGmmuGjRpG5bC7QATkljgr3dFAHCf8ACv01nxvB4h1/SNCszYz/AGiBbCESz3Mw4SWa4aNGwo5EYH3gCWbAA7uiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5t/ZG/5m7/ty/wDa9fSVfNv7I3/M3f8Abl/7XoA+kqKKKACiiigAooooA+bf2uf+ZR/7ff8A2hX0lXzb+1z/AMyj/wBvv/tCvpKgAooooAKKKKACiiigAooooAx/FnijTfBnhe817WnkW0tFBYRLudySFVVHckkDkgdyQMmqfgTx3o/xD8Of2zoBnWFZmhlhuUCyROMHDAEjkFSME8H1yBra1ouneItFudJ1u0jvLG6TZNDJnDDORyOQQQCCMEEAjkVX8NeF9F8H6Kmk+G7BLGyR2fy1ZmLMxyWZmJZj2ySeAB0AFAGtUV1C9xaSwxXElq8iFVniCl4yR94BgVyPcEexqWorpbh7SVbKWOG4KERSSxmRFbHBKhlLDPYMM+ooA8x8E67qWsJpJu/FXiOW+nuHWSKfRoks5FRnLL5v2ZAcohA2SE5OcEAiu88UeJLPwl4cuta1KK5ltrUAulrCZHOTjgD69SQB61z2j+D/ABTpWi2mjDxTYCwhlDSNb6TJFcOnm73QSG4YLuGVztJAPHPNWfEfw903U/Duq6foFrpeh3Wqrsur2LTlZpF3bjnayFiT3JP0NAEFx8UdOtHvlutF1qE6eYnu99ugEMEn3J2O/hT/AHP9aMHKDBxqat4wi0fWYLK60jVDbS3MFp/aKxJ9nWWZgqLy4duSoLKpUE4J645/WPh3rms/8JF53iPT4/7etbe3m2aS/wC68rPzL/pHfc3B6cehya/8ONX17Wo9Sm8QWRlhuLS6gFxpkkv2WWAox8kG4AjR2QlhgsQ2C5AGACt4p8Qx33hPWrvw7eavp8+n+I7O0ujI7p5redbq6qHJKRFZRwuzcQTyGO70SG4kku7iF7OaFISuydyhSfIydoDFhjodwXnpkc1wd38OdaudK1yy/wCEjsR/a2sQaoZG0pyYzGYzswJxnJgi54/j4+YbO6tkvVuJjd3FvLCwTyUigZGTj5tzF2DZPIwBgcc9aAOXufiZpdvq2o2X9mau66ZfQWV5dC1CRQtKUCNl2BZcyKPlBOPmwVIYtk+J2lx31/CdL1j7Npt+the3zWoSG3dtm1juYMykuOVU46nClWanqfw+1m/l8RNH4gsYl1rULa9w2lOxhEGwImfPG7IhjyeP4sAZG3K0TQ9T8Q+I/F1ndzzWWk3GsRXE8c+jzRNeKkUIzFNIQoUvEVICudoyCNwagDtLfxdDd64LG00rU57U3MlodTihVrZJow29Gw28YKldxTbu43ZqXxBrq6e0WnW8F/daheRSNHHpyRtLDGuA0370hMKXXg5JJACtyKq6T4a1LRNTuFsNYhXRri8lvTZvZZmR5GLuizb9oQuWbBjJAYgMOCIr3wzrVxqmn6zba5a22r28ElrcSDT2a3uIXYMAIjLuRlKqQ2898gg4ABgeDfHhg8M+FNKubPWNa1jUtK+1+YiKd6qwVmeWV0Xd82SMkjvjcobdsfiDZ3q6cx0rUoPt2pzaURKIf9HuIt4ZX2yHg+W+Cm4fLzjIzneHPh1qPh/UvDs3/CRJe2+i2M1l5c2nhZJVlZWYh1cBQPLTAKscbsk5BCn4dX41OFofEf2fT4Nck1qOCKxUzeZJvLo0jMylcyNjCAgHHJwQAXYPiHbXWuWGn2uiatLDqN1NbW1+BAIJGhLCU8yhwBsbqgJ2kqDWPql7da1d2kbNfXV1qEb3dlplrqUumw2topAE880X7wswYfKcjLBQo2tJWZ4Ts7uLxkt6IbgXU13O8tpeaFfxC3EkhaQrO0xtVfHV40/ee+4mm65Y2tvdX1rqnjK28Jz3OjJo8r3sIjaVI/M2TW0zuqkHzAXUbiAduUYhgAbvhnxdHa+EJNYuTfyaVJBHd2Ed5Ir3IjkkaOONnYgHdhCGdiRvO5yBmjxh4rvm0TS0sdD1xBqGppZ3KI0dtOgB+ZFZpVILcqroccEhwCpLtC0m41Xw3d2trd280E1vFbLfT6Z/o1xEnCxx27sd0GzcNxY7zKzK20LUcfw51Oz0PT7DSta0+0FpqjamY/7LkaBXzlY4Y/tAMUYJYldzcscbRxQBm61q8+n2Oj6To954jkhs/ENlbXGozyxushe5jL2skmfMYKr43AbTjazscqex/wCEwiXxRb6Lc6RqlsLueW3tb2aJFgnkjQuwX594G1WwxQKdpwTxnD1D4c6ndGe2s/E32LTZ9Wj1fy1sFeaKdZVlbZIzlQpdSwDI2CepA2lH+HGov44tfEL6/byyWuoS3UTT6e8lwkUiOhtxKZtqoFkO0KgAIDEMc5AOm17xJHoc9nax6de6pe3nmGG0shHvKIAXfMjouBlRjOSWGAecY9r8R7bUNH0+903QdYvJ9QtmvI7CFYPPSBTjzGzKEAJIAXduOfu8NjI8fWWo3LaLDqNxPvhFxK19puj3sqByQqoFtZxPGdjMCS+xsHIztC29L8ManJBpGs6Pe2mkX9rZtYeXJpMi281rvzGDbNKskTDAIy+QCQRzhQDW07x3YatqmmWum2N9cQapYvfWt8BGsLohUMvzOHDguo27e/oCRof8JFBD4SfxBqNrcafbRWzXMkVxsMiIoJydjMvIGeG7845rJm8A2y6Domm6ffTWzaRN5i3JUNJKrqyzKcYALiR+RwrYIHAFbepWOoXkdxb2t7bW1tLaPCqtZ+a6SngPkvtKAZGwrz/exxQBQHiyR9MFzD4b1uWc3IthZrBGJC3l+YXDmQReWBxv37Sw2gk4B0PD+uW3iPQbXVrKOaKG4UkRzqFkjIYqysASMggjgkccE1xsfwxu7fRGsbLV7K0SXUPtc1lb6fJHp8qeUUMJthODsYncy+ZsYjDKQSD0ngrw3N4S8MRaPNeQ3aQySNE0Nr5CojMW2BdzdCT3oA36KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5t/ZG/wCZu/7cv/a9fSVfNv7I3/M3f9uX/tegD6SooooAKKKKACiiigD5t/a5/wCZR/7ff/aFfSVfNv7XP/Mo/wDb7/7Qr6SoAKKKKACiiigAooooAKKKKACiuY+I1l4j1H4fara+Crn7NrUkQFu4fYxG4blVz91iu4BuMEjkfeGZ8H9L8ZaR4DS2+IV1Jcal9okaMTTieWOIkYV5ATuOdxHJwGUZ4wADuqjubhLW1luJRIyQoXYRRtI5AGTtRQWY+gAJPQCpKKAOUi+Jfhia1025iur1odVnNvZuNKusTSA4Kj93weD1x91vQ42rfXrC58QXWixG4+3WkSzTK9pKsYRjhSJCoRskEDDH7rf3TjynxJaal/xUvhnTFdZtEuj4n051U4YE+asPtmfzwMHouOK6LVdXv3+FeqeLNDaSGfVXhu0cwtI0FmWjQuFUhiBAGkwCCCzYwaAOv1vxFaaDc6XBeRXLvql4tnCYYiyq7AnLt0UceuT2B5rWrxK7ix4es5JfGDa1o8XiC0nfVLV5BDYxlHV1FxJNK+AdpLM/yGQYIP3bN3qt3ZeH5pbXxGP7Ii1iZtKm1HWJLc3kAgBG28IbcFnZtnm7kcLtORg0AevNcOt4ITbS+V5RkNzuTy1IIGw/Nuzg5+7jAPOcCnxSxzwpNBIskUihkdGyrA8ggjqK8d1DWF1e+uNLXWdRIvPBLTRaZc3oSdZgAylhGQTIVGW65Gf4SRVCe887S/D+mWfjP/hHtFl0RZLTUrie5kEt3uIkVJhcR7mTK7Y2Lr1AUhcAA90orH0WW2lmUy3zy6ubKBru3kmKsgIOGNvvKxEnd0HOMZOK4vxhpt6fF15pVlqmq2z+JdOxYSJqFwqWd1C43soVwFzHIr7RgN5LDuQQD0yivJQ174k+GV14stZ9Ytr+2jhmFrDqNzGGe1UfaItm8A7nWaMnA3YB681Lo8s9741m0177U303XjFrOmut/c5igjLLIobfwjHyW25AxcYx8owAeq0V4xqct/4emv0i1HVpP+EV1ddTuWm1G5lE+my7G8tgXO7aDJjcG/49mHO5ifQdPurTSvDqQ3OrtbX19BNexi7uGnlTI3tsSRizLGGA2jgYHAzQBuanqVro+k3WpahJ5VraQtNM+0ttVRk8DknA6Dk1hz+NobHwxrGt6voms6cmkBmntprVXlkUKG3RmNmR1+bG4NhcNuKgE15VqWr2t58KfFdprOsNK1pbwLFcweIHuLWeVlc7EkO2TeWEheCQsQDH1XaBf8c6to8mieJLGfxDdRWUfh530ELqkjx6jujk81t5Y/aTnahVy+1RkBck0Ae0wyrPBHKgIWRQwB64IzT68T8YeMbK0v7Caz1e+0+9t/7Md1vNUayiWBpV37LQ4Mx2M28yKAoH3vl212Xj/wASWS+Flns9XUQQ6jBFfx21+trKUJDNF5xdPIfaQ3zMmcbcjdQB3VFeMafqcdr4W0+e58RXcugX2vTJqV9Hrr3L2EJDNbQyXKSt5Q3eSGKOB8wBY7iWuhr6Hwv/AMJA+rald6XoOueda3CahKBe6ZlNxkKtiZULOwZs7liHJDHIB61RWJpEtjp0MbXF88U+s3D3EEN7eM7sW+YRxrIx24QDKJ8owcDFeYaN4rgg8N60dX1zUdRghtrRpr/R9XEikvNtOfN2tZyOT86MwVFztZNvAB7He3cWn2E95cZ8qCNpH2jJwBngdzUyksoJUqSMlT1H5V5X8Pdc/tyG90Qaol80OtmULHqT3/lWiRxyridhukUyELluzEcgVgyeJ7e01LWdQuPHU8j2PjK1toYpdURIoraQwCUFF2qybfOHzAhfKYja3mMwB7nRXi1hqNw2tXENv4s1G88R2/iswQ6fLfE77LzVEu63XCmMRmRt+35SnykEYrpfBt/Y32vJJqXiK+XxQs9zFeaM18xQKGbbm2PyoioqFZFVd2QSzF+QD0SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+bf2Rv+Zu/7cv/AGvX0lXzb+yN/wAzd/25f+16APpKiiigAooooAKKKKAPm39rn/mUf+33/wBoV9JV82/tc/8AMo/9vv8A7Qr6SoAKKKKACiivMvCfiDXPiTrXiC8stcuND0bS75tPtILO3geSdkALSStKj8HPCqFwDySRkgHptFeY+Ktb8WeHNX8DWt1rMLzalrT2t+LW1RYbiFnJQBXDMhCbRw3ryeDWxZfFDTbzxefDR0jWLbUXinltkuoY4jdLESMqpk3oGwSpkVAQOtAHbUVwuhfFjSNcj1CYabqVhb6S0y6nNeeQv2Exg58xFlLjJBAwpyQfSql18TpdX8M6qvhXSr2PxDHpC6pp9jeRxs9zA/3ZUWN23f7hw2cDHNAHotFeWeF/iVZXOk6lq8PiO71y00iwluL/AEy7s4YNSt3XaWyoEaMqqGHygYORuckBbC/HLQHt2lXRtez/AGUNXjQ20YMtrkhnGZMAKVbO4rnHy7srkA9LorzDVPijHbeJoLiybUriwbwy2tRaetrCEuUOGWTzS+9CBkFduOp54zjN8SPEsifDjUjHexLrrSLeadFBbv8AbP3YZDGckoCzYBZ0wBltoBNAHtFFeMePPiZc3XgHwv4w8F63f6ZZapq0djPE1pA7CM+ZvO1o3O8GPA2kj2NdJoGsXnjnTLjxJoPiq+t9GjieC2gijtmklkj3K0soaEmMk/MEB+7tY7dxQAHodFeJ+BfiVrOqWHw8/trUL6e91lNReeOGxtvL1AxNIEQvuQxFAqkFVw2QCepHV+HPjL4f8S6hpNrBY6pZDVhc/ZZ7yGNIy0AJlUkOeijO7G3tnIIAB6DRXK+F/iFpPiy++zWEF3AJYGubKW5RFW9gWQxtLGAxYKGA4cK2GU4646qgArn7nw5qk91LLF401y2SRyywxQ2JSME5Cruti2B0GST6k1w3jnxTrWg/Gjw1pUWu6nDouqQyzXNrZ6fHcupjQkBAsLyEMVG7qQCSCoHFDwh8RLu21bxxqPinxJqdzonhx4Y7eG6sIYJZPMDYDoIY33lgAo+UfNyO4APRP+EX1f8A6HvxB/340/8A+RaP+EX1f/oe/EH/AH40/wD+RapSfEiyj0i4u/7G1drizu/sl5YrFEZbRtgk3yv5nlJHsIbeX2jPXIIFSD4saHq2g6FdaNb6ld3PiJpo7Cyt44luMxBvMY+Y4jATb1LEdMZoA2P+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORaw/hJ4n1LxD4GvNS169lvZbfULmFZpYFicxIflBVVUA468A1h+FvEPiz4geCdU8Y2OvSaMolm/szTYbaCSLZF084uhdmYgg7WUDqKAO4/4RfV/wDoe/EH/fjT/wD5Fo/4RfV/+h78Qf8AfjT/AP5Fry1/iv4n8YW/gK28PLPosviIXQubu2hgmxLCpUhEmbGxWxIwOCVICsWyKoW/xG8ZS6ZrOu6vrepaZZ2Gu/2R9nttKsp1Qgx46yhg3DK5yy/vVKfdOAD2H/hF9X/6HvxB/wB+NP8A/kWq9x4K1C6ubWebx14jMlpIZItqWKgMUZCSBbYb5Wbg5HfqAaWD4hafdeJp9Js9O1O5htbprO61OGBWtbaZY97LI27cuOAW27QSBml8L/ELSfFl99msILuASwNc2UtyiKt7AshjaWMBiwUMBw4VsMpx1wALH4O1KKeaZPHPiDzJiC7GGwOcDAHNrwOOg4ySepNS/wDCL6v/AND34g/78af/APItdBcxPPayxRTyWzyIVWaIKXjJGAy7gVyOoyCPUGvIfAPxDv4ND1nUvF2sX2rzJ4ifQ9OsY7e2R52GzYF2ogLncclmCgDtQB33/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLWXN8TNKv4bGx0uLVZNS1RLhVt7OKFriy8klJXcO2zKMCAPn3EDaHB55nwB8UbrUfh14cXXZL/VfEmvG8WIafBAsqpE75lIbbGoVQMZ+8egbmgDuv8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWuF8G/Fa7tfhfa654pg1TWZpLm7WS5trSKNYYoWPMrExxx8YABIZm4AJqTXPiXdQ+NfBeoaPPfXPh/W9MubqbToraIvJ5cZdSCwBVhu5+cL8o9yQDqtO8A3WlC5Fh418QRC6uHupv3Vi26Vzlm5tjjPoOK0Lbw5qkF1FLL401y5SNwzQyw2ISQA5Ktttg2D0OCD6EVd8Oa/ZeKfDdhrel+Z9lvoRLGJV2uueqsPUHIOCRxwSOa06ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+bf2Rv8Ambv+3L/2vX0lXzb+yN/zN3/bl/7XoA+kqKKKACiiigAooooA+bf2uf8AmUf+33/2hX0lXzb+1z/zKP8A2+/+0K+kqACiiigDM1Lw1oWtXUN1rGi6df3EAxFLdWiSvHzn5SwJHPPFchP8LmtLnXV8O6jZW+meIHM19pmp6b9shEx6yRgSR7c8HB3DIGMYAr0KigDyy1+CNppFj4VtdB1OK1Gg332+eaexEkt/LnPzMrpgAEqMhiBt545TR/g/qej+KtO11PFUV1cafNeyobjTWZpjcAgmRhMCxGevGQAMCvVKKAPMrP4T6guta5c6p4lhubLxHatBq1nBpzQiZiGCyoxmby3AIHQggcgk5Emm/COS3mF1qHiBpNQg0u10m0urO0EBgggkWQNhncGUlB833R/dxxXpNFAHn+p/DS71u71i/wBV1mzbUr/R5dHiuLfTTEscMh+dpF80mV8YA+ZVHPy81gf8KS1Py0UeKrT5fDZ8O/8AIIbmAsTv/wCPj7/P09q9fqG0vLbULOK7sLiK6tplDxTQuHR1PQhhwR9KAPM7b4OXKXunyXfiKKWC08OP4feOLTyjSRMrASBjKQrDcD0I4PrxNF8KtXgg8HrH4ntWfwru8kyaUSsoKBACBMCBtXPUncSeBhR6ZRQB4/H8ENTh8C6H4Xi8VWn2fRtT/tOKZtIYvJICxVW/0jG3LtnHJ46YOdez+GWt6P4q1bWPD3iXT9Pi1iMfbNP/ALId4JJduGmA+0AqxYseDjBwc4yfSaKAPJ9B+DGoaC/hFoPE9tL/AMIt9r+z79Lb999oLFt2J+MbuMVHoHwRu9Hu/DT3HiS3u7fQJbtkiGmNGZ0ueJFZvPODycEDjjg4r1yigDgfh98L4PAThYp9OukhWSOG4TSY4btkZ922acMTJgYHAXpzngDq08NaFFrZ1mPRdOTVGJJvltEE5JG0/vMbunHXpV+G4huYy9vKkqB2QtGwYBlYqy5HcMCCOxBFSUAcNrvgHU9X+KGjeL4NctLcaOjxwWb6c0m9ZEKvucTDJ+ZsEKMcZDY5wLj4L3mpQ+LodZ8R20yeKfLln+z6Y0RgmiOY2TM7ZUHqp5PZlr1io47iGaSVIZUkeB9kqqwJjbaG2sOx2spwexB70AedTfCq5OladBZarpWmz2epRX7rp+hrBbXJjB2iSFZAWbdhsl8ZAwoqnonwYuPDuneHBpfiKL+0fDl1dSWd1Pp5eN4bhSHjkjEoycnhww44x3r1WigDlPh94NuPA+i3enXGqJqQuL2W7WQWvklTIckEb2B57jH0rHtfhnqGh6Tqeh+FPEcem6FqMjv9ml0/zprXzP8AWLDL5ihQR03I2PevQ6KAPOj8KBY6x4Nm8PanBY2HhOOVYLWazaZ5zNxKzyCRQCw5GF4Yk8ghRkzfBbU7jwpq+iS+KbTbqmuf208y6SwKSHlkA8/7pKpjuAG65BHrdFAHD6H8PrvQdf1qez1xTpOuXZvbywazy4lYfvNku/5Vc9QVJAGAQfmrC0j4U6h4J8NXkPhXUbFdRjieOwv4dDtxeANIGxLK77ZcLx/B64OAK9VooA57VdD1jV/DWmwDW20/V7SSC4lubdW8meRMb0dFZGaJuflDL2zwCDxsnwQtJfA50aXVVlvzrZ1xruWzDwPcE4Km3LcxlBt2lvfPavU6KAPPU+GEtjq+kazoepadpepafHNDIltpCpaSRy9VWFZAUIPIYuxJznI4GZ4e+DV74ZsvDjaZ4lgOo+H3ulguJtMLRTQz5LI8YmByGJIZWHHBB616rRQB5Db/AAQ1C30XS9MHi5Xg06e+k2vpp2yi5jKEsvm48xA0hV+g3fd67rEXwd1S3j8NLD4ntM+H9OubGIvpLHzRMrKWb9+MYUrwO4J74Hq1FAHO+AvC0ngrwTYeHpb5b/7CrKtwsBh3KWLcrubnn1roqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+bf2Rv8Ambv+3L/2vX0lXzb+yN/zN3/bl/7XoA+kqKKKACiiigAooooA+bf2uf8AmUf+33/2hX0lXzb+1z/zKP8A2+/+0K+kqACiiigArmPiN4mv/B/w+1XXdJ0/+0LuziDJCQSoywBdgOSqgljjsDyByOnooA4X4P8AjjVfiD4DTWtb02OxuPtEkKtCrLFcKpHzoGJIGSVPJ5Ruew7qiigCpqumW2taTc6bqCeZa3UZjlT+8p6j8elefeHfAnhd/HHijytA062bT9TspbSS3tI42tysEMuEIXKgsOQMZyfWvTKxtK8K6Xo2r3up2AvBdXxzctNqE8yyHjB2O5UEBQAQBgDAwOKAOT8OeLfEHivU7f8AtDw9CPC2rJPErziEEYB2qf37mYMFcFfKTHuATV34Updn4WeEGgnhS2XTl8+N4SzyfL8u1gwC4Oc5Vs+1bNt4J0Kzubqaztri3a68wukV7OqRtJne8aB9sTnJ+dArcnnk1Po/hbStAsrGz0lLqC208OtvCb6d0UN1BDOQwHYNnb/DigC5q9xPa6JfXFou+eG3keJcZywUkD868uiLeGNJ0PU/DSBtQ1Pw7d3d7KFBa/mSBJUnl/vv5jYyf+epHTivXayNJ8L6Rol7Nd6batFLMuzLTSSLEm7dsjVmIiTJztQKvA44FAHApo8umvpmm+C5ltL3XPDV7JPc85muFWDyrqRhyZN8rZc5J398CsmLWLjwreatJoXhZvDsmmeG2n1K2kkgaFrlmUQSN5MjgkbZyWfDMoye1eoad4Q0XSEuV062lg+0xeQSt1KTFFziOIlswoMnCx7QvYDAqxp/hzSdM0qfTrSxj+y3RdrlZiZTcs4wzSs5LSEjgliSQAKAPNWl1TwAuvQzQWN3q82lx3UevLCxmdzIIcXDOzFwhZWGNqbQQEQAAMlGo+DYNb0l4LZtSuorBjrlori5lS4uhbuJZHZmaRMsytkLjG1UAwPRNO8GaDplldWkFiZobyIQTi8nkui8QBAizKzHywGbCD5RuOByahTwLoUWh3+lww3AjvlVZZpbuSeYbR+7xJKzMAh5UZ2g5IHJyAYt9oGl6n46t/D+o2EDaLpuiCWytCgEUcjSFC6joGREUK3Vd5xjJrDuJJta8BfDPWdVlnlvjqGnsZDK6rKXAy7IDtYkAEEg43HGMmu5uPDEWv6ZaJ4tjjuL23DxtPZTS24kRjhh8rBtjhVLREsuQAd20Gpdb8JaR4hgs4dSiuBHYuJLZLW9mthGwxtI8p15GOM9OcYyaAMXx94Y07XLJ08pX1+62xaVdMMyWMikMJYj1jCEb2IwWwFyflFL4qvR4c8WaLqdtEzyXyXNrdoigNcpFbSzx59SpjYL6eY3rWrqXgzSNV1dtTun1OO7aMRF7XV7u3GwfwhY5FUDvwOTzT4dAz4hgvbgQpaaZD5GmW0QP7vcoDyMT3wNiqOihjk78IAcN4Ni1Sz8QaNqOtRabqt94j06W4TVEiczWrBVk8rezEeSQ/CoEAI53EljseGdG/sjxFf6Pq2mab/aF5ZtP/b2mQfZpr1SwEvm8l0kDspBDsDnI2kbRv6X4L0LRZppdMtJIGliaFcXUpEEbNuZIQWIgUnB2x7R8q/3Riay8L6bp9pdwW5vibxNk082o3Es5UA4UTO5kUDcxAVhgsxGCSaAPPkvZfAn/Ccm10Sy0eeGwivbK3sWBs2TDoszfKpEm8HzPlHyonJxuMTS6p4AXXoZoLG71ebS47qPXlhYzO5kEOLhnZi4QsrDG1NoICIAAPSLDwzpWnWt1bx273CXi+XctfTyXbzJgjY7yszMoDNhScDc3HJqDTvBmg6ZZXVpBYmaG8iEE4vJ5LovEAQIsysx8sBmwg+UbjgcmgDz4zan4Dt9fsFtrGXV5LS0li1yKNjLIZ5zB/pDyF2cxsd4J+XbwEUDbTPO1LwTZ69odvbWQ1eX+zhHrkCOrzLd3DQB7iSRpGZ42EhDMWGCMKBxXoll4M0Gx0y809LJri3vkEdyL24kumlQLtCF5WZtoGcLnAySACTS2/g7QrfSb3TTZtc21+MXX2y4kuXmAGAGkkZnIAHHPy9sUAYXgCzk0TWdd0C7s7I3VqLe4bVLWF0a/WUPgymR5HaRWSTJZ2yCvTpXcVnaPoVhoUMyadHLunfzJpbi4knllbAALSSMzNgAAZPAGBWjQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV82/sjf8zd/wBuX/tevpKvm39kb/mbv+3L/wBr0AfSVFFFABRRRQAUUUUAfNv7XP8AzKP/AG+/+0K+kq+bf2uf+ZR/7ff/AGhX0lQAUUUUAFFFcp8TtD1jxH8NtZ0nw3ceRqNzDtj+fZ5g3AtHu7blBXnjnnjNAHV0V5N8APBHirwR4X1C28Wt5Czzq9rY+csvkAA7mypKjcSOAf4fevWaAIL24ltbKWeCzmvZEGVt4CgeT2BdlX82FY/grxlpnjzw1HrWjLPHC0jxPDcqFliZT0YAkAkYYc9GFbF7fWmm2Ut5qN1DaWsI3STzyBEQepY8CvFPDVzeaJY6Dd+DWS9t/Fmk22nytbMsiWWpRQqPOfBwAIg5deuYeeeKAPTdB8cWXiTxLq2kaXY3zrpMnk3F8wjEBk/ur8+9u/O3Hynnpm54v19/C3hDU9cjsJNQNhbtObeORULBRk5ZuAAOT1OAcAnAPj82oWFpJ480vwrqEd0sMumK8NlciS4ks4o4kuSm07mIQOrEc5J71d1Ox06/h8Wr8Mo4bjQrvwtOk9to6Brd748RhEQY80x7gyjnGzI5FAHs1ncfa7GC527POjWTbnOMjOM1gXPim90/xN4d0TUNIVZtZE3mXEF0HhgaOMvtUlVZycdSqjnv0rzuwj8My31jqPhO8gj0z/hH7hfEN9a3jIhJWPyfOmDf68MZDkt5gG7Jxiq/hXXtI8n4OQ/2rY+altNGyfaE3BzbGMKRnqX+QD+9x1oA9xorxLwNZvceJdD1C913S4fE8Ekseq6fa6eyahPuBEi3LtOS0SkKysU2jEezAKivXNC/sT+zT/wjP2D7F5r5/s/Z5fmbjv8Aucbt2c989aALb3kCX8Vkz4uJonlRMHlEKhjnpwZF/P61gax44s9IvryBdO1C/TTY0l1KezjRkskYbgXDOGY7QWKxh2AwSOVzmXHhTWj4tsHHjHxAyCxugbn7PY/uyZIMJn7Nt+bBPIz8nGOc874nt7zSta1mx8HeJIdR1/W7WKK70q4sxczeYsSxfaXaN41t1KFCzMu3gbVJIUgHfax4t03SIrEKJtQutSI+w2digkluRwdyjIUIAQS7FUAIyRkUar4rtNF0+ykv7W7W+v8A5bXSokWW6lk27igVGK5UD5m3bF6lgOa8xutB0nw54lu7LxTr+oaWsXh60s9HvIb17XzREjK4jZCGeQOVbyskNvUlWwMNSMr4g07U/itq95ok03hi3jiukvDZKLgM7ToZEKkS8xtsBw3owUBQD2WznkurOKae0ms5HXLW85QvGfQlGZc/QkVl3HiRl159MsNG1DUjAY1urm2aARWzPyFbzJVYkKQxCq3DL64rG8K3fjYeEtD+36dZXdw9spu5r+9ktpwdxxmIQN82zaSCVO4kEDFZ+sx+GpvFcFx4PvrMeLo9QiW7j064Bllh81RcC6RDyixhsGQfKwUKQxAIB02r+LLXTNVi0m1s7zV9VlTzfsNgiF44+f3js7Kka5BA3MCx4APNbc00dtbyTzuscUal3djgKoGSSfpXiOrxDTbzxoV1rUbHxtNqYutItY7to2vFxH9n2RDi4jITy2Dhwm2T7vJr1C9Gr3qXljrlhpcOhzW8kdxeJqcglCFCGPlmEKvf/lpwOeelAEekeOLPVtQs7ZtO1CwTUo2l06e8jRUvUUbiU2uzKdpDbZAjYzxwcGm+OdO1PUbW3jtryG2v2kTT76ZEEN6yZLCPDFhwrEb1UMFJXI5rg9F0rVfEmraLYWHiC31rw94dhmMWqxWLRCWUwtBFGJvMZZyquxdkUKCoBJJIEmjz/wBqeH/h94c04r/a+g3MDapahsNZi3t5I380dVDuQFyPmDZGRQB6JdeKtMtPF1h4aeR31K+hknSNACI0QZy5zxnBA9cH0q5q+rWehaRc6nqUpitbZN8jBSx9AABySSQABySQK8ve38TWPxS8HnU9M0j7Zcfb5Z54dTlfziUiDtzbjbtUKETnIABYY3Hq/Ettea14X1ax8Zf2XoGltGGTUoNVZ2idZFaN2EkMarhgp+8eeO+aAL1r42sj9vTWbK90KbT7Q300OoLGW+zgHMqmJ3UgYIIB3A9QMjLdH8cWuqXHkXmm6ho7vY/2hB9vEX7+3BAZ18uR8bdyZDbT844POOM0469qt/rPi66WDxFZ6foM1lpqQ6a9qmrM+2R8RtI5dD5aKG4DbjtUgAmv8OmtdJv5oPC+pDxXpc2jm4dPN8x9NkTbstAST5cb7m2xN8y+W2c8mgDt9H8f2GrS2m/T9QsLfULV7ywubtI/Lu4UCkuux2ZfldWAcKSD04OLFh4xhuvEEOj3uk6lpVzdRPNZtexxhbpExu27HYqQCpKuFbB6dcec/DibT9H16zudL1i3vbG702WXU7KSTjw264kdE3HNvCWypjfBzGDkhTjrdE8W+F/Ffiy11G21vT7m4jSS20yzgulkmKthpJnjUkpkRgAEfKoySC5VQDu6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5t/ZG/wCZu/7cv/a9fSVfNv7I3/M3f9uX/tegD6SooooAKKKKACiiigD5t/a5/wCZR/7ff/aFfSVfNv7XP/Mo/wDb7/7Qr6SoAKKKKACiisrxP4k07wj4avNc1qRo7OzTc+xcsxJwqqO5JIA7c8kDmgDVork/h/8AEjQfiRpdxeeHzcRm1kCT291GEkjznaSASMHBxgnoa6ygAoqC9t5bqylggvJrKRxhbiAIXj9wHVl/NTXkvgXxY/iLQvDslz8TJ5tf1Ir5umQrp7hWAZ2V41hEirtQgncCMjmgD2GiuHuvirpFtLqudM1l4NHvEtb+5+yBI7fdtxId7KzJ84+6C2AW27cE2/8AhYulQprLanZ6jpg0izW/lF3CoaW3YsFkVVYkZKH5XCsO6igDraK4e/8AiLpaaB4jfWtK1vT20e3Rr20Cj7R5cqnayPBIwGcN829dpUklcZpIbq6T4y2NvFf3smnTeGpZ1spJcxq6zwgPjqXwxG5iTycEZNAHc0VXsLmW8sY57ixnsJHzutrlozInOOTGzL78Mev4VzcHxG0ma8tozaakltfTSQWN4LUyR3ciHDKgQs4xhjllUEKTnAralQq1k3Tje39fo36JvoJtLc6yiuYj8e6bJqltbra3os7u5ks7fVCifZppkDFkB3b/AOBwGKhTtOCRzTtL8c6fquqWVpDaXsUOpJK+n3sqJ5N2I8btuGLrwcjeq5AJGa1eDxCV3Hpf8/xVndbqz7C5kdLRXP654xs9C12w0eSx1G8vtQjke3S1t9ytsx8u9iFB59cKOWKggnPsfiTpl/8A2eyadqkUF9d/YftEsKKkNzlh5T/PknKEZQMvI5ojgsRKCqKGj/4P+T+4OZXsdhRXNP450+PVLe2e1vRaXN4bCHUii/Z3uBkeWPm3/eVl3bdpIxmub8R+LpdT1jww+itqtvp8mupbm6QIttfrhgwyDvIBXAyFVuSN2ARrSy+vUlZqyte7+enrptuJzSPSaK4aT4i6BpceqX7W+tMsWqpp84aGV8SlVAKox/dphh2XcegJIzNqXjt/+Eb8Rz6fpGoQ6lo8Bd7a4WEMgaIukv8ArNpTAyRndwRtzxS/s/EXXutJ2303t+rX3ofOjs6K858M6y2mw2U5tvE2oapqlik8mlyXcU4CqAWuV3y7Y1ZnwFDjPGEGON1fFSeItJ09vC8/ltqQkLXM0eGskjwJSyN/GrEKAeMsCcgYLq4CpCdlrHv06+vZ272dhKSZ1NFeStqyzCzvdLOvMmqX4sdN1RtakJuJs/NM1q2YVhIWQ8IRgcIoKkdi/jM2dvZ20+mXeo6xLHM8tnpqKSFhfZJIN7qAu7AA3FjuAAPNXVy6rC3Lrf0W2/V6aPezVndIFNM6miuT/wCFjaNPZ291pkGoajBNBJc7oLRkKwIVDS7ZNrMuWA+QMT2HFYlp4pk07x14jurm51C/tGsrCWz0/em4PKX/AHcSEqu48d8nHU8VEMuxElJyjZpbPfdK3lv1DnR6PRVCXVobPQpNV1eOTTIIYmmnW5KloVHJzsLAn6E1ixfEDTF+2/2raX+kGzs1vit5EuZYGJUMvls3ORjacNkgYrnhhq1RNwje3b9O/wAiuZI6miuSf4h2Fp9sj1fTNV0y6tbI3wtZ4EeSeEHBZPKdwSDjIJBGcnAyRHbfEmyvJ7OG30XWWk1C1+1WCm3Rftajbu25f5cbur7VI5BIIJ1+oYm1+TTv0777PTX0v2FzROxorN8P65a+JNBttWsFlSC4BISZQHQhirKQCRkEEcE9K0q5ZwlTk4SVmtGVuFFFFQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzb+yN/wAzd/25f+16+kq+bf2Rv+Zu/wC3L/2vQB9JUUUUAFFFFABRRRQB82/tc/8AMo/9vv8A7Qr6Sr5t/a5/5lH/ALff/aFfSVABRRRQAVleJ/DeneLvDV5oetRtJZ3ibX2NhlIOVZT2IIBHbjkEcVq0UAcn8P8A4b6D8N9LuLPw+LiQ3Ugee4upA8kmM7QSABgZOMAdTXWUUUAQXr3cdlK2nQQz3QH7uKeYxIx93CsR/wB8mvO/D/hnxrovgnR/D39n+HvO0tAsGpf2nM5ibDKZREbcAkK7YUtj1r0S8nktbOWaC0mvJEXK28BQPIfQF2Vc/UgVxbfFW1HhfTdfHhrXTZajdC0j4tlaOQuI1EgM42Avlck8FTu28ZAMfVfA3i3UNF8aWMcOjA+IryOaCRtQl/dqqIh3AQdf3QOBx8xGeMm5qvhfxrf+INc1SwfStMm1HRYbGGWO/ld4ZUZnJ/1K4BMjKGB3AAMBn5R10/iIw+KrPQ/7Jv5Hurdrj7UhhMMKqQDv/ebwcso4Ug54zhsHi/X38LeENT1yOwk1A2Fu05t45FQsFGTlm4AA5PU4BwCcAgHnUvw48TC08YQWGnaDaL4l06G12jVJ5GikTzFaR5Gg3TMwkLFmwxIwc53V1FnoPiRfiDpeuXNrpSWtvoz6dMsd/Izh2dH3KDCAQDGF5IyGzxjB7CzuPtdjBc7dnnRrJtznGRnGaS8e6SzlbT4YZ7kL+7jnmMSMfQuFYge+0/SgCKC7ng0j7Xry2lhJEjSXHl3JkhiUZOfMZU42jJJUY59M14xoWsaTYz6dqd7rehz6fbXcl3a2EfiGNPsxmY5dbcwBgQshOx5SFy3Tt7LBrNnc69e6RBJvu7GGGadRyEEpkCD6/u2OPQqe9Xq9HB4yGHhKMoX5vO3ddvMiUWzy3Qtd0zRrFvD48XeFH0VbiVorwawn2nyHcv5bREbS2WK7w44525qXwr4nstA02x0W48XeEpNP01Wjiuo9YTzbmNQVjR4yuEPKksHblenPHoGs6g+laJeahHayXjW0LSiCJlVpMDOAWIA/E1D4e1ldd8J6XrbxC1XULGG7MRfcIg6B9u7AzjOM4HStZ4+lUUlKn8Wr1W+uvw76vy8hcrXU4HUfFFnqHi7w7rP9v+Do10yK4FxF/wAJECS0oC4U+VyAFU5OMkkYGMnn7a5it9D06z/4SXwS0lnr7aux/wCEiADKXZxGP3XX5yM+wPfA9Wt/F2k3Vro1xBOWTW5THY9MyYR33dfu7UJz7j1rbrWGZ04RUY09F/e85Pt/eYcjfU8e0qPwfpOq7U1TwHPCuoG8h1eW7tzexqZPN2FShDNnKB/MBAIIGVwacc0UGkaBodv408FLZaDqSXNveSaoGkkiTeFVoRgbgH5w+DjtXttVdTvl0zS7i8dS/koWCA4Lt2Ue5OAPc1X9ra3cW/Vp66q/w+b028hezPF7+eK6h1mOPxL4JA1DXIdUQt4iHyrHs+Q/uup8sc/7R9OdC+1e3ub7xhLH4i8F7PENlHaxbvEQBi2xtHub91zw5OB/dA75Hb+M/GsnhHTpLmPSm1JoIUluEiuFQQB5FjQsWGdpO/kAn5OnOR1dP+1oWt7P8f8AD5f3UHs33PIrHWbTTNQ0nWLTxR4Oe+tdMGlXdnJryiKWJTuSRJQm5X3ZypQjDdcjNNjv/C+j6G1knjLRZLrU4L6G4uob2NliuLlg6ttDZEakEZ+hOBkj1+sDxp4nfwj4bfVk06TUAk8UTRpKsYQO4TexPYFh0BOSOMZIzeZwb+B/evO32el3b8b2Q+Rnm0Oqrb33hu6fxZ4Jjg0Kye1jtk1jzFhYxrGJwAoMp27v3fyccB+SaZe+IdJv7vRpfD/iXR7GW0spwbubWYrWd1kdcb2aGVcvtZzHtDIcElc4Po3iLxpbaLpfiKeztZNTuvD9kt3c2sUiJwyswUsx4wqbjwTtIwGJCm7ea69r4Nk16OxkuWSy+1i1jkUM3ybtu5sD8fbp2rT+1ad1J0tr9dNb7+7r8TF7N9zyi8m8O6l4f07T7bU/CcH9jxvBbJP4g2SW82QVuIbpF3kdCQVAZvTaMwX0cb+J5tcsvHfhUajBa20VlevrwUyvECrmaIKVKyKzZAJKkDB5NezaBqn9ueG9N1byfI+32kVz5W7ds3oG25wM4zjOBWhVRzlR0UHbXeV93d7rq9+/W4ezPOtW8U6H4o8OXmia14k8LWUN9YvHLPaa6kzRzFsAKrIu5cYbJIOflx/FVHUtfsvFfhS50fxH4y8KWDvbKonsNWjnEs6sjiUq6psAZPuAtkOeRtBPqdFckMdSp25KbVnda7PurxfZb327lcre7PINU1az8QCa/wBV8UeDYtRj0qbT7aC31wGFnn2iSVnKblAC8Jtb3buG2esW1rrHhi9PiLwYw0XS5LKRB4iH7xmCgMP3XA/dqf8AgR9OfYawPB/id/Fel3d3Lp0mmva6hcWTW8sqyODE5Qlivyg8cgFgOzHrWyzOmo8ns9NVvsmmmtvN/eLkfczfhan2bwPFZfb9Kv8A7LcTL5+lXv2mI7nMmC21cMPMxjnjBzzgdjRRXl4it7etKra3M7/eWlZWCiiisBhRVS5vxBqNlZonmSXJckbsFI0XJfHcbjGv/AxVugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+bf2Rv+Zu/7cv8A2vX0lXzb+yN/zN3/AG5f+16APpKiiigAooooAKKKKAPnb9raEtpfhebBwk1yhPYZWM/+y19AabOt1pVpOhDLLAjgjoQVBryb9p3R21H4TLexrk6bfRTufRGDRn9XX8q6/wCEOsrr3wi8OXituZLJbd+ed0X7s5+pTP40AdnRRRQAVzHxGsvEeo/D7VbXwVc/ZtakiAt3D7GI3DcqufusV3ANxgkcj7w6eigDhfg/pfjLSPAaW3xCupLjUvtEjRiacTyxxEjCvICdxzuI5OAyjPGB3VFFABXjmp+GrrV9X8WfDxUkisrhm12zmUlUXzUYCPPbF0PMH+6fpXsdFAHmOk6lrfib4W6z4o063mi1280j7LaIAQ4kiiYNtH97z2lwe4VK5VdKtr3QfE0/hXWNN1N7/wAM3EM2laDpjQnzcZje4UzyMLg73XDDe3zZ+7XvFFAHh/2fQrlIr3wLemK1fw3dJrt/pZadtxRPJMmD+8uAxkIBPmY3AkZFZOq3umr8MfFMNy+k232e5s1iuNEvmTTp38wsIooyR5bqmWkhywyd/UmvoaigDxPWIrG38ceOLnw5a2ja5qGh2t3o01nArTzBkuPOlhZMElgBllIydgzkrWn4Ks/D0epanew+IPDt/oVzpWNRs9N08W9nFhgfMuQ80m2RlZwQwBIU7vu16zRQBg63daXZfD69nt57S30xNObyJEdVhWMx4TaR8u3BAGOOmK8h8ML4VSb4c20E+mTz6x4dmttRSWdJHuiYogkUm4ncBJG6Kp4XYVAG3A98ooA+ddD07wcnhP4a3l5pek+XDdtb6tNJZIQZjay4jlO35n3qvynJ3BeM4qeW00Q6T4rtbCbf4xXxFKNEE08kl2rh49rRbyW28Hew42qd5+Xj6DrmvB3hrUPDf9rf2hqdtf8A9pX73w8iya38t3+8OZHyOBjpjnrngA4XT54bf4xQlDZ373Wp3GTCzQ6jCwSdCZ4+RPbKBtSTK7MhR3U9vAdFu7iw07wydP8AsX2qS8ulsNnllojyDs4D+c0ZPf5WzXUUUAeWfE28tT8KfEWpXt3DANSuYobV3kCExxyqFVSTznbJIMdmJrntYvbDTfEXivTfAd7aqbjR9PuWSymMzzfv2M8uEcPJIYG3MQ29gVO7JBr3SigDwmWPRNK8Oa7cWmt6XqWiahNYLPbaBCthptvIZlTMz+ZMEV12iUbeUAyMkVkya1oth8PfHGmLq+ixx/27ZyWkFi6wwbGNu5MKFj8nyucjg7WYYHA+jKKAPCfEjeFdL1L4o3DrpVtdahogmsJwkYaZZrWQM6MByHkwCwOGdlHJYZjl1bwroGp2/wBh1bTLdNS8GXAupWvULXM37vyt7Fsu/wDrAucnGQOBge9UUAeC+CPEHh2XTYR4rfT4dfh8PQto19BJFITarE6Yt3IDLOriVXQnO4Hb8uQGW15YaZ4Y8U2F3DZz2ogsoJbrQblre1KG5kTZcRurfZZCGzOvzZVmyM9ffaKAPI/hhr2gaPrHjG2bWNAtLFb23ngjsZUgtFV4I1JjBbBG/ClhgMwyAM7Ri+OrrTj428R2d3eWMesPcWY0/VrnVIbJ9Jj2RmSMF5FmVdpZswqwcyspIIbHu1cx/YHiO21C+bTPElulne3BnZbrTfOnh3KFKxyCVVwAvy743x33AYoA4HXmtNM+JkRjktb8C9soBDLPImpxhRAV8mRi32m3APmSI2MNucnOGrA8O+IfDVx4hul8YyaNeeGZPEOpPYXEk0MsSXTzSMGnDA4VoyTGwO3qWydhX36ztYbCxgtLVNkFvGsUaj+FVGAPyFTUAcF4/wBZ0+70ixeO+gu9GtdZii14QSiRI4NrZSYKThN5i3qeNpO4bc1zmpR+G9N0/TP7ImW78Bya88mqeWyS2MQeE7EXb8otxOUZgcqGJyeMD2CigD588QJolrbv9l1RbPwo3ivTn0kw35gt1Xchu2gKsB5SsSdy/KjbyCCDUXiVfCFpY/E62sZ9Li/s3yZdMt4rhAttceSiu8SA4WTzFCllG7ORnkivoiigDA0C8i1y+m1i2uIrq1WGO3tZomDK2QHkdWHBDFkXjvFW/RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQX04tdPuLhjtEUTOT6YBNfPf7JMJWw8Uz44eW1TPrtEp/9mr1r4tayug/CXxHes21jZPAh/wBuX92v6uD+FcZ+zBo7af8ACmS+kXB1K/klQ+qKFjH/AI8j0AeyUUUUAFFFFABRRRQBkeLNAi8U+ENU0OchVvrV4Qx/gYj5W/A4P4V4n+y/4ilto9c8E6oTFd2M5uIYnPzDnZKv/AWCn/gRr6Dr5o+L+mXvws+MemfEbQ4C1jezZuo14Uy4xIh9N6ZIP97ce1AH0vRVLRtYstf0Sz1bS5hNZ3kSyxOO4I7+hHQjsRV2gArH8WeKNN8GeF7zXtaeRbS0UFhEu53JIVVUdySQOSB3JAya2Ko61ouneItFudJ1u0jvLG6TZNDJnDDORyOQQQCCMEEAjkUAZPgTx3o/xD8Of2zoBnWFZmhlhuUCyROMHDAEjkFSME8H1yB0lZPhrwvovg/RU0nw3YJY2SOz+WrMxZmOSzMxLMe2STwAOgArWoAq6nFLNpdxHbXc1lKUO24gVC8Z65AdWX8wa8p8A+N9U1XWPCUMXigeJTq2nPNrNt5cBOluIgwbMKLsBc7NsmTzx0Ner6jDdXGnTxafPDb3LoVjlnhMqKfUoGUn/voVmeENCvPDPg+w0S6v4L17CBbeGeO2MIKKoVdyl2yeOSCM+goAzdd1fUr3x1Z+EtIvG0zzLB9Ru76ONHlWNZFRUjDhkBLE5LK2ADgZIIZoWs6jYePrzwfrF4+pldPXU7S+kjRJTGZDG0cgQKpYMAQVVcg8jIybWo+Fb+9vtN1q31S3tPEVjC0DXaWbG3uInILRvCZN23KhhiTIYA5IyDY0Pw1JYaxd65rF8uo6zdxJbvPHB5MUUKMzLHHHuYqMsScsxJPUDAABy/iPVdQsviNLp8vibxFa2EunJdRw6VpMd4Y3MjIR8trIwXC5+buTz2Fzwt43un+HujX+tBdX1a/le3t4tLMRe8Ks+Gxv8tG8tC7guApDDg4Wr974b8Rt4zn17S9d0u3ElotokFxpMk21AxfJZbhMtuY84AxgY7nPtfhpLYaRZGy1xxr1rqkuqnUpbYNHLPNuEytCGGI2ViNqsCDg7uDkAnn+KOk2tjbXtzp+ow2z3rWF5NMIY002deqXBaQBRyMMNynIweRnpNB1dtd0aDUW0290wTjctvfKiyhexIVmAz6E59QK51/AU09s1rd6jbXFrf3Ut5rMDWbBb6RkVFC4lHlooVflO/O0ZPUnX8I6Pqug+HodN1vWU1mW3JWK6FsYW8v+FWy7liOm7OSAM5OWIBk6Fq93c+Mri21m81fTrqQSyWuk3UFuLeaBWCiSORFZmIBUspk3KW5UDFJ4d1e9vPEl3Bq13q1hqJSSWDRb6G3WAw7gFkjkjQs4G5Q2ZCQScqAVrWsdG1R9Vj1DxBqVney2yOtotnYtbrHvxuZt0shY4AAwVABbg5BDbTQdRnvftniPUrW8uI4JLe3NjZtarEsm3ecNLISx2Lg5AGOnNAHJ/DnxRrOtaldJqGpzX8tnZf8AE2sJ4IYpLG+38RQhFBeIgSYZmcHamGzuxNb+L7rSdE8R6nrN1qv9raZYPey6FqENukcIIZk8p4k/eR5Xbu8x8Y+bDcVo+HvAt5ol3Z3E2r21zJpeltpWmMlgYikRKEGfEh80jykwF8sff4ywI0F8Ky6nBqA8W3dtqUt9ZtYN9ktWto0gbO4BWkkbcSeW3Y+VcAYJYAraJeavpvi2HQdb1J9Te80xr8SvDHH5MkciJKi7AP3f71CobLDDZZsjHU3EbTW0sUc0lu7oVWaMKWjJH3huBGR15BHqDXKx+H9Z0tbvV31CPV9YhsfsdhssVQJGDuIKNMod2IXcfMRflXAXnO1qFrrN94dWKy1GLSdVZYma4W3FxGjAqXXYxG5SAy9QcHIINAHC6D8Qo/D/AIFstR8X6zNqV9qF3dRwJPJZ2xKxTNGQrN5MYACqTubJLcdgNHVfiBZaz4La48Nf2pO97pbXomsI4/NsovmHmOHOMhlYbVDudrbVOKt/8IHNZWOhnQtVSz1HRzOVnmtfOhnE53TK0YdTgthhhwRgcnnLL/wNqct9Le6d4iFvdX2ntYak1xZ+esyl2dXjHmKY2UyyBQS6gMAQduaAMrVfFc8fwsS1s31afVf+EdjvLi8sdjSWgaI7ZXaQ5O5kf7oZ/lYgDANbJ8aroul6X/aGlatc27wWa3GpxxoYYnmIRdxZw7ncQWKK2NwzWcfhpqNtpzWml+KDH9r0dNJ1B7qwWUzKgZUkjCsgjcLI687gRtyCRkwax8LNS1RLaJvEsNxHaw2qwnUdOM7QSQMG8yIJLGiFsAMQm4rkbsGgBuh+MJdF8U+JrLVzq+o2/wDwkMVrHduEMNkJooFijySvy73IxGrFer43Bm73VbW+vbZYNP1BtOLP+9uYo0eVVweEDqyAk45ZWGM8ZII4m4+HOuzQaqn/AAkthu1HV7bVS76Q5KND5eFIE4znyY8nj+PA+Yber8S6Xq+r6SLPR9Wg013YefLLaNN5id0G2VCuehIOQCcEHBABzUureJo/hHrmoLqMK6nYJem11GS1D/aIoS+yXywVUMyrkHG3OG2lTg6er6pq48E6fc2EGoz3FxFE91cabHC88CbNzukcvysSQF2gMfmyFOMVLfeHdZ1HwPqWh3Or2C3N9C9us8OmMkMELIEKrF5uc43EEvwT0wNtWI9M8Q2fh3T7HT9X0xLu2jEctxPpkkkcqgYG2MTqVOMZyzfhQBUj14DwhaSaJqcms3d5DI9rdXcaqxC/ekkREQAJkArtU52qcMc1m6d4q1Sf4T6PfpKlxr1/o63RlkQBVIiDPMyrgYBI+UYySo4BJGvL4B8O3ejxWWqaTY6nJEsu24vrSOVw8jF5HGR8u52LYGB6VnWXwr8NQeCbHQb3SdKvZrOx+ypey6bGW3lcNKAckEt8x569+9AG94RvrjVPBOh399J5tzdadbzTSbQu52jVmOBwMkngVzfj7xHdeH9Y01r3U7zRNAkifz9UtbRJ1S43oI0mLI+yMgtyAMkj5lxzp+H9FvfCsGhaBpUFsdItLLy7qZLZYt0qgDeMSZDO2WI2MDliXBwGu6tpetXGoi80XWobP9z5L2t5Zm5gYZJL7VkQh+gB3YxuyDkFQDPk8U3OjeGbG7ubS68SyS20lzJdaJFH5JjUBjIC8iqAQw2qGZjzjdgmmy/EOwj+2+Vpuozra6VHq6tGsQFxbvnlN0gIIw2Q237pxnjORefCtn8N6Xolhq0CWFnFcJPZ3dk0ttcPM4ff5KSxqCjbtitvVMggZUNT5fhtqh0+GC38RwRTNof9iXczabu8yEFtjRr5oCMAxHO8GgCt8SvGTt8P9aXw/wD2vDcxaYLqS+sRGv2LehaMOzHdlsc+WGKg5JQENXW2etafdeOtT0mFL4ahY2cDzNIXW3ZHZyuxSdpbg5dV9FLHbheWv/hfqM2j6nplh4pMVvrFhHaX7XWnrK7ukfliRCroEyoUFcMMLxg810Gl+F9RsPHF1rtxrMd5DcafBZGJ7PbMfKLESNIrhSxaRyQI1HIwBjkAPHN7rkWhvaeEJYo9bmjeWAyRiTCxrub5T13HZH7GUHtUd38QNMs/BmkeJGt7y5ttWNslvFaQ+a4afAUN0C4JwSSOeOpAL7rwZb614hub7xVb6PrVn5ax2Vrc6WHa1AJJw7uwJbPOFXOF9K56L4Z65b+FxoNv4k06Oyh1SPUbNBo74tgs3nCED7Rym8LjuBkdxtAN/UPHH9ktA2peHNat4HaBJ7ho4THatNJ5aK5Ep3HOCfL3gBhn0rndF8YS6F4i8WQ61/bGo2UOuLF9uZUeGxSSGHYhGVITcx+4rY6vjO43vF/w71DxTqzXY1u1ji/cPDDeWD3H2WSJ9++LEyKhYgBjtLEZG7B4sS+ALia/v1fWVbStVu4b3ULZrT99NLGqDCyhwERvKTK7CcbgGGQQAWrfxZZNca++l6ZrV/dWOox2U9sikmSXYnMSyuFSMKwJY7FOC3O4Ftfw7r9v4k0n7fbQXFttmlt5YLlVEkUkbsjq20kZDKehI965e48AazNNr0kfiSCH+19RivdkdjIihURY/JkKzhnRkRc4KZIOflO2tjwP4Vm8IaNPp0l5a3ET3UtxFHaWX2aKASOXKKm9+AWIHOAoUYyCSAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVS1jVrLQdFu9V1SYQWdnE0ssh7KB+p7AdzQB4V+1D4jkmtdE8F6YTJd384uZokPzEA7Il/wCBMWP/AAAV7T4Q8Px+FfBulaHCQwsbZImYfxsB8zfi2T+NeAfCPTr34rfGbUviJrUJWwsJc2sbcqJMYiQeuxcMSP4tp719MUAFFFFABRRRQAUUUUAFYvi7wtp3jTwteaFq6Zt7pMB1+9E45V19wef06GtqigD5h+GvjLUfgr42uvAXjssmkyzbre6OdkJY8SKf+eb9/wC6fT5q+nVZXUMhDKwyCDkEVxfxN+GWlfErw/8AZL3/AEa/t8tZ3qrlomPY+qHjI/HrXi3g34leJPgrrQ8HfEq0nm0lDi2uVy5hTPDRn/lpH7dV/DbQB9PUVS0jWdN1/TItR0W9hvrOYZSaBwyn29j6g8irtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVS1bWNO0HTJdR1m9hsrSEZeadwqj29z6DqaALjMqKWchVUZJJwAK+Yvib4z1H4z+NrXwB4DJl0uKbNzdLnZMVPMjEf8sk7f3j0z8tHjP4m+JPjPrJ8G/DS0ni0uQ7bm5bKNMmcFpD/AMs4vbq3Tvtr2j4Y/DHSvhroH2Wzxc6hcANeXrLhpWHYeijsPxPNAG34P8Kaf4K8K2ehaQuILZMF2HzSueWdvcnn9OgrboooAKKKKACiiigAooooAKKKKACsXxV4Q0TxpozaZ4jsUu7c8oTw8Tf3kYcqfp+ORW1RQB8z6l8IviH8KtUm1b4WarPqFgfme0GDKQOzxH5ZPqvzegFavhz9qGKCYWHxA0C40+7jO2Wa0UkA/wC1E+GX82+lfQdY3iDwj4e8VQCLxFo9nqAAwrTxAun+63VfwNAGPo3xb8B69GrWHinT1ZukdzL9nf6bZNpP4V1Vve2t2oa0uYZ1PQxyBgfyryLWP2YfAuoSNJp0mpaUT0SC4EiD8JAx/wDHq5ef9ki2Zj9m8YyxjsJNOD/ykFAH0ZRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0lRXzb/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AH0lRXzb/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AH0ZcXtraKWurmGBRyTJIFA/OuU1n4teA9BQnUPFOnlh1jtpftD/AE2x7iPxrySD9ki2Vh9p8YyyDuI9OCfzkNdRo/7MHgXT5Fk1GXUtVI6pPcCND+EYVv8Ax6gDB8R/tQwzTGw8AaBcajdyHbFNdKQC3+zEuWb8Sv0rJ074R/ET4ranDq3xS1WfTrBTuS0OBKAeyRD5Y/TLfN6g17/4f8IeHvCsBi8O6PZ6eCMM0MQDv/vN1b8TWzQBieFPB+h+CtGXTPDlilpAOXYcvK3952PLH/IwK26KKACiiigAooooAKKKKACiiigAooooAKKKiubqCytZLm8njt4IlLSSyuFVB6kngCgCWivFvFv7TfhXRJpLXw9az69cIceZG3lQZ9nIJP4Lg+tcmvxX+Nfir5/DPhD7JbP/AKuVbByP+/kp2n8qAPpWivm3zv2mp/njj8sf3dunD/0Lmj/jJ3/P9mUAfSVFfNv/ABk7/n+zKP8AjJ3/AD/ZlAH0lRXzb/xk7/n+zKP+Mnf8/wBmUAfSVFfNv/GTv+f7Mo/4yd/z/ZlAH0lRXzb/AMZO/wCf7Mo/4yd/z/ZlAH0lRXzb/wAZO/5/syj/AIyd/wA/2ZQB9JUV82/8ZO/5/syj/jJ3/P8AZlAH0lRXzb/xk7/n+zKP+Mnf8/2ZQB9JUV82/wDGTv8An+zKP+Mnf8/2ZQB9JUV82/8AGTv+f7Mo/wCMnf8AP9mUAfSVFfNv/GTv+f7Mo/4yd/z/AGZQB9JUV82/8ZO/5/syj/jJ3/P9mUAfSVFfNv8Axk7/AJ/syj/jJ3/P9mUAfSVFfNv/ABk7/n+zKP8AjJ3/AD/ZlAH0lRXzb/xk7/n+zKP+Mnf8/wBmUAfSVFfNv/GTv+f7Mo/4yd/z/ZlAH0lRXzb/AMZO/wCf7Mo/4yd/z/ZlAH0lRXzb/wAZO/5/syj/AIyd/wA/2ZQB9JUV82/8ZO/5/syj/jJ3/P8AZlAH0lRXzb/xk7/n+zKP+Mnf8/2ZQB9JUV82/wDGTv8An+zKP+Mnf8/2ZQB9JUV82/8AGTv+f7Mo/wCMnf8AP9mUAfSVFfNv/GTv+f7Mo/4yd/z/AGZQB9JUV82/8ZO/5/syj/jJ3/P9mUAfSVFfNv8Axk7/AJ/syj/jJ3/P9mUAfSVFfNv/ABk7/n+zKP8AjJ3/AD/ZlAH0lRXzb/xk7/n+zKP+Mnf8/wBmUAfSVFfNv/GTv+f7Mo/4yd/z/ZlAH0lRXzb/AMZO/wCf7Mo/4yd/z/ZlAH0lRXzb/wAZO/5/syj/AIyd/wA/2ZQB9JUV82/8ZO/5/syj/jJ3/P8AZlAH0lRXzb/xk7/n+zKP+Mnf8/2ZQB9JUV82/wDGTv8An+zKP+Mnf8/2ZQB9JUV82/8AGTv+f7Mo/wCMnf8AP9mUAfSVFfNv/GTv+f7Mo/4yd/z/AGZQB9JUV82/8ZO/5/syj/jJ3/P9mUAfSVFfNv8Axk7/AJ/syj/jJ3/P9mUAfSVFfNpv/wBpax+ee1NwBzgRWL5/745pg+PfxJ8JSAeOvBQMAP8ArDby2pb6OdyH8BQB9K0V5p4J+PPg3xnNHafan0nUHwFtr/CBz6I+dp+nBPpXpdABRRRQAUUUUAFFFFABRRRQAUUVkeKvEth4Q8MXuu6u5W1s49zBfvOeiqPckgD60AZnj/4iaH8OtD+363NumkyLazjP7y4YdgOwGRljwPqQD4BYaL8QP2idUfUdWvG0fwxHJ+6TB8oYPSNOPMYd3PHXn+GpfAvhbVfjz8QLjxn40Rl0C1k2RWwYhZMcrAn+yM5Zu5PqTj6gtraCztYra0hjgghUJHFGoVUUcAADgCgDjvBXwk8I+BYIzpWmJPeryb+7USTE+oJGF+igV2tFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjoskbJIodGGGVhkEelLRQB5R49/Z88KeLke50mJdA1MjIltIwInP+3EMD8VwfXNea6H478a/AnxJH4d8fxz6noMnEEwYybUH8ULnqB3jOMcdO/1DWP4o8LaR4x0GfSNftFubaUcZHzRtjh0P8LD1/pQBZ0XW9O8RaPb6rot3HeWVwu6OaM8H1HsQeCDyDV+vlnwrrer/s9/EuXwz4ld5/DWoSB0nA+UKThZ1HYjo6+3fAz9SqyuoZCGVhkEHIIoAWiiigAooooAKKKKACvm749a1f8Ajr4j6P8ADLw+33Jke5PYysuQT/spGSx/3j6V9HySLFE8kh2oilmJ7AV82fs9QN4v+LHivxteqWZSxi3fwNO7Hj6IhX6GgD6C8OaDZeF/DdjomlpstbKERJ6t6sfcnJPuTWnRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef/ABE+IHiPwMlzf2vgr+1dEtYVkm1H+1Y4NpJxt8sqWOCRyPWvQK4D45f8kT8Sf9cE/wDRqUAYp+MHiOystGvde8A/2daa1fWtpaS/2zHLvEwY78KmRgAHBxnPUYrr/FfjX/hGPEvhjSf7P+1f29dtbeb52zyMAHdjad3XpkV5l8UbX7b8K/hla+fNb+fqWmx+dbvskj3QEblbswzkH1qPxR4K/wCET+KHw8k/4SbxFrf2jVHXbrN/9oEWAvKDaME55+goA77RPipaajo/i/VNR06SytfC97PbS+XL5zTiLPzAbVwTjpn8azfDXxfv9T13QrLxL4Qn0G28RwmXSbwXyXKz4UOAwVQUyrDrzkjjuOZ+H7vH4c+K7x6L/bxGu3m7TN203S5O5BhWOSM4ABJPA61zHgrVtOsPHXhm2+EWs65JFfXRbWvDd4Hkt9PhZlMhBZQAU6BvmY4GW5wwB7f8S/HP/Cu/Bkuv/wBnf2j5c0cXkef5Wdxxndtbp9Kp+MviHeaB4o0/wz4b8OSeIdbvLdrr7MLtLVI4VJG4yOCCcg8e30zz37Sv/JGbn/r8g/8AQqofGd/CreL9Hj8eafqOk2ccPmWXizTZnEkE4bd5BVY25+XcDyRngD5iAD0LwD42t/HnhttTgs5bGeC4e0vLSY5aCdMbk3fxD5hzgdeg6Vm/Ez4k/wDCvrXTls9IfWtQv3k8uyjn8pvLjQvI+drZxxxjnPtg5fwL1bXNW8I376xfXeqafDfyRaTqV7GUlu7cYw5zyRnPJyc5GeMDk9Q/4Snxv8edW1TwVHok0XhW3GmKda80wmSQP5pURjlh86H2x60AeyeF9ftvFXhXTdcshthv7dJgmcmMkcoT6qcg+4riPF3xki8I/FHTfCNzoxmgvVgaTUBc7RAJJCmSmw5AIHO4dayfgNNf+HZfEPw817yUvtEuRcQrCzGMwyjd8hbkqCc5PP7wVzvxN8PnxR8bNb0uIE3D+DzLb7c586ObzI8Ecj5lA/GgDuPFnxjh8NfFPSPBkGjG+e/mtoZ7sXWwWzTSbVG3YdxC/NjIz+tVNP8Aix4w1++1aPwv8N/7UtdMv5bGS4/t2GHc6H+66A8gg9+vWvK9Pa91weEPG2sKBfeIvG9mcjoYoMRIPwIcVH4f1PwfZa54sj8UfELxP4Xujr900dro9xNHHIm777BImG7OR16AcUAex+IPif4k0BPC9nL4F8zXvEDXKDS/7XjHkGIrj97sKNuVg3bHTk1c8P8AxLv7jxjB4Y8a+FZ/DGpXsLTWG68S6huQudyiRAAHGM7eeOuMjPnHinxZ4Z0/WvhPrsHiG91LQ7ObUFfVL9ZZJpMCNSXygZjuOPu1u3HiTT/iv8XvB83goz32m+HWnu7/AFE28kcUZcALF86g7zs6ehyM4bABvab8atOn+Hd14r1XTZrRYtSbToLK3k8+W5lGNoTheTknHYKetP0z4neIY/E2k6T4x+H99oa6wxis7iC8S9BkABIkVFBQBckk9ACSMBiPJfDukaldfCHT9a0qxm1FvD/jNtRns4F3SSxIV3bV7kccehJ7V6zp3xw8PeIvEulaN4Ntb7X5bxibx4IGjFhEAP3j7wARuZQcHHXknarADvib8XB8PdTtLC10OTWp5LV7y6WO48o20CsFDn5WyCd3p92r/wAQ/iXF4I8D2HiWw07+2Yb+eKKGNJ/K3LIjOrA7Wzwo4x3ry2x0/wAW/Erxl408TeFIvD02l3u/QkbWTPzAqqGMXljgNw2T3NYF/q91J8E9M8Maucap4Y8WQafOuc5QeaUP06qPZKAPXtf+NFlovwl0jxrBphvH1XYsdgtxtKvtYyDftPCbGBO3sOmaov8AGbWby98P2PhzwT/at7rWkLqgg/tZIPKUsyldzphsbc5469K81vNBv4vEPjLwzcIRo3hDTdX1GxHQf6VB+7THfaGcg+oNZ8t1o1prXw/l8R+ItU8OWX/CIxg32lSOkwbzJMLlFY4PfigD3Q+PPFem+F9d1rxV4E/saPS7Q3EKf2xFcfaSM5XKL8nbkg9azx8brCf4MT+PbDTfPktZEhudMNztaKQyKm0vtPGGDA7eQR0OccgdZ8JXfws8dWvhbxz4g8VTNpZklXWpZZPs6ruGULxoBktzjOcD0rg/H/he/wDCvwq0jWtBXGi+J9F06LVoAPljuUSORJuOm7aRn1LZ5YYAPefG3xD8SeFdOGrWHgj+1dGjskuri+/taODySc5TyypZsDHIHOfar/gHxf4j8XW6XuseD/7C065tY7mzuv7TjuftAcAqNiqGX5Tnn6VQ+JX/ACb/AKv/ANghf5LW98OP+SWeFP8AsC2f/ohKAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPOvjb4AHj34fTx2kW/VdPzc2RA5YgfNH/wIDH1C+lYv7OXjp/FPgE6RfuWv9DKwFmPLwEHyz+GCv/AR616/XzR4MT/hAv2t9V0OIeXZaqZVRB90CRBOmPoRtFAH0vRRRQAUUUUAFFFFAGF44uWs/h74iuUO1odLuZAR2IiY/wBK8n/ZRtVT4f6xdAfNLqhjJ9QsSH/2c16j8R/+SWeK/wDsC3n/AKIevNv2VP8Aklmpf9hqX/0RBQB7bRRRQAUUVwviPxTqejfE7SbNJl/saSyL3sJjBILzxwpIG6ja0i55xt3EjuADuqK4e78U6jJ8XdM0SymRdKWOeK6UIC0twsSybckcBVeM8YyXOegq9Z+P7G8ks5Rp2oxaXfzi3stVkjj+z3DkkJgBzIoYghWZFU8YPzLkA6qivO/FfxDuI9PRvD9lqMcB1i2sF1fyYmtpT9pSOZFBYvjHmJvKBcj5W5UnXXxrZWpv0VdT1G7GsNpsFkscPmSSiJZCkWCq+WqZbdIwIw2T0FAHW0Vzv/CWudPjlTw5rbXr3DW507yIxKjKNxYuXEOzbghvMwchQd3y1RPxJ09dLS5fStVFy2qNpBsBFG06XIQuFOHKYIAwwYqNwJIGSADsKK4tfiZaBLh59B1qBLG6W01F5I4cWLsVC78SneCHVsx78A5OKval43ttPvb6KDStT1CDTMf2jeWccbRWhKhyGDOruQhDFY1cgEcZIFAHTUVyV/8AEK0ttRvbPT9H1XV5LKyivpWsUhK+TIHKsC8i5PyH5RycjAPOI7Xxncah8RbHSbCylm0a80f+0I71QgDbmG1zlw23Hy4253N0xyADsaK53W/E9hoXiBI9RuryGKPSrrUJVSNGh8qEx73bgybwG4C8EFsgnFT6F4jk1qVo59C1XSj5KTxtepEUlRs/deKR1yMcqSG5BxigDborG1jX5tMvI7Wz0HVdXlaIyv8AYkiVY1zgZeWRFJJzhVJPGSAMZs6Brdp4k8P2Wsad5gtr2FZYxKu11B7MOxB4P070AaFFcZoPxM07Xo9KuU0nVrGw1dhHZX15DGsUshXPl4Vy6nhgCyhSVOGORl1v8SbC50q61IaVqiWcM7WkMrJFm7uBL5QhiQSFixfgEgL3LDBwAdjRXLjx9p0FrqbaxZX+k3WmRxyzWV1GjzOkh2xtH5TOsgZwUG1idwwQKxZfiBd2ni/U/wC1dN1LTdP0vw9LqU9hcRwNI5Rwd6PG7KcqGGN/UcgcGgD0KisS58V6faahptpcCWM6jZz3scpA2RxwiMvvOcg4lXoD0P45bePJZtHnvbTw3rKI1nJdWM08MQjugq5HSTMeQQwEvlkjOOQRQB19Fc34e8SXN78NbLxFqdhcLcNpq3ctugjLykR7jsAcr83VQWHUZwcgLbeOdGu9W0+whkkLahpf9qwzFR5YhONuTnhiNxAx0RueKAOjorzi3+It5deMkGnaTq2padeeH7bUrext4YVkj3yzAyMzuoGVWMBd5Pov3sbUfjrRZru2vRqF1HYTaG+rhmiQQCBWTLtx5gcBvujjGeM4oA62ivPvFXjvUIfAOu31jpGraHe2+mPeWVzfW8TI+PTazqrDIOyQK2M8HDY6HRvFsWraw2mTaXqOmXJtReQC+SMfaId20uux2xglcq+1huHHXAB0FFZGr67Npt3Fa2eianq88iGRlsliVY1BAyzyuiZJPChixwTjAzXGa147v9Yfwf8A8Ivb6vDaa3LK8z20dqJx5cbkw4nYqpDLljjovytnggHpVFeaeEfHWoy6Tc6jrltq93eX2qz2en6XHHac+XLKCsWxhgKi/O0z4ynyk5G7pP8AhPNPXTpJZbG/jv471bBtKaNPtP2hgGRBhjGQUIffv2BcksMHAB09FcJr/j3UrKHSvsXhvVIri51eKyube5SEOqkFvkbzfLYsBwysyjDAlWFa9n40i1DV3tbPRtVms0vZLFtTjijaBZoyQ4Kh/NADKV3FAue+CDQB0lFZmq67baNeaXBdxzFdTuvskcyAFI5CjOofnIDbCAQDyQDjNZk3jvTo45/JtL25mTUm0u3ghRN95Oq5cR5YDauGyzFQNjegyAdNRXLJ4/04Wu66sr+0uk1KDTZ7GdE86CWZ1WNm2uVKHcG3KzDGe4Ipdc8f6X4fbWhe297J/Y0VpLceREHLi4kaNNg3ZJBU5HHGMZ6UAdRRWYdRupvDlxeyWFzplwsMjCC6MTOhAOCfLd07Z6n3rlvA3j99X0Xw1FrdhqEF1qunJImo3EUSQ3cyRK0u0I25c/Ow3IqkKSOMZAO8orlrHx9ZX01k/wDZupQabqMvk2OqTRx/Z7ljnbtAcyKGwdrOig8YPzLkuPHcVpfW8d3oOswWNzfJYRalJFEsLSu+xfkMnmhS3AYx4OQc7SDQB1NFeYyePNes9SjtktJdRS48WzaXujWFTFAsPmBBudPmJBOTn5VfJB2Zs+H/AIiTqdRXXbHUp7aHxBc6aNTSGJbeD/SWihjI3Bz1jXeEYZYZbO7AB6LRRXNeIfGf/CP/AG6Q+H9Zv7XT4PPu7u1jiEcS7SxA8yRC5CjJ2BsZx14oA6WiuTvviDa2+p3Fhp2jatq81vYxag/2KOIL5Em/DZkkTn5Pu/eORgHBxNN45smFiNG0/UNbkvbFdRSOxRAUtmxtkYyugGc8KCWODgcHAB01Fcz8O9au/EPgLT9U1CYzz3BlJkMYQkCV1X5QBj5QB0rA0z4gXN14g8N2dpa391pWo6fdXct7dJAsuY5FXJCMAAu45Crk7kxn5sAHotFc74f8YR+Intng0bVbazvYDc2d9PFGYbiPjByjsUJDAgSBCRnjIIFnW/EkWj3lnYxWN5qeoXgdobOyEe8omN7kyOiKo3KMlhksAM0AbNFcxJ43h/0KC00XVrvUruN5TpiRRxz26IdrNJ5rqigNgA7juyCu5eagb4jaY8OjnT7DUr+fVzOkFrBEiypJD/rY5BI6hGU5BycZU89MgHXUVyg+IFjJYWclvpuozX15eTWMemKkSziaIMZFJZxGNqoxzvwRjBORVyDxdbSXGj21xp+o2dzq000McNzCEaF4lZm3/NjGEOGUsDkEHBzQBv0Vyl78QtNs0mxY6jcyR6udGWGCJGeS48rzBtywG0jA3EjB64AJFZfiZaBLh59B1qBLG6W01F5I4cWLsVC78SneCHVsx78A5OKAO0orkNQ+ItnYavq9iujaxdrohQ6jdW8MZit0aNJA/LhnG18kIGYbT8v3c5eq/EC4g8QeIrd7e8i0bTtBTUo9QslgaQhhIfMUO5ByEAUFOqtuGCpIB6HRXK3vju1sprmK20vVdUXT4Y5dQntIoyLQOu8bgzqWbZ8xWMOQCOORlt38QbOPVGsNK0nU9alXT4tS3aesWxreQsFYNJIgJ+T7vU7hgHDYAOsoqnpurWeq6Ha6vZTBrK6t1uYpWG392y7gTnpwe/SsTTPHNtqKx3L6Tqllpc8L3Fvql1CggmjUbt/yuXjBX5h5ipke/FAHT0VzGl+OrTUdQsLafS9T06PVFZtOubyONY7wKu7C7XZkJT5gsioSAeMggVNC+JVhryaRPFo+rWllrWVsLy6jiWOaQIzmPAkLqcI+CyhTtOCQQSAdlRXnOifE65fR0udb0HUftV5rdzpdnb2ywEuyNJtX/W4BAiKsxIG7JB28ja1fx5/Ytpc3d14Z1xrSygWa9uUjg2W2V3MpzKDIUH3jEHUHIBJBAAOsorlr3x3Bb61d6XY6LquqTWdol5O1osIVY3DFeZJEyTsIwBn9cXLHxdp2pXejQWKzznWLFtQgdVG2OEBPmfnjJkUADPOfSgDdorlNb8UX+m/EXQNCh0+SSxv7a5uLi6BjAXy9gHLOCFXflvlycptzhwF074gWGoXVh/xLdStrDVHMen6nPHGLe7bkqFw5ddwBKl0UMBxyQCAdVRRRQAUUUUAFFFFABRRRQAV82fFMfYP2s/B08XyNcmxLEd91w8f8hivpOvm34yf8nTeAv+4d/wClslAH0lRRRQAUUUUAFFFFAHN/Ef8A5JZ4r/7At5/6IevNv2VP+SWal/2Gpf8A0RBXpPxH/wCSWeK/+wLef+iHrzb9lT/klmpf9hqX/wBEQUAe20UUUAZsOg2cGtPqiTagbh85R9SuHhGRjiEuYx+C8Vi6/wCDn1/xNPdXEsa2FzoVxpbgE+arySIwdRjHAUnOcg4+tdZVXVLz+z9JurzdbJ9nhaTddz+TCMDOXkwdi+rYOB2oA43RfBOrWt14bvNWu7W5u7Q302qyIzDzprgD/VjH3R90ZxgAcVneGvho/h+TTLNfDfhCSLTplK609ruvZY0OUPliNQsvC/vPNPILbTnA7a68V+H9PmSDU9d0u0uGKr5U17GpLMAQACQTkEEccgipdS8R6Jo91Ba6vrGn2Fxcf6mK6ukieXnHyhiCeeOKAOGu/BHigaHF4ZsH0j+x7bVor6G7lnlE7QrcifyjGEKhgcgPvO4KPlXcStw+B9XtdVm1mwlspL+HXptTtYJpHWKaGW3WBo3cKSjYBYEKwyBwcnG23jzQYvF2oeHrjULaC506zW8uHmuI1VFO7I5OQVVdzZxgMp71pWPiPRNUmEWmaxp95IzSIEt7pJCWj27xgE8rvTI7blz1FAHLa/4f8V+IrOybUo9KmSO6ka50aPULiC3nhKYVZJ1QtLhhkqYwjBiCDtBOXoHw11XSo4kYaPbRr4oXW/IsQ0cUURtvLMSLsHIboeAw5+UnbXf3Gv6PaadPqF1q1jBZW8phmuZLlFjikDbCjMTgMG+XB5zxWTefEDw7aanoNmuqWc412R0tZ4rqMxkKp5zu5ywCDGcscdaAMjU/A2p3uieM7OKe0EmvX6XNsWdsIqxwKQ/y8HMTdM9R+FXVfh07eI9Yvrbw74V1tdVkWdLjW4cy2cmwIRgRP5sfyqwXdGclhnnI68eJtMtdDXU9a1TSbG2M7w+eL9Wg3K7KF8xgo3fKcrjhgw5xkzz+ItFtbC3vrnWLCG0ukLwXEl0ixyqFLllYnDDaC2R2BPSgDEsfCl3Z65r90Gs1g1HS7Syt44FMYRoVmDfJghU/ergAngH05peG/CGr6BqfhmdjZTxWHh6PSL3EzqyugQ74xsO8ErjBKYHPPSumPiXQhoQ1s61p40k8C/8AtSeQfm2/6zO373y9evFW7DUbLVbGO90u8gvbSXJjntpVkjfBwcMpIPII/CgDA1rw5qF/4xttYspLJY4dIu7LbdI0gMkrxMpZBjcn7s5G4Hkfhl+DPBl9oXiWfUfsOm6BZS25WTS9HvZpra4nYp++8tkjSIqsYUBFJbecnjno38TaZY2Vzd61qmlWNtDdtbec1+uwMOiuzBQsnXKc49TWnaXdvf2cV1Y3EVzbTKHimhcOkinoQw4I9xQBxni3wlqmueJY7sWum6xpgtVjTT9WupVt7eYM+ZjCqMk5KuOH2kbOGGcjV8AeHrrwp4D0vQ9QkhluLKNo2kgJ2MN7EEZAxwRxjg8c9ai1/wAe6Ro17b6fb3llfalJf2tnLYpeIJoFmlSPzGQZbA8wHBAzkcjNac/irw9a6yukXOu6ZDqbMqLZSXkazFmxtAQndk5GBjnNAHnHw10bxBrfw78Fxaj/AGdDpFgsN8k0ErtPcbATHGYygVACRlg7Z2dBu46CHwLqUPgC20yO5tV1XT9Vl1S0clmgd/tUkyI/AYAq+0kDKk5G7GD09x4q8PWmoJYXeu6ZBePN5C28l5GsjSYU7ApOS3zpx1+Yeop+peI9E0e6httX1jT7Ce4GYYrq6SJpO3yhiCfwoA5DUvA+s+JptV1PWZbCw1KaG1hsIbWR7iGH7PN56tI7LGXLSHBAUYUdSTmluPCHiHxJrWrXXiM6ZYW9/oE2jrFYzyXDRmRsmQsyR56njAxgcnOR1moeJ9A0i1trrVdc02xt7obreW5u440mGAcoWIDcEHj1FP1DxDoukSRR6rq9hYvNjylublIzJk4GAxGefSgDi28GeI9evtN/4SYaXaWlro15pcqWFzJM7mdIlMilo1x9w/Kc4wOWzxr6dpnix9JXRdVGjQ2UVk9q11bySyy3J2bEbyyqiL+8Ruk9Af4q3V8RaI+uNoqaxYNqqjLWIukM4+XdzHnd056dOalbV9NS1nuX1C1WC3lMM0pnULFICBsY5wGyQMHnJFAFHwfp9/pHg3StM1dLZLqxtY7ZvsszSowRQoYFkU8gZxjjOMnrXn8nwk1Y+FL7ToNStYbw33l2NwhYeVp3lvCImO3O8RTTEAfLuK+ma9Im8R6JbazHpFxrGnxanLjy7J7pFmfPTCE7jnHpVPxp4stPBfha41i9MJ2FY4YppxCJZGOAu45x3JwCQATg4oAjsvDctj4+n1iHyI9PbR7fT4YVJ3o0UsrdMY27ZFA5zweK4+x+FN8/h6y0jVb22SJPC0uizyW7MxWVpEYOoKjKjaeuD7d67WDxdo8dtpv9r6zotpeajGr28MepI6z7jhTEzBTIDkYIUZq5deIdGstSj0691ewt76VkWO2luUSVy5IQBSckkqceuD6UAcr4g0Xxp4q8HatomopoVmbrT3t0eG4ml86ZsAOSY18pRg/KBITnqMc7s2hXMnxGs9fV4vssGlT2TISfMLvNC4IGMYxG2ec5I4rY+22ovxYm5h+1mIzC38weYYwcF9vXbkgZ6ZNUrrxLoVjpi6je61p1vYtKYVuprtEiMgJBQOTjcCrAjOcqfSgDnfGPhXU9c8QW11Ha6drGmpbGM6Zql5LFbpNuyJmiRHWfg42uBgqCCCcih4W+H+qaFY+Dra5nsX/sC5vZJzBuVZEmEoTYu3g/vFypOBzgnv3UeqafMLMxX1tIL9N9oVmU/aF27tyc/MNvORnjmpLe8trvzfstxFP5Mhil8tw3luOqtjoRkcHnmgDzqb4Z3UmgaelxbaPql3p+rXt6tlqCl7W5iuJpGKMSjFHCurBgrYZcYIORaTwJexWFpdafpXhzRdQ0/VF1C3sdNiaO3kAjaJo5ZQgLFldsOIxtO35Wwc+g0UAcXrWj+K9csbO4uItGjvbDVYb63so7mXyyiKQVecx5JJYkERADgc/erPvPA2q3fjSHVobLRtLmjvRLJrWm3E0FzcWwdXMMsCrslLbFQs8jDGWCg/LXolFAHIfFKW0h+Ht/JcXMVvdx7ZtN3thpLyM+bAiDqzF0A2ryRmqNv4H1Kw8L+F20+S2bXNDnN5KtyxWK6llR1uAzKGK7jK5DANg44IrvaKAPPrvwRrepW2papdyafFrl1qNlfQ20cjvbRi0dWjjMhUMd2G3PsGN3CnbzXv8AwR4l1ubxLd6i2lW02sLpiwQQXEkiwi1nZ3DOY1LZByCFHJ2kcbj6TRQBXv4GutNubeMgPLC6KW6AkEc1x9p4IvotM8BWs81sf+Edg8q92u37z/Qntz5fy8/MwPOOPfiu4ooA808MfDaTQJNKtf8AhG/B7Jpsi/8AE6+y7rydEzsPl+WuyX7uZPNbkE7ecDOvfhhr1/eW811Dotze2urR3x1q7upp7qeJLnzFhVWjxbLsJ+VGZcjG0biw9cooA8+n8EazHKt1aPYyzw+KX1qOKWZ41eJoWi2FgjFW+fPQjjGeciSfwNqcngnVNHWe0+0XniBtTjYu2wRG/W4wTtzu2AjGMZ745rvaKAKFhqMl5qOp2zwoi2M6xK6SFt+YkfkFRtI39ATxg55wOC8ZfD3WPEuo65vh0rUbfUIPKsJ9UuZX/srMSq3l22wxltylhIGVhu7gYPplFAHGeH/COo6ZqV5dXclqRcaHZaeFidmxLCJQ55UfL+8GD1ODkCs7QvBviLwpb6TcaP8A2VeXkWh2+lX0NzcSRR7oclJI3WNiRl3BUqMjByMc+iUUAc/4F0K88NeC7HSdTmhnu7fzDJJBnYxaRnyM8jhun865zQvA+t6HP4Vmjk0+Z9Ks7yzug0rgATSI4dPk+fGzBU7M5+9XodFAHn3hvwPqWmeLbfVfsGj6FGiML1NEuZhFqTbSqlrcqsceCxbOZGzgbsZJ3Nd0TVP+Eo0/xHoC2k93bWs1lLa3szQxyxSMj5Eio5VlaNf4SCCRx1rpaKAOLk0XxVFrln4khXR7rU2tHsryyaaWCERl/MQpLsdiyn5SSgD5zhMYqDRPAuoaZqmg31xd2001tPqF5qBQMoaa6O4iIYPyhiRyQcAHviu7ooA4C48Eag2k6jaT6boGtwXmtXN+1nqe8KY5AQpWQI3lyKT12NxkAjOaisvBGv6XY6Lc2s1pc32k6hPcQ2N1fTvDFBJE0QgW4ZWkO0EEMU5ORgDGPRKKAPO7HwNrvmRXGoz6f558U/23IsDuVWIweX5YJUEsDxkgAgZ4ztE+p+BtTvdE8Z2cU9oJNev0ubYs7YRVjgUh/l4OYm6Z6j8O9ooA8titfEl943+IdjoQ0wW15c20Ek93K6yWpayhBkVFQiX5TwpZOV688W9Z+HmpyJrFno0lm1nqPhmPRY3up3SSJ4xKEYhUIZT5gycgjB4Nej0UAcJL4X8SaXda0PDzaXNBrkcZme9mkRrOVYVhZlVUYSqVRSFJTkHnB4teHvBUvh/W5JIJ45LBNBstJg3E+YTAZRuYYxgh16HrniuxooA5zwx4Zk0z4a6d4Z1WRHkh05bK4e3Y7T8m1ipIB+mR+FZmn+H/ABPJ4dTwrrP9kpo6afJp8t7bSyvcXSeX5aERlVWE4O4/PIMjaOu4dtRQBw9h4Z8RXd/4dTxE2mR2nh1mkjkspZHkvZBE0KMyMiiIbXZioZ8kgZAHMWmeBtTsvCPgXS5Z7Qz+HbuKe7ZXba6rBLGQh25JzIvUDgGu9ooA890/wNrNteaasz2H2bTvEd1qqyLM5eWKYT/KV2AKwMyjG4ggE5HSs/xn8N9a8Tz+II5ItI1AagjLp17qlzK50tTEilIrbYUUlkJ81WVvmyQ23afUqKAOW8P+HrvRfEmqatfy2wgutNsbcBJCSjQCXeSSANv7wYPscgVz/wAKNGjivNc1a2uY7vTPtL2GjSxncgs0keT5G6FfMlZARwREvpXpNFAHMeIvDt7qfi3RNUtfs721pb3dpdRyzNG3lz+Vl0IVgWHln5TjOeoxWNpng7xCtn4c0LVZNNGkeHZopIru3lkNxdiAbYFaIoFj4wWId8lcADPHoFFABRRRQAUUUUAFFFFABRRRQAV82/GT/k6bwF/3Dv8A0tkr6Sr5t+Mn/J03gL/uHf8ApbJQB9JUUUUAFFFFABRRRQBzfxH/AOSWeK/+wLef+iHrzb9lT/klmpf9hqX/ANEQV6T8R/8Aklniv/sC3n/oh682/ZU/5JZqX/Yal/8AREFAHttFFFABXN/EW1uL74ZeJLWygkuLibTLhIoYkLvIxjIChRyST2FdJXP6x4s/szxBBotpoupatezWrXeyzMChI1cISTLKgzlhwM0Acj/YNxJ/wsN5NKlZ77SoIIC1uSbjFoRsXj5sMcYHeqGsWd1aWyz2sWtQapd6NZxXVrJoX9o2OqBEf9xIqqWjbLsrbniHzA8gEj1DSr641C0M13pV3pbhyogu3hZyMD5sxSOuOfXPHSotZ1y20NbE3aSv9uvYrKPygDh5DgE5I4456n2oA808VWOrzP4qWbR7oXWqeDYoIo7S1kliNwguC8QdAVBBdQATk5GM10OsQtoniPwbqpsLx9OsLG6spVsrOS4aBpEhKZjjVnC/uWGQuAcA4zXU6Drtt4hsZrqySZEhu57RhKACXikaNiME8Eqce3pWnQB5Do9pqNmdN1zUtF1AWNt4j1W6ntPsbyTxedJIIZhEoLOBuIygPD5HAJGzeyx3HiXwrrWn6BqVnYrq1357HTXV3aS3dBO8Sguis3G51U9zgEE+i0UAeQ+GrK/8PXXh/WNY0rUZLG3bWIGjhspJpbWWa9aSOUxKpfa0asoZVPDjs2ak0nw/evrHhe6l0e4gsJPEd/qMVtJAR9jhe3lMRkXpETJhsHBDOAcNxXpt1q9nZ6tYabPIRdah5nkIFJ3CNdzEnoMAj8/rU9zPJAsZitZbkvIqMIig2AnBc7mHA6nGT6A0AeYzaS0a67NqFprlosPiw3tjdaVZCWSHNrGvnCIo3mIWeRTtR+WJ4wSOn+HT6q+hXR1m3jVvtjeTdjTTYSX67E3XEluxJR2ffnOMgAhQCK62ueHjXSXl09Lfz51v9Tl0uJ0jwFmiWQvu3EHaDE4yAcnHbmgDhZNKmtlvLy4TxBpd5H4h1CWy1HTdN+1GESJgM8JR2eNx0KoeR95c5Pb+Am1BvCqf2pYw2UnnzGNYbM2glQyEiUwkkxs+SxUnOWOQCcV0lUrzV7Ow1LT7C5kK3OoyPHboFJ3FELtk9B8qmgDyV7S5j8N+GfDk/h7U59Y0zxJa3N1cjTnMIAugz3QmA2MGVsnaxYbjuACtiv4xGv6jpus2UWn6nBKmrLLFpemaGfImjS5Vzcy3LI3msyKrARMrA/KVODj13w/rtt4j0ddSsUljhaaaELMAG3RSvE3QkY3ISOemOnStKgDyjWdAvJfC/wAVvL0q4e61Cdjahbdi9yFtItmzjL4fdjGec96d4hZtHj8d/wBuaTe339tWaNayw2LSxvGtts8p3UFYtkgdv3hUfvMgnnHqtcbqGh+F9c8eX2m3tjeG/ewgu7zy7uWK2uoi8kaLLGkgWUjy2BDqQVwMkcAA4+y069sNQ0zUr2816ysrvw3Y20Fxo+mpfbWQEyROpgmZM71YEAK2DkkqK2fCXh1tN8ZeH3i07U4rOz8NzwxvqUaeZCzXEbCNjH+7VtucKvRRjsa9IVVRQqAKqjAAGABUF/fW+l6bc399J5VtawvNNJtLbUUFmOBycAHgUAeUw6ffN4R0/wAJDRtQXxDba5HcvetZuIF23XnPdC5xsO6PcMBt5L7SvXDddjv7bwz4s8Ppo2rXF/ea59rg8mwleKSF5opN4lAKcDcCud2VPHevWrS5S9soLqHPlzxrIm4YOCMjP51NQB5Vr9teWPiPUR4dtdUlnutSjuZtH1DRRdWF7JtiUTpcqAIcbA2Xk+Voz8nTPV/Eqzub/wCH2oW9jby3M7vAVihQuzYnQnAHPABP4Vu6Tqker2clxDDLCI7ia3Ky7c7opGjY/KSMZU45z64ORV2gDzHVYpNNvvHFnqmhahqkmv7DYNb2L3EdxGbdYlhZwCsWyQOf3hVQH3A9cX/Buh6hpvjq7l1aGSSaLw9pto16yErLKhm80K56nO0n6jNd/RQBwHxVlvtCstP8W6JAZ9Q0x3tVhAB81bkCJV/7/eQfwNV49EPgfXPC089peahpWm6PLpxmtLWS6eG5YxsZjHGC/wC8COC6g4JwcBq7fUdEsNVvLK5v45JXsZfOgTz3WMPwQzRghXIIBUsDtPIwa0KAPJNL0++0WTw/rtzpOoQaamr6jcrZwWbyzWdvcq5i3QxgsuTyVAJUvggEHHS+Ap5ra31u4v8AT7+zGoeIJ3t0mtJNzIyptcgD5VIH3mwB0JB4rtqh8+T7d5H2WXy/L3/aMpsznGzG7dnv93GO+eKAJqKjuLiO1tZbi4bZFChd2wThQMk4HtVTTdWj1W3srqyt53sr20W6iujtCYYAqpBbduIbP3ccHnPFAF+iiigAoorn38aaV5losPnzi71eTR0dI8BbhFkL53EHaDE65GckcZBzQB0FFFFABRRRQAUUVz9l400rUrrRYrHz5k1qKea0mEe1SkW3cWyQwzuGOPrigDoKKKKACis2y1y2vte1PSYUlFxpohMzMBtbzFLLtOcngHOQK0qACisefxHFF4sh8Pw2V3c3L24upZYvLEdvEWKqzlnBOWUjChjxzitigAooooAKKKKACiis3xFrtt4Z8N3+tX6SyW1jC00qQgFyo64BIGfqRQBpUVT1fVbTQtGu9V1KQxWlnC00zhSxVVGScDk1XtfEFrd+JLnRI45hc29nDeO7KNhSVnVQDnOcxnPHpyaANSiiigAoqG0nkuLVJZrWW0dusMxQsnPfYzL78E1NQAUVSutXs7PVrDTZ5CLrUPM8hApO4RruYk9BgEfn9au0AFFFUdY1iz0LS3v9SkMcCPHHlVLEu7qiKAPVmUegzyQOaAL1FQwzySXFxG9rLCsTAJK5QrMCoOVwxIAJx8wU5BwCMEzUAFFFFABRRWPfeI4rTxPY6DFY3d5d3cL3DNB5YS3iVlQu5d1JGXHChjweKANiiqNzrFna6zY6VNIReXySyQRhScpHt3sT0GN6D1O7gcHEfh3XbbxN4bsNasEljtr6FZokmADhT0yASM/QmgDSooooAKKKKACiiigAooooAK+bfjJ/ydN4C/7h3/pbJX0lXzb8ZP8Ak6bwF/3Dv/S2SgD6SooooAKKKKACiiigDm/iP/ySzxX/ANgW8/8ARD15t+yp/wAks1L/ALDUv/oiCvSfiP8A8ks8V/8AYFvP/RD15t+yp/ySzUv+w1L/AOiIKAPbaKKKAM2GfXG1p4p9O09NMGdlyl+7TNxxmIwhRz/00P41yet6fc6j8ZrGKz1e80p10CdjNZpCzMPtEXynzY3GOc8AHjrXfUUAef8Aja2Sxt/DUHie+l1Dw6moP/a9zfrGI3Bjcw/aBGip5YlKDlQuQm71rl4/snmx/wDCObP+EX/4S+w/svyP+Pfdt/f+R28vzM/d+Xdvx3r2aSRIYmkldUjRSzOxwFA6knsKbb3EN3bRXFrKk0EyB45Y2DK6kZDAjggjnNAHimnnTxJpv/CW/Z/+EX/tnXPtP20D7L9p+1HyfO3fLjb5u3dxux/Ftpxux4c8PL4x02KSTRtF1y4TTURWZX06eJY9sY6+X9o2lccYVcfLivbaKAPIfCWlX9l400zwdfl5YdBMmtSzsciZ5o1Vf/I8t22O3lrWz8VrbT5pNKl1HVNEtJIUuPs1r4ktTLptzIVXHmNuVUkGPlJJbDSYU849FooA8dsjol7rHw31S90ez02DN5a2ZuZfPX5SBbeVNKoZg2N8XAOGG0VT0TRtOsfhj4Q1C1soEvbzxBZG4uhGPNmxdnaGfqQBwATgAACvbqhW8tnvpLNLiFrqONZHgDguqMSFYr1AJVgD3wfSgDy7w2fCP29T4r+zDxz/AGxPvBDHUCTM4iChf3hg8goOP3fl5zxmsPw9Y6PbTaFp9la2MMsfjXUI7u2ijRWVfLvBGrqOg8vAUH+HGOK9yd1jjZ5GCIoJZmOAB6mloA8n8DW1xceMrbw3eKzQeA45oldwT5jSkrannuttnPXl62fHlppH/CwPAt9rNvZbFvp4hcXaJgOYHMS7m77wCo/vAY5rqtC0CLQxeOLq5vrq+n8+5u7op5krbVRR8iqoAVVAAAHGepJN+C8trqWeO2uIZntpPLnWNwxifAbawHQ4YHB7EetAHi2kaNp1h4O0LxDa2cSaw/jAxG+C/vhG+pSQvGH6hCjMCv3TuJxkmq72kdxqmqNrfiLRdK8TDWJfKMukSz6si+d+48hlnDvEYtgASPZtLhgfnJ93ooA5L4lmUeDiT5n2AXlt/anlBi32Lzl8/O3nbszux/Burzq6/sv+3/GX/CsfK8n/AIR+0x/Yv3M/aJfN8jy+M7M/c/jz/FmvcqbJIkMTSSuqRopZnY4CgdST2FAHjsjab/aN23wWFmU/4Ry7N0NIwITcYX7Ju2/L5+fN6/Pj73GKfc2nw9vvAeqW3hmCzudVk8P3BnhtIzJIzLEGBulAP70OFIM37zeGxzur12G5gubWO6t5o5beVBJHLG4ZHUjIYEcEEc5pLS7t7+ziurG4iubaZQ8U0Lh0kU9CGHBHuKAPH7ZvBpvdJ/4Sg6OfCp8PRDS/tHlmx+0+Y/2nbn5PO/1f+1jdj+Om+HNHTW/Efg628VWRvo00fUpIodRjMhMQuohAXV+SREUPzc5wTyK9gN/aLdQ2zXUAnn3+VEZBuk2cPtHU7cjOOmeanoA86+KFhpSwaT9r1DQ9PEJuGtrTX7MyaZcylMgSHcqo45KsSThpMK3Nb/w8vI73wLYPbaeNPt4zJDBClw88ZiSRlR4ncBmiZQGTIHykADAFdNRQB4J4UHh+TQNA/sAwt40XXV83y2/0sQC5bzfM/iFv5G7r8n3cfNirsmipH4B8W6tplqiajL4kvIry+S3aWdLL7f8AvlGwiQpsDEojLn5sYJzXrnh/Q7bw3ocGlWLyyQQFyrTEFjucuckADqx7VpUAeMWunaK2m+JF0zxdo8WnSaXtul8LaNKlpA2/iZ/LmkQttDBlBVjHyTtUEV7a68vwz4qsfDFno8qBLaWfUPCLyLbSw+ftkUQqSsU4g3kiN2Yjbk8LXs9xqFnaTpDdXcEMskbyJHJKFZkTG9gCeQu4ZPbIz1qS3uIbu2iuLWVJoJkDxyxsGV1IyGBHBBHOaAPIfFcfgS48Cazb+BmsgspsFuhozEW4Bu4wpJj/AHYl5PPEmMZ4AxX+I+mWOit4otNHsrfT7aPwc5SG1iWJFJuGJIVQAOea9qrN8RaFbeJvDd/ot+8sdtfQtDK8JAcKeuCQRn6g0AeYpY+Gb/VpbfwJb291p0ugXKazHbqJI5JPk+zicc7rjPm/e/efezWLppc+HtO/4QMw/bR4Am8j+ztuftHmQ78bf+Wm/dnvu9696ooA8cQ+Fjqtufhp9k+znRrv+2fsAwPL8r9z9ox/y235xv8A3n+s96n8LaRp+iT/AAwu9LtIra61LT2ivbiNcSXS/YhJiRhy+GRSM5xjjFeuUiurMwVgShwwB+6cZwfwIP40ARWl5bX9stxY3EVzA+QssLh1bBwcEccEEfhXhdpofh+WKx0WOysYx/wn90l3ZwIqHytt4YkkVcHYUGAp4KcdDXuOn2MenWYt4WdwHd2eQ5ZmdizE49SxNWaAPEtbtG02LxRo+ki307w/Z+IrM3UP2dpLa3tXs43k3RIyfujIVZwCBgsTxmut+GttYw6jrD6Jruk6jYMIVNtoWnNb2MEoDElG82SMuyldyoRjCkjJyfQKKAPHfGOi6dqN78UL6/s4ri50/R4prOWVdxtpBbSMHjz91sqvzDB4HNSXenTaNrE0Xgy1W11PUfBl3cFrdcSXN2jRCORz/HJmV/mbJJY5PNevUUAeN+CdN0K617SU07XfD9z5lpKl/pul6NIk11GYtrLfMZ5MEMQczLuLblzlmzleDdD8P6vb/DvTZrKxuYI7fUvt1oEUo1wvk5WZBwWHykhhnIU9hXvNFAHi0Qs7fTLKy11Y08HWPijULa7im/49YkVn+zJKDwIhIQAG+QN5ee1IxsxaXJstn/CvB4kh3bATa/Z/I/e7ccfZvtWN3/LP7/8ADmvaqKAPNvhp/YX/AAm3jL/hE/s/9lZs/J+yY+z58t93lY+Xbuz93jO6snxIfD39u+MB448j+1cx/wBgfaB+/wDK8lfL+x/xb/P8zPl/Nu25/hr1+igDzLw1o8Z+LFtfazp1qdcXwtZy3NwYE8wXBaSORt2M7to25/ujHStPWdUsPD/xbtNQ1y9g0+0uNEkt4p7lwiPKJ0bYGPBbByF6nnA4ruqKAPA7aLS7nwN4Zu9R1HQ4HFtfeTp/iq1Y2M+66zkOSFimAGB95trN8uATV7Up4dT/AOEXm10aVoegNpTC0h8TW8l9aCcPjlpJIsuYgCjSfMVLYAO6vbqKAOZ+HsKweC7ZIdV/ta38yVre5FtJAnlFyUWNZGZjGoO1G3EFQuCRg15C+paXc+IPD2qadBoWn3//AAkcKzwQh7jVY1aVo5Gu7ncDHkuVMbKw5UBjwB9CUUAeJXGj6fB4T8SeIktIjrFr4tc298RmaEfb0Uqj9VUhmyoIB3NnqaofEM+Hf+EX8dDxR9n/AOEs8+b7B5oP2r7NgeT5H8XlbM7tny/6zd/FXvlFAHH/ABZs4774SeJo5bZbjbp0siK0YfDKpYMB6gjIPbFcpZ+HPCviPx/fg6fpuo6XD4YsxaRoiSW6gyXHzIo+XIxgMORlsEZNet0UAeCQTPqlh4QuPF2qaJDpcnhq3ME3iWyN3ay3WT5py00aiXYIyC2WI3bcfNn1jwBF5HgbT0GqPq0eHMN29tJBvjMjFAFkZm2hcKrEncoU5IOT0dFAHiHg7R9O1zUPBFrrFnDfWo0LUXNvcIHjci6hxuU8MBnOCOoB6gVC8FhN4I0ddQ1XRbQadearbWFp4ltmm02YJcOkaOxYKjoqhUOSQpfCnnHutFAHjtkdEvdY+G+qXuj2emwZvLWzNzL56/KQLbyppVDMGxvi4Bww2iqWj6Tpek/Crwvry2tvbuus21xqOoGMb/KW4cbpJMZ2LkDk4UDsBXt9FAHjGrarFrGoeNbvRrhrvSmudIW+uLNiwksw3+kFGX7y+XvBK54DelP8Y2nw+u/Aeq/8IrBpU9pb32nT3X2KMPZREXMas4IHlK/lFw5XDbCN/GK9kooA8X1Nrb+0/EzRlD4d/t/TTqJg5iNj9ghznb/yyz5e7tszn5c1U1+LS7jSfFMPhFol8LSXGjIjaa+y2F0bxBKYGT5QdnlbinAb/azXudFAHk2s6PpOka/4u0XT2Xw7pE/hy2uZjp9qfLhkM06NKYo8ZBVVD4xlV5IAzWj8MLmyTWdYsNKtNAkgCRytqPhl2WymO5wqmHlIpguCwV2JBXJ4WvSKKAPLfEp8Lf8ACc66PiX9l+zfYYv7H+3Djy9p877Nn/ltvxnZ+8/1f+zVfwhpDy+PfC134o0+F9dXwp5txNcQKZxMssShmYjO8KSM9eSPWvWqKAOA8VWmkp8ZfBl9qVvZLK9rewxXFwiBmlDQGJAx/iG6QqOvLY6muO8GaLp2jeEPhdq+m2cUGpX15HBdXij97PG9rOSjv1ZQUTCngbFxjAr3CigDwjRLWGXUbZtT8R6Lp/i0atuuI10iWTWC4lyYy4n3NC0Yxny/LERzgAZHu9FFABRRRQAUUUUAFFFFABXzb8ZP+TpvAX/cO/8AS2SvpKvm34yf8nTeAv8AuHf+lslAH0lRRRQAUUUUAFFFFAHN/Ef/AJJZ4r/7At5/6IevNv2VP+SWal/2Gpf/AERBXpPxH/5JZ4r/AOwLef8Aoh682/ZU/wCSWal/2Gpf/REFAHttFFFABWB471O70b4e6/qemy+TeWenTzQSbQ2x1QkHBBB5HQit+sXxjo9x4h8Ea1o9k8aXF/YzW8TSkhFZ0KgkgE4yewNAHIXt7rulNbWmqa4dYh1zSLuSRJLeKL7NLHEHzFsUHyyHK4cuR8nzdc1fB17q+gaf4BjvNbe8s9Y0vZJazQxJFbbLUSoUZVDjAQqS7NnOcCuw0bwNoejW7LBaSNJJZizZpbqaby4ccxRb2PlJ0+VNo4Xj5Ri8nhnSI00lFsxt0aMx2IMjERKY/KI5PzfIcfNn86APOtP8X60PEvhmWHVdY1PStYvTA9zd6dbWtnOrQPIpt0wLkAEDDPuUgH5m4JRNe8VN4DXXx4jl+1Xmurp8UTWkBhhi/tHyM4CBmO0EHLdDxg812dp8OfDFldWFxDYztJpsgex82/uJRaYGNsSs5EakcFFAU4XIO0Yvjwnoi6NFpQsv9Chu/tqRea/E3nGfdnOf9YS2M47YxxQBweqaj4p02PxssXiy7lHhmzW/tXls7XfOTA0hilIiClMxnGxUb5zljgYteK/E2pyyXf8AYWq6wLm305bg2mkWFsyWxMbPvuJrkFCD8uI0ZXwCcNnK9tc+GdIvBq4ubTf/AG1ALe//AHjjzowhQLwfl+ViMrg81Sv/AAH4d1K6M93ZzEvDHBNFHeTRxXEaZ2rLGrhJcAkfOG446UAc1oev6343ubC2g1ibRAPD1lqc0lnbws801yG4/eq4CL5Z4AyS3XjmTUNV8YDW9c0bS7qK7v7XRLKaERwpGDM80qyyIHJAYomVV2KhgM5Gc9DL4E8PyWdhbJbXNuun2ws7aS0v54JVgGMRmSNw7L8o4YkcZpz+BfDT209v/ZMSQz2kVk8cbMiiKJi0YUAjYVZiwZcMDg5yBgA848Sapd6r8O/EWnXms65HfWlxayta6rp0EF1EhuBGPnRPJmjZo2ZWjHbBYg4r0Txjc6povgG8vtJupJb3TIVuWkeNGa5SIhpFIChcuisPlAwTxinJ4F8Prp1/ZSWk9wmohVupbq9nnmkC8oPOdzIAp5ADDBJIwSa2orOGLT0svnkhWIRfvpGkZlAx8zMSzHHUkknuaAPL9Q+IOrm+1qLT7tDFqrJaeGmWJSRKsyW08nIw22SUNhuAEPHUVTupta0YfEnxBpWtzWw0nUBcLaC3iZLpktIGYSllLbWAA+QoR8xyeMei2ngnw7Y2ui29rpqRxaEzPpy+Y58gspUnJOWyGP3s889QKmn8KaNc2OsWk9nug1ti+oJ5rjziY1jPIOV+VFHy46etAHNXWo65r2ueJI9L1yXRodCSJYI47eGRbiR4FmLS+YpJT5guEKHhvm5GNzTNa1PX/hpa63pVvDHqt/pK3VtBMT5QneLcqk9du4jn0p2reCNA1u6NxqFnIZHhEE3k3UsIuIh0SVUYCVeTw4Ycn1Na9xp9ndabJp9zaxSWUsRhe3ZAUZCMFdvTGOMUAeXr441bw3o+vPq11q8mrWWmtcRadr1hDGGdAm6WOe2AikizKgZclxjqtamrT614ev00jUtdn1y31fSbwsbm3hie3lhjDbk8pF+Rg5BVtxBC4brnptN8E6DpbztFaS3LT232RzqF3NeHyD1iHnO+1DxlRgHAznAw3TPA3h/SDMbO0mZprX7GXubya4ZIP+eSGR2Maf7KYBwvoMAHFeFbrWdb0G003T9Zk0e30fw5p8iiO3ik+1SywFsyGRSfLAQDCbGJL/N0x0nwzief4M+HIop5LZ5NIiVZogpeMmMAMu4FcjqMgj1Bq9deAfDl5FZxy2MiLZ2YsY/Ju5ot9uMYhkKOPNTj7r7hy39452NK0uz0TSLXTNLh8iztIlhgi3FtiKMAZYkn8TQB4t4Q06/uNL+Flvaa3c2jy6XeublYoWkhTbAdkYZCvYDLqxwT3wRut4w8SS2lhottJe3d9Jq9/ZTXtjFarcyRWzHBVZisIdgVycEYDYXoR3Wl+DNC0Z7FtOtJI/7OEq2ge5lkECybQ6qGYgL8i4XoMcAZNFx4L0G6sZLSSyZUe9fUN8VxJHJHcMxLSJIrB0JJP3SOCR0JFAEPg248Qy2d5H4mtLqHybjbZzXhtxPPCVU5kEDNGGDFlyuAQFOAc1xer+IPFMWn+JtZs/EDQjSNejsbWyazheF42eAESfKHb/WnG10PHU16No2g6doFtJDpcDJ50hlmklmeaWZz/E8jku5wAMsTgADoBUE3hTRZ7G/s5bLdBqN2t7dJ5rjzJgUIbOcjmNOBgcdOTQBxGseKtd8J/wDCU2C38+tT2Vvp8tlNdwwCRGupmhIIjESMFKhhnb1ILAcguPEnjLwxpOtajfafqlzYWmlyXEc+t/YQ6XKkBVxaPzGQSTlQRs+8c8d3c+GtHvbrULi8sY55NStktbsSkss0SFiqlSccb26DPPsKq6d4K0HTZJ5I7SW6e4tzayPqF1LeN5J6xAzM5VD3UYBwMg4FAHE6za6vofxC0WW88QT6tKmh6pLHJcW8KNFIBBkgRoo2khcBgSMHLHPFvw/q+v8AjGS0sU1640lrbw/YX09xa28DSXU9yrkkiRGUIvl9FAJLdQABXR2Xw88NafdJcwWVw80dq9nG89/cTFIHABjXe5wvAwBwOcYyamufA2gXVvZQm2uLcWNqLOB7S+nt5BAAAI2eN1Z14HDE889TQBy/irWtagup7Gw1vVJtRsrBZJoNC023EcblWJmmkutyKpKjESuHAz9/ORW0nX/Efiy40dItdl0lLrwtBqs5tLWFma4YkHBkVwE56YzwMEc5624+H3hm5kQnTmhjWCO2a3trmWGCaKPOxJIkYJIo3EYdSMHHTirmmeE9F0Zrc6dZmI21iunxEzO+23U5CfMxzg9zz70AcP4a8T6+8fg3VdU1WS9TxHZSvPYi3iSKF1g81WjKrvB+Qg7mYHccAcAM8J+IfHGtRaHrQsdVnttTaOW6imGnrZQ28nO6IpJ9oygK/f3FsNlVJG3vLTwro1jDo8VrZ+WmiKU08ea58kFDGep+b5SR82fzqrbeBPDtnfxXcFjIPIna5ht2u5mtoZSSS6QFzEjZZjlVBBYkdaAOJs/EXiVNEtvEd1r0s0Z8SNpraf8AZYBC9u181uMkJv3qCCCGA+Vcg8k7vw2tJrfU/GTzajc3Str8qhJljAUiKI7htRTkggcnGFGADknoR4S0QaSumCy/0RL37esfmvxP53nb85z/AKz5sZx2xjinReF9LgvL66tkuoJdQnS4ufJvZkV5ExhgocKpO1Q2ANwGGyKANeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+bfjJ/ydN4C/wC4d/6WyV9JV82/GT/k6bwF/wBw7/0tkoA+kqKKKACiiigAooooA5v4j/8AJLPFf/YFvP8A0Q9ebfsqf8ks1L/sNS/+iIK9J+I//JLPFf8A2Bbz/wBEPXm37Kn/ACSzUv8AsNS/+iIKAPbaKKKACuD+KemLH4TvdZtr7VbS9iMCI1pqtzAgBmRT+7SQJkhiM4zXVQ+G9Dt9afWING0+LU5M771LVBM2Rg5kA3HI96h8VaD/AMJN4audJ+0/ZfPaM+b5e/bskV+mR124696AOU8WxXfhO48KQeGm1C6e71zY8F1q08gmBtpvleSVnIjBVWIAONuQpPBmu/idHpWj3smt2VrY6naaoulGB9QUWxleMSq5uGVdsfltuJKZG0gKTjPSa54f/tnU9Du/tPk/2TfG82eXu839zJHtzkbf9ZnPPTGOaxrzwAZ7zU7631U299c6rFqtnL5G4WsscCw7WXd+8VlDAjKnDkAggGgCx4N8c2ni261GyjfT3u9OEbStpt+t5bukgbaVlCqSfkYEFQQR3BBOb4u8Xaq2m+Kbfw5pizxaNaPHd3n24wyRytD5n7lQh3sisjHLJycDJBrqNGstYtmuZde1iLUJJSvlx21mLaGBQP4VLO5JJySzkcDAXnOBrfgbUL2bXl0TXY9NtPEEYF9FJY+cyv5XlF4mDrsLIFBDB/u5GCTkAg0/xZrE9naab4e0qLWL+00i2u76S9vzbDdKh2IreW5d22OTnAHGW54swePJNc/s2Lwjpkd7cX1j9vdb+6NqttFu2YcqkhL7wy4CkfIx3dMp/wAIVqmmzrdeGNeg0+6k06Gwu2urD7SkvkgiOVFEiFHG5upZSCMjjJIPAUmhtps3hHU0sriysRp8jahbG6S5iDbwWVXjIfeWbIIHzsNvTABQfxdrlt4/T+1rOPT9Hg8Py395byXQaSAq/wAzYVCHII2gb8bSW4PynS07xpqD6hoya5ocenWmu7hYTR3vnOr7DIqTJsUIzIGPys4BUgnoSTeCLm81S3u9S1gXyyaVLpepLNaANdRyHcShRlERB4+63y8dfmpNN8F6jHf6O+ua6mo2mhbjYQx2XkuXKGNXmfewdlRmA2qgJYkjoAAWvAnifUvGHhy21u90iDTLS9hWW2Rb0zSEHOd48tQo4BGC2QeQp4rJ8X/Ee48HzyS6hp2mxWSzKka3WsLDeXSblV5IYNhDgbjwXUnaeBkZ6TwjoH/CLeD9L0L7T9q/s+3WDz/L2eZgdduTj6ZNchrPwru9Tg8Q2lprlrZ2uvTmeeUaXvuychljaYyANGrdF2ghTtDDrQBd1f4ganYX3icWfh6K5sfDAR724k1Dy3ljMCTMYk8ttzKrNlWZRwuGOSFm1rxfqEzara+GNKS/XT7NZrud73yGQyIXVYlCNvfZ82GKDlfm5OLN54JN3Z+M4W1DafFMRjLCD/j2/wBFW3zjd8/3d3brj3qC78Eaik122g69Hpy6laR21+JbHzi5RPLEsR3rsfZx8wdeF44OQCfwtfahL8H9Fv0f7XqL6Fbzb7qYjzZTApy74Y5J5JwfxrivDvifxde3vgaUQx313qPh2eeaGTUGigkO63InkIjOGwSMKjYL4Bxlq9L0LQ10bwdpugPOZ1srCKyMwTYZAkYTdjJxnGcZOPesHwx4DuNButBmutWiu/7E0uXS4xHaGLzI2aIqxzI3zARYPY5zxjFAFG6+K9nbaFpFxLDY2d/qctxD5OpakltbwPbuUm3TlTkBgAuEJbcDgDJHQeDfF9p4x0y5ubQ25ks7prS4+y3K3EJcKrZjlXG9CrqQcA9QQCCKyrb4fXGm21jLpOspDqlheXs8NzLaeZE0d1KZJInjDgkfcwQ6nKA9Mium0a01Gzs3XWdTGpXUkrSGRLdYI4weiIgJIUAfxMzZJ5xgAA5Gb4jahBFrOot4cX+xNEvpLS8u/t374hGw0kcWzDKoIY5dT1xuxzmnxjrmha548vf7OOp6To95HNM02oGNoYvssTOkEexgxHzMVJQEsMEknC6V4M1rWI/E+n6hqLWWh6lrdw89nJYnzpoi4J8uYuAsbgAH5GON2GGRjor7wL9s0zxlZ/2js/4Sjd8/kZ+zZt0h6bvn+5u/h6496AK/jPx5d+FLae9Ww0s2MUHmRTalrK2bXj7SxjgXy33tgAfMV5OBxzU0PjS91LxZaaRomjxT282l22qyXdzeGLy4pXddoVY33OAmQMgHn5hgZo6l8N7q61PV7ix1i2tV1iySyuZn03zbqOMRhGSGYyAIjbQxUq3zZPU8a3h7we2h6vb3734uGi0S10koINgYws7eZ9443eZ93nGOpoAwNO+JetajZ6Fdp4Wgjh8QM0Vhu1X5xKqM/wC9HlYWMhHIZSzYA+QE4GxB4x1C58O3V3Do1sL+xvZbS9il1ER2tsI8lpWnKZ8vbg8R7ssMqACwZpngH+ztM8JWn9peZ/wjczS7/Ix9o3RSR4xu+T/WZ79Md6q6h8NjeK7JqFs8v9uSaxHHe2H2i3JeMx7Hi3rv253BtwIODigCLTPilFqWi308FlaXV/b6lHplvFYaitxb3U0iqyFZ9q/JhjuO3K7WwGIxV+/8Q6latpkXiHQ/ss02rwWsTWWqO0Lh1Yh9wVGcAggxugB4PNU4fhvdbdWuLvX/ADtSvtRg1SC6WzCLbXESBQNm47o8Lt2k7tpwWLfPWlP4U1jVHspdd1+G5ls9Thvo47bTxDCqxqw2KpdnyxbJZnYcDCjnIBV8PePrrxJrM1rYabYPDDNNDKi6qpvLQxsyA3FuUBjVmTHys5+ZTjGcTfDLV9Z1vwcbzxCITcG+u41eKYvuVLmRQD8i427doxnIUE4JIEcnga+v/EmnalrerWd6NLuWntZl0tYr3b822J5w5BQbuQsabtoyeudbwl4en8MaXPpz3sd3bfbLi4tsQGN41lleUq53EOQXI3ALxjigDn9e+I9x4c1qC21TTtNt7e4vI7eGKTWFF9LG8gjE622wgpuyf9ZnaMkAgqJpfiFLay+JLu80qOHRfDszwXN39szLK4iRwI4tgXnzFHzOoGc564zrn4VXktnd2FvrtrbWdxqg1N3XS83M8gn84LPMZP3igkgYVWGF+bAIboB4HtptM8T2F9dyyQeIL1rpmhXy3tyYokG05OWUxBgSMZPTjkAzvCvxKttf8QRaNcNoxuri2a4hOkaymoKuwrvSQhEKN8wI4KkBueMGz4v8f2vhjWLTSRJpSXlxC1wz6tqi2MCRg7fvlXLMW6KFPAYkjjOno2m+JLe7SXX/ABFb38ccPlrDaaaLYSN3eQtJISeOAhQcnIPGI9Z8O31zr9vrmganDp+oRwNayi5tTcwzwk7gCgdCGVuQwbuwIORgAwT8WLGLw7YeIrmyI0KaSW2vL2Cbz/sk6MygYRSJI2ZSFkU8lk4+bid/G2vi90LTU8Kxrqes2s915E+o+WtosbR8SsIiQSsnIVWw2ByMsLGqeBJ/EltYWPi3WTq2nQB5Lq1+yrCLqZgQpJU8RoGO1OTkKWditYdz4Z8U2vjTwmlprJuJdO06+ibU7nTmljdS0ASOYK65cqM7g6lmTOMZBALl78VbWx0qyN1bWlhqtzdzWcltqeorbW8EkJ/elpypyvK7SFJbevyjnDI/iqL7TLNtG0601K+n1oaM8dvqQe2WQwtKJFnVDvj2qMnaGGW+XK4OhH4BntLawutO1ny9etbme6kv57bzI7h5yDMrQhlwhwu0BwV2J8xwd1qXwpqWof2PNrWurd3Wnar/AGiTHZLFEQIpIxEi7iyjEmcsznIPYgKAc8PG3iDR9b8Y3WvWFq9lpFnayJb216ziJ3U9zCvyEksznlQowrdus8KeILrxDZzXM9tp4gVgILvS9TW9t7gdDtcKhDKQQQVx0wTzirP4W1JPEGt6npGuLYNqttCg/wBCErwzRZCOCzbShBIZCuTnh1NHhnwc2ia/qmt3k9jJf6kqJMNO0/7HC21mbey73Z5CXbLlumBgY5AMzXfHA8O6rr5h0q4vZrJtNiKC+bE32mRoxsRvkjK9eMbuMkYBra0HxHe3+vajomt6bb2GoWMMNwBa3ZuIpYpS4UhmjQgho2BBX0wTnjP1rwD/AGvqeq3f9peT/aE2nS7PI3eX9kl8zGdwzv6dsdea2Lfw/wCR42vvEH2nd9rsYLP7P5eNnlvI27dnnPm4xjjHU5oAxde8barp+uaxp2kaDBfnSNOj1CaWfUPs4ZG835FAjc7v3XHY5OSuBksfH7teWp1jS00+w1DTJtUspxdebIYYhGzCVAgCNtlU4VnHXnjnQuvCX2nW9f1D7bt/tjTItP8AL8rPk7PN+fOfmz5vTj7vXnisfAkMraAt3d+dBpOkz6XLF5WPtKypEhbO75eIunP3uvHIBj6D8XdP1fVtNtZ20iOLVWZbYWesx3VxCQjOBcRKo8vKqclWcBsKTzmquo+Mda1hfCOoWmnNYaNqusQeRcxXxM00JDlRNEEAVXUbsB37AgHp02i+Hdf037HZ33iWK80qyQxpCunKk06AbUWaUuwbC9SiISQDkDIOVb/DvUoI9B0//hI0bRtAvEubO2+wYmZE3BI5JfMwwVW2ghFPAJ3HmgA0rxtJcWlnZ6HpRn1K+vdQSOC91JyiJbzskkjysrsASVCoFON4UYUZE154tubHWLNdV0Sa1vhpd/dNEuoloh5Bj4AUbZA+4FXZQyjI2glhRa/D640uOxudJ1iOLVLG6vpY7iezMkTxXUpkeJ4xIpODswwcHKZ6EqZrnwRfaleQ3uq699puk0++snYWaov+klCNihuFQR4AYsxzy2eSAM0fx3e3Vxox1rRYtNs9bsnu7SVL7znTZGshWVPLXadrEgqW+6c4rM0T4w6bq+p6ZHnSRa6tMIbVbfWI5ryMtkxma3CjywQOcO5UlQQOcdAvgtM+GBLeeYmg2z27IYsfaQ0AiJ+98vTPf096ZoXhjXdEhsNOTxKj6NpxCwwjTwLmSJQQkUkzOysoBAysaMdo+Yc5AOqrzCfxZrEviDRLfQrZYrabxNe2N2tzqMjmbyklPBMbFF+UsFUgAqq9CSPQNGuL65sHk1NFSUXM6KFhaPMaysqHaSTyoBznnOcDOBzP/Cv54ZrW5s9WjS5tdeudYRpbQuhEyyK0RUODkCQ4bPUfd7UAL4f8ez+ItflsrPTrIwQ3E0E6Lqim9tPLdk3zWxUbFZk4w7HDKccnB8QdR1XT9S8JDREkmmuNYMTWy3BhSZfs0xxI3PyAgMeGPy5CkgCluPA19qXiLTtQ1rVrO9j0y7NzayjS1jvQMkrE04fbsGQCFjUsFGT1J0vFfhu71+XR7jTtUXTbrSb37ZG723nLIfKkj2Mu5flPmc4OcZAIJyADEv8A4mpoum3a69YW+n6tbX8dgYJb9VtWeRDJHJ9oZVxHsDEkoGBVgFJxmqPi7bHQdXuoLSz1K90mWzSSDSdTS5hmW5mEaGObavzAlsqyryo5wQ1aT+Abi4gmvbrWd3iGTUI9QTUI7XbDFJGhjRFhLn935bMpBcsd7HcMjE+o+E9Y13Qbux17xDFPJPdWs8f2bTxDDAsEyS4VC7OS5TBLSEDjAGDuAK118Qn0FdaTxbpsFjcaVaQ3gFne+fHPHK7RoA7pHtbehU7gAMg5xnGdbfFBtUi1HT7E6HLq6abLe2p0zWlvIQEwGEjiIFHG4EDYQ3PPBxua54Fg17WtTvbq9kiS+02CxVIkAeF4ZnmSVWJIJDOOCMfL3zirFvoniGeC7i1/xFb3cc1o1tHFZ6aLdAzAgyPukkZm6YCsi9cg5BAB57pPiHV9I8B5gimfWz4SbV1u7nW7i6QnC/MVlVgH/jxggH5M7SWrfX4halYDSdIl0/TJNWn02G52Xms/Z/tbOSqx27NF+9kO3kHYAWUZOcjRT4dJ9ijtZdTZkXw0fD7FYMEggAyj5jjp93n60moeC9d1Hw/DpFzrmk3Vr9kW3ngvdCE8JZCdssaGYFWxjO9nGVBAXkEA7CW4eOwe4FrNJIsRcWyFfMY4zsGW27u33sZ745ridM+I803iseH9Us9JjvTaT3DR6brIvGgeLbuimXy0MbfNx1ztPpXQXHheCXwC/hWG7uYrc6d/Z6XO/Myr5ewMTxlscn1rn9P+Hd7b6xpV7davYLDpdpcWcFjp2lfZYFSYDcwXzWIfcoJOcEDAUHJIA7QPiHfamvhy61XQodN0/wARQlrSZdQ82SNxCZcSIY1AUqj4YMTwuQucDL1HxjrWsL4R1C005rDRtV1iDyLmK+JmmhIcqJoggCq6jdgO/YEA9Ogs/Aa2uk+DrF78Sr4ZwCTBxdAWzwdN3yff3fxdMe9ULf4d6lBHoOn/APCRo2jaBeJc2dt9gxMyJuCRyS+ZhgqttBCKeATuPNAG74u8SXPhyDS/sOmrqNzqWoR2EUb3HkqjOrsHZtrfKNnOATjJAJGDz9/48bQbjW5NQ01IrqzfT4Z2fVHNojz5AZnZAIY1PVwmWyCRmuo1/QP7cn0eT7T5H9mail9jy93m7UddnUY+/nPPTpVGfwtqEetazquj62LG61JrVl32glRBCCCrgsCysDztKMOxoA5zxN4xuk8HaXrd/JBpNsmuWYku7DUhcW1xbeYpZ1lUKWQjIIZR0PBGCbdz8SprfwzZ67JpNtaWOqXKRadPf6h5EZiZGdZp38thCrBflHzkllB2knBbfDCOKFzJeWcc02sWuqTR2OnC3tswEEKkW8lS2Ms5ZiSc9MCr1n4O1bRbO6svD3iCK1sWvDcWdpcaeJ44I2U+ZA3zqWj3EsoUoV6ZZeKAN7QNRutV0eK8vbSK1kkJKiC6W4ikTPyyRyADcjLhgSFPPIFaVcx4U8IyeEtLe1sLmyQ3N+13dJBYeTAAVC+XBEr/ALoYVOSX53E53cdPQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV82/GT/k6bwF/3Dv8A0tkr6Sr5t+Mn/J03gL/uHf8ApbJQB9JUUUUAFFFFABRRRQBzfxH/AOSWeK/+wLef+iHrzb9lT/klmpf9hqX/ANEQV6T8R/8Aklniv/sC3n/oh682/ZU/5JZqX/Yal/8AREFAHttFFFABXJ6zq+vyePLXw/oV1ptnHJpsl9JNeWUlySVlRAoCzR4Hz5zz0rah0u8j1p719e1CW3bONPeO3EKZHYiIScdeXNc/rUOrWHxKtNcstCvNWsxpEtm/2OW3VkkaZHGRLKnGFPIzQBb0fxNPDc6zp3iySzt7vRkS5mvIcxW8ttIGKS4ckpjy3VlLNgpnODgXdF8W6Pr909rp0063KRLOYLuzmtZGjYkCRVlRSy5GNwBGe9cpqPhLWfFGm+KNQu7dNMvtWgt7aysriVX8uK3dnXzWj3KC7u+QpYKu3knIrSsLbWde8dabrupaJNodvpmnzweXczwySXEszRkgeU7DYoi6kgkt90YzQBs6v4t0fRNSi06/mnN7NCZ4ra2s5riR0DBSQsaMTgkZ9uelMl8aaDFpOn6il69xBqY3Wa2ltLcSzjGTtijUvwPvfL8vfFV5NIvG+KltrIgzZR6LNambcvEjTxsFxnPIUnOMcVymg+HPEPhqTQtXfSJdQltYdRs7mxhnhEyJPdedHKhd1RuEUEbgQG74IoA39T+I2m2x8NvpqTahba7eG2WaG2mfyQqMWyqoSHDLtKNhh8xIwjYt+NvFZ8JQ6Pcv5Yt7zU0tLhnjZ2EbRyN8iryXJRQAASc4AJIrl4/DGvW8ej6s+ltJc/8ACSzavdafBPGXtopYZIwu5mVGZdylsHqWxuxk9H47sdUuk0G60XTv7Sk07V47uaATJGTEsUqttLkAt8wwMjkjJAyQAXbfxtoFzDFIl5InmXq2HlzWssUkc7DKpIjKGjyOhcAHK4PIzpWmrWV9qF9ZWk/mT6e6x3KhTiNmUOFzjBO0g4BOMjNcFq3h6/1bRfGOtalbf2LNeQQS2MU8kbSW72gZ45pCjMgJfsGPyqMnkgb/AMOLW6TwbDqOpxmPUNZlfU7pCc7GmO5U/wCAx7E/4DQBov4t0SPT7y9kvdsFlefYZyYX3JPvVAm3buJJdcYBBDAjIOahvvHHh/TtTksby9dJIZEimlW2laCB3ICpJMFMcbHcvDMD8y+ozyWoaHcy/GyCztyP7JuVi129jBxi4gDQpkf7RMLfWA+9Jqnh7xCuheKvCtpozXcWv3VxLBqv2iJYYEuD8/mqWEm6PLYCqwbC8jJwAdxN4m0i3i1qSa72poS79RPlOfIHlCX0+b5CD8ufTrxVaTxroMesLpZupmuzDHOyx2kzrHE+dru4Qqi8H5mIA74rjvEOgeIba38c6dpOiTamPElkq212lzCkcb/ZBbskgd1YN+7BBAYHeMlecbmg+H9Qs/FGu3l3YxNBdaRp9tCJZF2yvGs4kQ43ED50BOMHPGcUAa2k+M9D1u6+z2F1MJGgNzH9ptJrdZohjMkbSIokXlfmUkfMPUUaV400LWr2O10+7laSdWa3aW1lhjulXqYZHULKMc5Qtxz05ridL8Ka9LFcaTY22s6Bot1pc1pc2eqalFewwyGIRx/ZWDvKFB3E7mQYAwuTxa8L+GbiLU9FGo+F9Whn0wFnvb7xJLcW0cgQx7oIvOctuDHAdI8KT3wpAIdI+Jeq6xd+DrERQ29xrNpJd3ki6ZcTxgK6KEQqwC53HLszBMLuHzDPc6prdvpmr2VvdX0UCzQXExha3d3lWIKWZXU4XaG5BBLZGMYNcZ4N8J61pN34LfULLyl0zRry1uz5qN5UkkkJReCc5CNyMjjmtjxhoWo6p4l0q6sLfzYLfTtRhlbeq7XljjEYwSCclTyOmOcUAXtM8feHdYmhj0+7nkNxbNdW5axnRbmNQCxiZkAkIDDKoSR6cGqGgfEnTNU8I2utahHc2bXVzLbxWq2c8ksrKzcRoE3yfIMkqpAw2cbTirp3hvVbaL4co1rsGi2pivwJE/cn7GY8cH5vnwPlz69Oa5228Ga1FpXh973RtSkbQ5r63mtbHVBazXEc8gdZoZI5kyBtAKOyEgtxkDIB3tx488OWuk22ozX7iC6u/sUSraytKbjDHyTEFLrJ8jfKVBzgYyQDH/wsDw79subX7ReefZwie6T+zbn/AEVDF5oMv7v93lMkBsEkEdQRXNweErsroU9loFxp4TxL/aN3HeaqbyfyxayRCWR3dvmJ2DYjvgbTnqBrJ4ZvrjU/HgliWGLXEjitZi4O8fZBGSQMkYbPUfSgDof+Eh0vzdOj+1fPqkTTWg8tv3qKodj04wrA84rK0j4i+F9dktk0vUJJhdoz2shs50juNo3MsbsgV3AzlFJYYbI+U45yw0/xHdar4TkvvD02nW+iadcW93LNcwPukaBEBQI7EplTyQD0yorL+H9trPiDwH4Cs5NEaxs9MEN9JqMk8TxyokbBFiVWL723jduVQAHGW4yAd34H8Wp4z8PNqaWs1qVup4DHLDInEcrIpBdV3ZVQTjocqcEEDmZ/iwn2VrtLR7W3g8QjS5zc2k4Jhw3zKCqkyEr9wBiMgEEkZ6D4e6dqGjeG5tM1WxktpbfULx0kLxsk6SXMkqum1iQNrjhgpzniubXwxrhvTbtpUnlQ+MBqwuDNF5clu287lG/dlTjIKg8jGecAHYQeNNBn0e+1P7a0Fvp77LsXNvJBLCxAIVonUPlty7Rty24YzmrOjeJNM15549PlmE9sR51vdWsttMgYZVjHKqvtPOGxgkEA8HHE+JfBmsarf+JriC3ZkkvtOvrSNbswG6ECr5iLIjBomOCFY4w209Oa2fCOjC21y71E+H9U0wtbrAs+r6097PINxYqE82VVQZznfkkn5QOSAX9X8d+HtD1SbTdQu5/tsFuLqW3t7Ke4dISSPMIjRvlBUgt0GRnG4ZnvvGGiWAtN11Jdtew/aLdNOtpbx5IuP3oWFXOz5l+fG3kc81yU2panpvxm8QPpegz6xu0WyBW3nijaN/MuNufMZRtPOSCSMD5TnjMtfh7qPh250ua4stS1mJNGhsJ00LVnsXgljkkfIHnQh4j5pAy2V2jj5jgA7q78eeHLRdOP297o6pC89ktjay3TXCLt3FRErE43DPtk9jhqeMdLttPlur7UluR/aM9jElpYzGRpEdlMSxDe8jLtOWUYO0sAB0w9D8KXmn+JPC91Fo40+zstOv0niN+bowSzzRSAGRzvdjhyTyAcjJGCaFj4Z1/RtRttbTS3vXs9b1aZrGKeJZJbe6mJSVCzBNwAU7WZThm7jBAOx/4TXQP7DXVhfM1s1x9lCLbyGczhiph8kL5nmAg5TbuGCSMCqnhHxd/wlOseIooQv2PTbuKC3YwvFIcwI7iRXwQwdmXBCkYwRmuZj8M+IINYHi7+y2e5OuvfnRVuI/NEDWv2UfOW8vzQAHI3bcFl3E8ne8FWGrRa/wCKtU1jS20xdUvopraF5o5GKLbxx5bYxAbKHIz1zgkYJANHVfHHh/RdQks9RvXjkh8v7RIlrLJDa7z8vnSqpSLPB+dl4IPTms1fF13dfFiXwxbL5NpZ2cdxO0mmzu0zOZOFlyI41GxfmIYMSyjkHGTqWj+IbCHxfo+naG2pxeJJ3mtr8XMUcVuZoUhcTqzB8Js3ZRX3KQMAjFbGgeHL3SfHd1dSKZLEaHY2MVyWXMkkTzbvlzkcMp5456nBoAmu/HFrZePJvD1zb3EcVvpjX8t39mlZBgnIyE24CqTuzyTtHIwZY/iB4dm0qPUYrm6e2mlEVuRp1xuumIJHkp5e6YYBOUDDAJzgVl+JNF1a48ZXt1ZadJdW194em08TRyxqIZtzuocMwOGyACobk84HNZ+qeENRbRfBk/2C8un0Sz+zXdhp+om0n+eKNSY5FkQEqyfdLgEE85ABAOrbxroK6Omp/bJGhe4+yrElrK1wZ+cxeQF8zeACSu3IAJIwM1j658TtK0/wy+q6ZHdXrR6hDp8sDWVwkkEjuoO+Mx71wr7gCBuOFBywrHfQdds9FD6Bo2raUl9qTvqcMWrpc6nPB5JjDedO7JGxZY8hZCQighg3Ay4fBviJNC8TBdGuka61uw1GztbjUluZpYYmgLKZZJD+8xEchm2g8BiADQB3N38R/C9hd3Nvd6hLE9nJHHdsbKfZal1VkMz7NsQIcfM5A+8M5VsXbDxhoeo/bvKvGg+wRCe5+2wSWvlxHdiX96q5j+RvnGV4PNcdq/hbXNQ8OfEGKHTmWfXLiKWxheaPc4FvAhBIbCkMjDk9uMjBq54w8Har4j13XRahYbe+8PxWkM8ku1DOk8kmxtp3gYK5YDgMcZIxQB0Gn+ONB1JJ2gubiIwWxvGS7sp7Z2gHWRFkRS6jjJUEDI9Rlmn+PvD2qSIljdXEhltmu4M2E6i5iUAsYSUHmkbl4TceRxXL23hu5vkuph4U1mxu10u4gjm1jxE94VklTBjiTz5VIJAyzbOi8HnGpZ+HtUguPABNrsTR7N4r7Ei/uSbYIB1+b5hj5c0Aa/gfxSvjLwjaa2LWS1NxkmF43XZz0BZRvGMfMBgnOPSorH4h+GNSvYraz1F3aa4NrHK1rMkLTjOYvNZAnmcH5N249hzUfw407UNG8B6fpOr2MlndWCmBg7xuJcHO9SjH5TnjOG45ArhvCdprPiHwBp+hQ6K0FomuPdNqrTReUIor9pjtUN5nmFk2Y27eSd3agD0BPHvhySTUgL91j0ppUvbh7WZYIGjOHRpSuzcOPl3ZIIIBBBqSDxroM1vezSXklmLGH7RcpqFrLaSRxc/vNkqqxTII3AYyCOorlLrwVq194C8R6Z5Ihu7rX5dStozceWJ0W6WZAZIzlNwTAPBUkHtSweGPtkeqzP4L1Jmk0uS0EeveI5J3uQ7AtCuJZlRTtB8zKsDjAxkgA6u08Z6FeQ30n2uS0GnxCa6XULWWzaKM5w5WZVO35W+bGMgjPFV/+FheGl0+7vbm9ms4bONJpxe2U9u6xu21ZAkiKxQtxuAI965F/CvijVNL1vT7Y6tZ6ZNFHLa2niG/iuZPtCzLJtWSNpHERVNp3uxyxwMDnW8UL4h8X+EdR09PCs+nlkgKC8u7cySuJkZlURuy7Qqk7mcEnACnrQBJ4i+ICWWgarqGjTA3Fpo81/DY3+mXEEjFGxvYvsOzPG3AJzkHFbei+M9E1yZoLS7ZZ0thdFZ7eWASQnjzYzIqiSPP8abl5XnkZ5j4g+FdZ1y91uTS7Pz1uvC89hCfNRd07SBgnzEY47nj3pdY0DW/HF0VvtLbw/Hb6Pe2HmzTRSmWW5RUzH5bHEa7M5baxyvyjBoA6fSfGeha3eR2un3UpknQyW5mtZYUuUHVoXdQsoAIOULDBB6EViX/AMSbCTWtAsNAlFz/AGlqn2WSWW0mWOSIRSszwSkKkmHRBuUsMN7g1laJ4TnuLrTotQ8N6zZT2cEqvqF74kluYYJDE0W63i86TdkOwG9I8KT3+UstNH8Tvb+BdHuPDjQR+G7yMXd8LqExSJFbyQq8QDbyrZBIZVIyBg8kAHRfEDxbceFbHTFsEP2rUb5LVZTp892kSnlmKRYLNgYC7gTyRnaRVw+ONCt9QXTrq/Y3CzLayzrZzC2WcgfuzNtMaOcj5GfdkgdSKb4w0q91WTw+bCHzRZ6zBdT/ADquyJVcFuSM9RwOa5K58NeIf+EW1bwXFpDyQ6jqM8yayLiIQxwzTmYsylvM8xdzKFCEEhTuAJwAdxa+LNIvfENxolpNPNfWsnl3CpZzGOFtgcB5NmxcqRjLc9BkjFTv4g0uO+1CzluhHPptutzdK6MvlxMGIfJGGHyNyM4xg1l+FdIvdN13xXc3sHlR6hqouLZtynzIxbwpng5HzIwwcHiua+KOi3V9ruiRaY219fLaHqChsFrRj50jevypHKo/660AdTfePPD+n21rPPc3LrdWgvUS3sJ55FgIBEjoiFo156uByCOoONK317S7zUYbG0vI557izF9D5WWSSAkASK4+UgkjHPOc9K5q7tdY8N+NNV1jSdBm1u21Sxt4kitJ4Ynt5YPMwrea6jYwk4KkkEH5eRWTofhjW/BV5oNxFpr615GjPp9ytjNGnlSmVZQR5rJmPllyPm4Hy88AHf6Vqtlremx6hpc3n2spYJJsZc7WKnhgD1BFXK5P4f2OqaD4M0jS9Y0547v9+1wYpY3jgJlZhk7snIbjaD74rrKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvm34yf8nTeAv+4d/wClslfSVfNvxk/5Om8Bf9w7/wBLZKAPpKiiigAooooAKKKKAOb+I/8AySzxX/2Bbz/0Q9ebfsqf8ks1L/sNS/8AoiCvSfiP/wAks8V/9gW8/wDRD15t+yp/ySzUv+w1L/6IgoA9tooooAK5nWPEmrW3i638P6HpNnezy2L3ry3l+9sqqsiptG2GQk5cHtWpDBri608s+o6e+mHOy2SwdZl44zKZip5/6Zj8K5nW7z+x/ixZapd2WpS2R0Sa386z06e6AkM8bBT5SMQcKTz6UAbnh/xE+qXGoWGqWa6dqumuourdZvNj2OCY5Ukwu5GAbkqpBVgRxk29I8Q6Lr6SvoOr2GprCQJGsrlJghPTO0nGcGuA1jRtW8Waf4x1awsLmBNRsraxsbW6jME11FA7vISj4KCTzWQB9pwMkAEGtTTZP+Eg+I+maxpGlX+n2VjpM1vdy3thJZmQyPGYoQsiqW2bJDkAqN3ByaAOr1PxFouiHGs6xYaedm/F3dJF8uQu75iOMkDPqRS3niDRtO0uLU9Q1axtbCbaYrue5RIpNwyuHJwcjkYPNYVxpssvxmsdRezkeCHQp41uTGSiSNPF8u7oGKg8dcZ964/wzZX3h5/C+q6vpOoNYWcGp2nkwWMkslnJJdbopPJRS+0xIVDKpwGGcA5oA7nWfHmg6LLoS3GoWzprs4itJVuIwjLsLeZuJ5TgAEZyXUd62dS1bTtHthcavf2thATtEt1MsSk4LYyxA6KT9AfSvL7bTL+yg0DU20m+gsP+EruNQS0jtHeW0tpYZlQtEgLJl23EY+Xf82DnHXePNOl1K58KCO0kukt/EEFxLsjLiJVjlIdsdAG28nvigC5rGs+Db2xtLbX9S0K4tdR2yWsV7PC8dzyNrIGOH5IwRntV3VPFGgaJIY9a1zTdPcBSVu7uOIgNu28MR12Nj12n0Nefa/plzaeNPE8+p3PiSKz1eGEW40fSor1LiJYQjQOWt5Sh37zhiqESZHO6qthLp/hf4kSQ3+j6verB4SsbVGNkb64QB5gYpPJDDcwUZYfIShy3TIB6Nd3Xhjws02p38+k6M2oSKJruZ4rc3LgHbuc43kDOMk8ZqxqHiHRdIsIb7VdXsLG0nIEVxc3KRxyEjI2sxAOQCeO1eWWXh3WfDk/hy41WfW9Nhg0T7EG0azjv3s5fMLmJl8mYgFCi70GMxYJ+7VuK3utBsNAt9Ntta0/T3ju5Tqs+ii91G2LzI/lJFCjLbiQFj80ZACqpVWAwAdnqvxA8PaU+h79TtJo9cuPItJo7qPyyApJfdu5XIC5GfmZR3qz4q8YaT4OtbO41q4igS8u47VDJKkYG9gC5LEfKo5J7AV5p4e0/VrDQfDM+o6VqyfYfFt5cXCSWReaOKRbgK7JCuCCZFyyDZzxgV3XxGhnfR9KuILa4uUs9asrmZbaB5pFjSYFmCICzYHOACaAJtL8faNe6vf6ZfXtjp95b6i1jbQTXqCS7wqEMinBOS+MDPTrzWvf+ItF0q+t7LVNYsLK7uiBBBc3SRyS5OBtViC3PHHevN9S0K8fwN8Rmt9JuGvb/AFZprYfZW8ydVSAxsoIywDBsY6EHvmk1rSLi38TeLk1i48TJbayY2gTSNLivIryDyBH5LM1vIY2DBxh2RMSAjqxoA9Zd1jjZ5GCIoJZmOAB6ms7TfEmh6zbT3Gj6zp9/Bb/66W1uklWLjPzFSQOBnms7VNIgm+Gk+kXlpqV7AdM+zyW6PGbuRfL2kZyEMn0OCfauHE2uvaeIGt9Nk8T2q6YBHPrXh5rW5bDjFsy7Y/tKBTK+1UXk7cktQB6Lp/izw7q8VzLpWv6XfR2ieZcPbXkcghXn5nKk7RweT6Goj418KhLlj4m0cLZkC5Jv4sQZOBv+b5cnjnvXmLW2tal4q1a8f+3NUin8J31oLq60Y2aG4LxsIYozGsgGCdokLE8gMxBrpdK0KS38XeBZRpTRQ2Ph64hd/s5VbeQi3AUnGFYjeMcH73vQB2l14g0ax0mLVb7VrG206YK0V5NcokLhhlSHJwcjkYPNW7S7t7+ziurG4iubaZQ8U0Lh0kU9CGHBHuK8cstF1exs/Cl/ef23p1rYf2nA7abYLPPavJcExOYXhkOwxqy7lTI3ryFY16D4C0+Kw0O6a3/tcpdX01zu1eCKCWQsRlxHGqbFYgthlVskkgZoA0h4n8PS6oulLrmmPfyl0WzF3GZXKllYBM5OCjAjHBUjsaSw1Xw7bXkfh/TL/TIbmBCkem280avGqjkCIHIA9McV5PYBNT8O+KPD+naJevq174ru5IbpbJ/JDLeEidrgDYvlhDwWDfKAAdwz0EvhrVL7wj8RrOxs5Yb3VNUnaDeBGbqPyYRhWcbSrAOoJ+XJOe9AHeaT4j0PXkmfQ9Z0/Ulgx5xs7pJhHnON20nGcHr6Gl0jxFoniBZToOsWGpiHAlNldJN5ec43bScZwevoa86tdJstdlmlnXxpqoXRbizkhvNLg08LDKqg24zDAXc7Rt2llUrkkZGaYsfEetab4g0rRmvL+G40OWC21DWNFOnXls5CrHa+aVjEqn962VQBSRljkUAel2vi3w5fQXk9l4g0u4isV3XckV7G62688uQflHB646Go4vFek3V4osdX0e4tFjmaeVNRQvGYtu75QCCFD/MSw25Xg7uOM8V3Vp4i+H+s2eh+FNWjvo9Cmt4mk0l4DCCoAtkLgM+SBxGGX5ASfu5Xxzps8V9bS29nKtna+FNVhaRIj5cRKQ7UJ6AkKcD/AGT6UAdlZ674Vub/AFC6sNU0eW7t4R9vmhuImkijTcR5pByFXLfe4GT71U8NeN9P8WWWmXukT2Zt79Zj5cl4v2hCmPlEaghiAwLDcNuV65rk/Cirq9x4DOkaLeWCaHaP9tlnsnt40Rrcp5SOwCy7pCr5QsuI8k8jOXoOjaxcaP4QsbeyvrK8sdK1SymlntZYhbzskYQ7ioGCejDIODgnBoA9VsfEWiapqFxYaZrFheXlqSJ7a3ukkkiwdp3KCSuDxz3qOy8U+H9S1BbHTtd027vGTzBbwXkbyFMZ3bQc4wQc1wekwS6jJ4E07TtB1DTLrw85N/JcWLwR28a27RPEshAWXe7IR5ZYEJuJ4FQaDoF7Y+AfhzDHpM8FzZ6sktzH9mYPAGjn3s4xlQSwyTjqKAPUpLy2iu4bWW4iS4nDNDCzgPIFxuKr1OMjOOmRUSavpskMc0eoWrRSTm3R1mUq8oYqYwc8sCpG3rkEdq5j4kw39vpFhr+iWE9/qWiXi3EVtboWkmR1aKRQo6/LJux/s1zvhjwjqmj+ONN0W4gmk0bSYzqyXbL8kt3JAsBXOMFt32mQjt5in0oA6dPiHpK6xpOj3F3p7ahqdpJdRi1vkliwhAAVyFLFiTt+UZ2P/dqfwf470fxdpdhJBe2MWp3Vml1LpaXiSTQBlBwVGGwNw5KjqPWuH8KabqOmf8IG99pl/GI9FvrOX/RJGMMrvCUWQBSUyEblsDjrU/h3QLzT/CPwqii0me2msbgNdoLYq1vvtJ/MLjGUy7DOcZJHegD0aPxFosutvo0WsWD6pGMvYrdIZ14zzHncODnp0qU6xpi2kl02o2gt4pvs8kxnXYku/Z5ZOcBt5C4654615ZaaffN4T0Pwn/Y+oJr9hrUNzPeNZusCbJzJLci4I2NvQsMBi5Mm0j72GapFf2/hjWvDa6Nq01/N4oF6rRWErQm3fUI7gSCULsYBTggNuBByAFJAB6JoXjLSfEOu6zpWm3MUlxo84gnVZkYsdoJIAJO0E7STj5lYdqu6j4i0XSLy3tNW1iwsbm5OIIbm6SN5ecfKrEFueOKwPCkU9p458ZRXVrcxfar6K6gla3cRSx/ZoUysmNhO5WG3ORjpWdK6aJ4q8WnX9Dv9Vg1nyWtRa6a92l1CsAQ27FVKphw/EhVf3uc8tgA7C98RaJpuqW+m6jrFhaX11tEFrPdIks25tq7UJy2TwMDk8VHqPinw/o85h1bXdNsZVKgx3V5HGwLAleGI6gHHrg155qVtLZab430W/wDDmo3t54gfdp/lWTTxyo9ukUUbzLlIvKdTneyhR8wJBzWhZeH71NZ8ZHUrOS6mn0GztBctEzC6YQzCRVJHzZYjI9xntQB22qeI9E0OWGLWtZ0/TpLjPkpd3SRGTGM7QxGeo6etWxfWhuprUXUJuII1lli8wb40bO1mHUA7WwT1wfSvJbqyurHRNKuVTXbLV5fD1nb3Uf8AYR1G0vlRSWtpo1UujZd1OWi+/wBTg41IpdT0TxFd32r6FeCfVvDllAkGmWbzxR3UfneZBuQFYwDIuGchcfxcGgDe1n4jaTolxcSXDRy6ZDorauL2G4RhMocIsaA4Vi5I2ndySB3q3pHiHRI9PiksrjRbPSfsS3u6G8RfL3u25igAUJuz8+7ltwxxmvN7bw9rL+DY7UaVeCdvhzJYiNoGUi4KgCI5HD/7J5qXxXpt/rWm6xLZaVqMsdz4Qt7VFaylR2lW4fdHtZQ24DnGM4IPQg0AesabrukazJcR6PqtlfvasEuFtbhJTC3PDBSdp4PB9DUOn+KfD+rXX2bStd02+nyw8q2vI5GyuNwwpJ4yM+ma4vxv4d1TUtf1K18P2zQm58JXNlDMkeyPzPNTy4t/RTgtgZ4BJqKHUbHU/iv4POn6Ne6d9m0u9jYXdi9qUUCECJQ4G8JnquVG7gnJoA9I+22v2/7D9ph+1+V532fzB5nl5xv29dueM9M1Ru/E+gWGmx6hfa5pttZSyGKO5mu40jdwSCoYnBIKtx14PpXI/FaTUNEt9O8U6DF52pWjSaesY/5aC6ARB+E4gP0DetRxaQvgXxJoE0tle3uk2WiHTIp7OzkungnDKzO0cas48wLywBGVwSMjIB3q6lYu1qqXtuzXiF7YCVSZ1ABLJz8wwQcjsarXXiTQ7G3ae91nT7aFJmgaSa6RFWRQSyEk43AAkjqADXm2j6bf+Hv+EX1e+0m/hsIb/VJBaW1o88tjBclngRoogzAAAKQoO0sAcUzT9K1C/v8ASbm40W+ii/4Ta7vik9swMcRgl8uVhj5RuK4J7kDrQB6vHfWkunrfxXUL2bxCZblZAY2jI3Bw3TbjnPTFYWleNtM13xW2k6LcWmo2y2P2v7daXSypu8zYY/lyMjg5z36VH8RdOu9T8E3ENjbPeGO4tp5rOMAtdQxzo8kQBIBLIrDHfp3rifENhfeMPEPiibw3pGoW5vfDH2OO5u7OWy+1SiViY8yKpB2nblgOvoM0Aem6T4i0TXmnGhaxYakbfAmFndJN5Wc43bScZwcZ9DVKfxv4ahsdTuY9c065GlxtJdx293G7xBeMMN3ynIwM454rjNWgu/GOpRSeEdLv9HktdAvbR7i+sJLLY8yKsMA3qN+113HblF2jnkZv289pqfhaLSLHwvqUGoWmjTWyNPpjQJZkxBTEsjgBtxAH7oup2gk4ANAHRWvjnw5N4X07XrvWdOsbLUIw0UlzeRopbHzJuJwWUgggdCD6VJqWoeE9Jv4Na1i70ayu5bcxwX91LFHI8IYEqsjEEpudTgHGWHrXD6BPJpGoaHrep6Tq0lifDUOmqE0qeSW1uI2JlVoQnmKHGz5tu0+WOfu5b4U8N6jY654He/0uaGO0t9YlVDHkWCzTRtDEzDKqwjJUDPGGA4FAHqwIZQVOQeQR3oqG3uo7nzfLWVfJkMbeZC8eSO67gNw5+8Mg9jU1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV82/GT/k6bwF/3Dv/AEtkr6Sr5t+Mn/J03gL/ALh3/pbJQB9JUUUUAFFFFABRRRQBzfxH/wCSWeK/+wLef+iHrzb9lT/klmpf9hqX/wBEQV6T8R/+SWeK/wDsC3n/AKIevNv2VP8Aklmpf9hqX/0RBQB7bRRRQAVTOrWS64mkGb/T3t2ulh2NzErBS2cY6sBjOeahh1S8k1p7J9B1CK3XONQeS3ML4HYCUyc9OUFef+PdH13XviVDp3hrVYdKnm8O3AknkjZiU8+P5FKkFNxwCw5AzjnBAB3+leItM1u7vbfSrhrlrGXyZ5FhcRB+6rIRscjoQpO08HFadeT3Pign4S2tt4fs4/D1xb30Gk6lZef9n/s0s4V181Vbyw2QFlAJxIGGG5EGs3fijwpoPiBI9RsrUeVZlLY6/Nfz2IknEctwZZod8cZQk5IcKULAfeBAPX6K8h1keIvD2g+KQdSt7CMeHbi5htIvEdxqF0kq/duEaaNZEXBIOGK5C4AOSdvQydN8W+G49M12/wBVi1nTJbm9W6vHuVcKI2S5UEkRAtJtwgVDuGB8owAeh1RvdZsNOvrSzvJ/LnvBIYE2Md/lrufkDAwvPP4VyvjW4e78RWOj2cep3V2bWS6+z2+qtptskYdVMs08Z804zgKgYcncvRhxXhnVrrWdL8DXV9dNeSrJrMQuGnM3mIglVP3hAL/KFG4jJxk8mgD2PS9TtNZ0m11PTZfOs7yFZoJNpXejDIOCARwehFNj0myi1ufV44cX1xBHbyy72+aNGZlXGcDBduQM8/SuT8GyPD8BdHkidkkTw/GyupwVIgGCD2Nczo2nXFxd+BI7jXtekTXtGluNSU6rOPPdY4HUghgYsM55j2EjhsgkEA9eorxmDWNf1LTfDGjQ3Mk8U99qlvLJcatNZSXP2acpBGbmNHk3bNzEDBbyyS3UHQhn1gS6X4e1vW4ksLrXZraSTTtYkmmhVLfzY7OS6KpIHLgnPDlQqknJyAeiR+INOmu7u2gllmms7pLS4SK2kfypHVWUHC9NrqS33RnkjBrSrxWxlfSdS1yHStUu5Yx440+2aY3TO7J5cCtE75y4HKHcSTt+Yk5NdN4Y8rVLNfEut+Ib+x1IaxPbvC2otHbxlZ3hS1Nux8vlAo5XeS24HJBoA760uo7y3E0KyqpZlxNC8TZVip+VwDjI4OMEYIyCDU1ePaJNqGvXXhGyvtZ1QW91ca79qEN9LE06xXREal1YMAoxjBBAGOhILG1XXZ7bTdAt7yWa3bX9QsDLdarLaSTJAzGGE3SI8gJGenzN5eC3JyAeyUVyvgVdUt4NUs9WvrO5FtebYIINSe+ktEKKTFLK6I7HcSw3AttYDJwK47Wr+6k8O+M/EcutX9prOiX8sVjbxXrpDEIyvkRtbg7JPNyPvqzN5mFI+XAB63Vdb+1fUXsEuI2u44lmeANlkRiQrEdgSpA9cH0rzvUtcvbWy+J0t1qE1s9nYRy2ymcj7MWssgpz8uZA2MYyw9aXwjZJJ8V7u/kmu5Lh/DenSMXu5WVmZpgSULbT90HGOCWI5YkgHpdZuq+INO0W4s4L+Sbz76Qx28MFtJO7kDJO2NWIUDqx4Hc1zOrg638TJtD1TUb2y0+30dLu2js76S0aaRpXWSQvGys2wLGNudo8zJByuOV0YSeI9c+Hmp6td3k9wV1FFnju5IhcRwuRFIVRgp3qFYkDDg4OVwKAPVtN0my0eGeLTofJS4uZbqQb2bdLI5d25JxliTjoO1XK4rxpFNf+MvCWl/b760s7yW6+1JZXclu0wSHcoLxkMPmAPBB6joTXIXMnibUJPEt/a6ja2Euk30ltb3V94kuLaOxjjx5ZlthE0cgZcMWkZiwfqOMAHslFeOfEPVrmW08Vahpc2pJLotrslvW12SwtbSbyVdEhiiyZ3YyA/vVAYkKHxgDctnbxZ4kvbfXdW1DT4bLR7S5tks7+Szz5yuZLgmMrvwyBRuyi7Tx8xyAd3b6rZXeqXunW82+7sRGbiPYw2bwSvJGDkA9M1Ne2cGoWFxZXieZb3MTRSpkjcjDBGRyOD2ryeXTo9U13xvqUGu6g/wBm0i0mtbrT75oFlf7M7LOTEQsmcAgEFOT8uDXa3eu6mvwhl16yTztU/sQ3kahM7pvI3j5R1+bsOvSgDpLW1hsrOG1tU2QwRrHGuSdqqMAZPPQVS0XxBp3iG3ln0mSaaCOQx+c9tJGjkEglGdQJFyD8y5HvXDWka2WueE7fTNd1LUoPENpML/zdTlm82IW5cXKHd+5O/aMxbF/eAAcLjT+D1jFZfDDTDC87ed5jt51xJLg72Hy72O0YA4GBnJxkmgDuKp6Tq1lrmk2+p6VN59ncpvik2Mu4euGAI/EVxHg3ytS0fTPE2r+Ib+21W7vHSaGTUWEDSb3T7J5DHywRjHyqHymc5znmvBdtNofg/wCH+qWupai02pX62lzDJeSNbtC8cxCCEny1wUUhlUMSCSTk5APVk8Qac2oWli0k0d1e+d9nimtpI2fySBIfmUYAyME8MCCMjmprvVrKx1Cwsrqby7jUZHitU2MfMZUaRhkDAwqsecdPWvILTVtT+1aPqKPNf6hbjxKbcTOXZjHNiNMnsNqqB2GBV21trRPF3wyv4devdRuNSa4uJRc37TrOfsMpaVEYlYwC2MRhV+YAjgYAPXqK8UsZ9XtvhP4YvoNUv7q+1+9htr+6vtXnjURnzSqq+HEG4rHHvRAx3DncdwtayfEekaFq9i+tR2WNQ0pYILPW5b+6svNuVWQvJLGr7HGCFfcOHH3eAAew0VxfhtZNJ+I2uaDBd31xp6adaXkSXt5LctFI7zI+15GZsERpxnAIOMZNdpQAUUUUAFFFFABRRRQAUUUUAQXtlbajYz2V/AlxbXEbRSxSDKurDBBHoRWZo3hHR9BvGu7CK5e5MIgE15ezXTxxg52I0rsUUnBIXAOFznAxtUUAZ9/olhql9ZXd9HJLJYyebAvnyCMP2Zow2xyOoLA7TyMGtCiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5t+Mn/J03gL/uHf8ApbJX0lXzb8ZP+TpvAX/cO/8AS2SgD6SooooAKKKKACiiigDm/iP/AMks8V/9gW8/9EPXm37Kn/JLNS/7DUv/AKIgr0n4j/8AJLPFf/YFvP8A0Q9ebfsqf8ks1L/sNS/+iIKAPbaKKKACoTZ2xvhem3iN0sZiE+wbwhIJXd1xkA46ZAqaigCi+h6TLPezyaXZPLqEXk3kjW6FrmPG3ZIcfOuOMHIxxTNN8PaLo1lNZ6RpFhYWs5JlgtbZIkkJGCWVQAeOOa0aKAOa1HwJosnhDWtC0HT7DQ11a1kt5JbKzRACylQxVdu7G48ZrS0Xw5pHh9JP7I0yyspZwv2mW1tkiadlzhnKj5jksec9T61p0UAZ2r+HdE8QLENe0ew1MQ5MQvbVJvLzjO3cDjOB09BT49E0qJkaLTLNGSSSRCtuoKvJnzGHHBbJ3Hvnmr1FAEENjaW+npYW9rDFZpH5SW6RhY1TGNoUcAY4x0pkemWETWjRWNshsozFalYVHkIQAVTj5RhVGBgcD0q1RQBnXHh7RbvS30260iwnsHkMr2slsjRM5YsWKEYJLEnOOpzQfDuiHQv7EOj2B0np9gNqnkfe3f6vG373zdOvNaNFAGbbeG9Ds4Fgs9G0+3hWVJljitUVRIgAR8AfeUKoB6jAx0obw5oba4NabRtPOqjpfm1Tzx8u3/WY3fd469OK0qKAKcGj6bbPA9tp1pC1uZDC0cCqYjId0m3A43HlsdTyajuNA0e70+ewu9JsZ7O5lM09vLbI0cshbcXZSMFi3OTznmtCigCrp2mWGj2KWWk2VvY2keSkFtEsca5OThVAAySTUFx4d0W71iHVrvR7CfUoABFeS2qNNHjONrkbhjJ6HvWjRQBmah4a0LV71LzVdF06+ukjMST3NokjqhzlQzAkD5jx05PrU40fTBqEF8NOtBeW0XkwXHkL5kUf9xWxkL7DirlFAGfq2gaPr8McWu6TY6nHE26NLy2SYIemQGBwasmwtGmt5mtYDLaqVgcxjdCCMEKf4QQADj0qeigCGWztprmC4mt4pJ7fcYZXQFotww209RkcHHWqV34a0LUNWh1S/wBF0661CAqYbua0R5Yypyu1yMjB5GDwa06KAMu88L6BqGpf2jf6Hpt1fbPL+0zWkby7cEbdxGcYJGPQmk1Hwr4e1e3tYNW0LTL6GzUpbR3NnHIsCkAYQMDtGFXgeg9K1aKAK506yMlzIbO3L3ihLljEuZ1AIAc4+YAEjB7GpYYYra3jgt40ihiUJHHGoVUUDAAA6ADtT6KAM7TfDui6Ncz3GkaPYWE9yczy2tqkTS85+YqAW5JPPrVu0s7awtUtrG3itrePhIoUCKvOeAOByamooAzU8OaJHrbazHo2npqjfevltUE5428yY3dOOvSpk0jTYra1t49OtUgs3EltEsChYGAIDIMYU4J5HqauUUAU4dH0y2likt9OtIpIWkaJ44FUxmQ7pCCBwWPLY6nrVa08K+H7DUW1Cx0LTLa9aQytcw2caSFyGBYsBnJDuM9fmPqa1aKAKf8AY+m/2QdK/s60/s4oYzZ+QvklP7uzG3HtioLXw1oVjpx0+x0XTrayMyzm2htESPzAQQ+0DG4FVIPX5R6Vp0UAQrZ2yX0l4lvCt1JGsbzhAHZFJKqW6kAsxA7ZPrU1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzb8ZP8Ak6bwF/3Dv/S2SvpKvm34yf8AJ03gL/uHf+lslAH0lRRRQAUUUUAFFFFAHN/Ef/klniv/ALAt5/6IevNv2VP+SWal/wBhqX/0RBXpPxH/AOSWeK/+wLef+iHrzb9lT/klmpf9hqX/ANEQUAe20UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFc94+1i60D4ea9qunYF1aWMssLEZ2sFOGx7Hn8K860P4R+HD4f8M+KLbXb7T/EEz2t5NrxvWaW9aUAtGQ7Ff3m/aOCTwDuyQwB7NRXluu+PfGl34n8Q2XgXTNGksvDMatfPqkkgkuXKGTZCEICnAIy3Ge+Kt6D8TrjxH4u8LWlnaQw6drmjSahIJAzSxSK23YGyAQDkZ289eKAPR6K8Ym+LnidvCemX9hp+lTX994qbQ1hkWRI2jywU53EqxIHzcgf3amHxd1/w7pHjZPG2naZJq3hc2pQaW0iw3H2gDYPnyRgkEn0OMcZIB7DRXleqap48i8C+LIviFoOiTWyaJNcRT6dNIIHOwhreRS4lzjncuBjOGzisfwZKk/xa8FSxQR2ySfD+BlhiLFIwXUhV3EtgdBkk+pNAHtlFcJ438X+ILLxVpHhTwTZ6dNrGowy3Tz6ozi3ghj9QnzEseBjp6YOR5j8RfF3iPxh8MpdMu7TT7O8svEEek6xCsshincFShjI58tm5IJ3DAxzQB9E0Vz+kw23gn4eWqX8dtZwaTp4a5W1Z2ij2Jl9hcliuQcbjnGM814T8JvHmlx/E2yul1j7Rf8AjATjWLUpIFtbkSM9vhmUBhsby8LnB+tAH0tRXmth4x8Z6z8U9f0PTbfQo9E0G4gFzPdeas7RyR7sLgld2QeSAAOxrK0L4neKm+JmjaDrqeHr3TNa8/7Nd6Kt0yL5ce8ETyKI5h/CfLzg5ztI2kA9for5w8DeMfFvgf4cW2tLp2kzeEotVlhud0khvX33DKZEx8gUEgYOSdp7Hj0b9oP/AJIT4h/7dv8A0pioA9JorwTxbr/i3VvEHw/g8TeCv+EftY/EVo0Vz/asV15rcjbtQAjjJyfSmah+0ZPaeN7i3CaQukWupGxezdbj7dKgbYZlcL5IGfm2k5wpHcGgD36ivIPiX8TvFfgvUL280pfDl/o9g8S3Fsv2qa7TcUBErovlQE7/AJfMPIHG4/LWR4h1TWNL8d/FHVfDMsEF/baHZTxyXC5CKEyxA5+YLnbnjdjPFAHu1FfOkN540udd+FF1/wASu91640i7a1kuJpfKaNrdCkk7EF2factjq2cEZzXrHww8X6l4w8PX8mvW1rb6npepz6bdCzLeSzxkHcoYkgYYDknpnjOAAdnRXzINbXwP+0B4j8W3T7bA3s+nXWTx81uJYx+LxYrA8KRSaP4M+I1zq9rFqMtzpenX00F0XVJDO3m4OxlYffB4Yc0AfXVFeSal438bf8Jc/hrwZp+gslroUOo+ZqJmAXPBQbWy2eAOnuapWnjNfF3iP4Raxd6TafatUTUSZS8ubV0jCv5YDhcMVPDh8DGOeSAe0UV454N+K3ibWfiAmi+JU8P6IJHkI0i6S7g1BE3ER4d18mVjwcKRuGSMYIGFpnxO8Z+GtJ8d654ok03UY9P1U2EEKNKBFc5RAFGMCBVy3TexBycnNAH0BRXhvh346ajqvhjxZJIdFvtT0Ww+3W1zp8dwtrKvQoyTBZMq2ORwQ3bGTf1T4g/EfR/ANjr97pWhA6i6TCeGG6mg0+2MW8vcBMtntlflGO+aAPY6K5X4c+J7jxb4Oh1O9vdGvbgyMkkujSSGH1AKyAPG20jKtz0PfA6qgAr5t+Mn/J03gL/uHf8ApbJX0lXzb8ZP+TpvAX/cO/8AS2SgD6SooooAKKKKACiiigDnviDGZvhn4niXq+kXaj8YWry/9lOUH4a6rDxlNXdvzhiH/ste1X1ol/p9xaTf6u4iaJvowIP86+eP2XL2TS9c8V+Fb75LmFlmCZ6GNmjk/UpQB9HUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAR3EEV1bS29zGssMqFJI3GVdSMEEdwRXnVt8C/DMF9aGXUNdu9Ksbj7Ra6HdagZLGFxnbtjIzwWPVjnJByCQfSaKAOE8T/CPQ/E2uXWqtqOs6VNfxCHUI9LvfJjv0A2hZlwdw25Xtwak174UaFrLaO9leapoEujQG2tZdGuvs7iE4+QsQSRx9eTkmu3ooA4Gw+Dvh3TdE0nSrS41FbXSNZXWbYGVCfNU5CMdnKe33v9qtC7+GmgahqXie71AXF0PE8UEd9BJIBGohXahTADKeAcknkdq66qer6lDouiX2qXSyPBY28lxIsYBYqiliACQM4HqKAOL074O6HY2WqxXWq63qtxqentprX2pXgmngtmzmOIlcKMnOMHmtbSfh7pWja9pOrWtxePPpOjJo0CyOhVoVIIZgFBL8dQQPao9T+JGkaV8MovHNxbXraZLDDMsMcaGYLKyquQWC5ywz835111AHLeMfAGmeM5bG6urvUdM1HT2Y2uo6Xc+RcRBxh1DYPBHXj6Yyc0B8JfDqeEYPD8cl8kMd+mpS3XnBri6uFOd8jsp3E9+B7YrpbrWvs3iKx0n+zdQm+2RySfbYoN1tBsGdsj5+UnsMc1p0AY/ivw1a+L/DV1oeoXFzb2t2FEzWrhXZQwbbkg8HGD7E1B4p8G6b4r8Pw6TdvPaRW08VxbTWZVZLd4zlChZWA9Oh4JrfooA52y8D6VZav4k1DdcTt4kCC+hlcbAFQphMAEAqxzkn2xXO+H/gvoXh7VdI1GDV9evJ9HdzZC9vRKkKMhQxKm3aqYOeADnv2r0SuV8NfEDT/FfiPVdK0rTtU8vS5Hhl1GW2C2skqMFaNH3ZLDOcYHAz6ZAObsPgN4bsbi2/4m2v3FlBdfbG0ya+BtZptxYO8YUAkcDjHCjOec9n4x8KWPjfwneeHtVluIbS82eY9syrINjq4wWBHVR26VR8c/ELRvh/aWNxri3MgvZzDGlrGHZQFLNIQSPkUDkjJGRxXUKyuoZCGVhkEHIIoAwvEHg+w8SS6JJfTXMZ0W+jvrfyWUb5EGAHypyvPOMH3rET4U6Xb+KJdY07W/EOmxT3Ru59LsdSaGzllP3mZFGfmIBOG9unFdzWFqPi2x0zxlo3hqeK4a81iOaS3kRVMaiJdzbiTkcdMA/hQByuufBDw5r+o6xcXWo65BBrD+bc2FvfbLbzuP3oj28vlc/NkZPTpjbl+HWj3Go6/eXM15K+v2CafeIZFCiNUKArhQQxB5OSM9q6yvN9U+NemabrGrWEXhbxVqI0eVory5sNPWWGMqMklvM4GOeccUAaOhfCvStBvvD93HqusXsvh+OeKz+23CSfJKoQofkHyqAAoGAPetrwt4RsPCMeqppstxKNU1KbUpvtDKdssm3cFwBhflGAcn3qlbfEXQ77V/DlhYG4uf8AhJLeW4sp0jAjCxrubfkhge2MHnriuqoA4DXfg34c8RWmuW9/cagF1q+jv5mjkjDRSopUeXlDgYJBznr1qxqnwo0HVW8RebPfQr4ht7a2uUhkQCJIAAnl5Q44AznP4V29FAHN2vgfTbTxRca9HPdG6uNMTTGRnXYIlOQQNud3vnHtWbpHwq0PRv8AhFPst1qD/wDCK/afsXmSIfM8/wC/5mEGcdsbffNdtRQBwdr8JNLi8TW2s32veJNWFncm6tLHU9Ua4t7eTnaVDDd8ueCWJ9c02f4PeHrm58RPPd6q9v4gczXFn9qxDDOWDefEAuVkDKCCSfTGOK76syPWvM8TzaN/ZuoJ5Nstx9uaDFq+TjYsmeXHUjHSgDnbX4Y2cXhjV9Ev/EXiTVodWiMMs2pakZ5IkI6Rgjav12k1f1fwRb6p4Y0/RYNa1zSk0+NI4rrS7428zKqhcMQNrZAHVfpiulZlRSzkKqjJJOABVPR9Z0/X9Lj1LRrpLuzlZ1jnjztfaxQkZ6jKnnoeoyKAMzwb4M07wTpM1lps15dSXVw91dXl9N5s9zK3VnbAycADgDpnqST0FFFABXzb8Xv3/wC1X4HResf9n5/C7dq+kq+aQ3/CY/tnbofnttHfDHrt8mLB/wDIpxQB9LUUUUAFFFFABRRRQAV8xePhN8IP2jbPxhHE39j6wxkmCdwwCzr7sCRIB6kV9O1xnxV8BRfEPwLc6SNiX0ZE9lM/RJV6An0IJU/XPagDr7e4hu7WK5tpFlhmQSRyIch1IyCD6EVJXz78BfiXcaddn4beNFa01CydobFpuDkHmBvcfwnuOPTP0FQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWR4ssZtT8F63YWq7p7rT54Y1HdmjZQPzNa9FAHzPqfjHSfEvwM0v4a6Yt7J4tb7NYS6WbORJIXhkHmFiV2gARknnI7gYONzxR4P0fxb8V/iGNdhlnSx0a3uLdFndFSYQNtkIUgMV5xnI+Y8c175RQB4B4Wu72+8S/Cm4aUzXjeHbwLJKxO5hHhck9egrk9EFiZNE/sn+2f+Ft/wBsL/anmGff5fmN5nm5/d+Vs25xzjGeM19V0UAfMviPwnpWrWvxY16+Sd9Q0jUjJYSLcOgt3wpLBQQCTgAkg8AYxXuN9cazd/COa40ZnfWZtFL27KfmMxhyCP8Aa3dM98V1NFAHzN4Gi0CbxX4Qj8ADVT4iYsPFwmM4UxlMTefv+XO/O3b/ABdfm213H7P/AIa0nSbTxVd6faeTOuu3NgH8x2xBEV2JgkjjceepzyTXsNFAHiHiix8UfEH4oa3/AMIpFoc+naHYto0g1ky+W8k6hpjH5YzvUBUOeB6HqOd1q8m1r4QeG/DOus66lofiy20W/wDLchvk3qrq3XBQrhu5BNfSNFAHzr8UdF8EaTfWfgseHntTa6XJLo08hvbpZZnkYmCKGJxl2Y5Mjtx8oIIArH1C80K80/4UXHjq4u59JbR7xbySF5WYqFC4cx/Pt4wcfjxmvqKigDy34Df8itrH9mm5/wCEb/tef+whcbs/Zsj7u7nZu3YzzndnnNcxofhjxR4j8a/ESLw94zbw9aPqzQ3EK6ZHcmbcmMh2YFeDjj617zRQB4b4m8BaNF8RPht4Nk+0y6TFp9/A6/aGjeZRECQzIQcMc5AwDkjpxXN2d/oui/CnWNC8RadPfeHbbxpc6bHvuZ1isIVwyu/lHe6qxJ2cbmPUHBr6WooA+TiscHwS8d6ZZyuthBrdm1pGIpYAsUjIVdI5WZ0VhhhuJJHNd34h+GvheD4r+DPCsNlLHo89pfy3EC3UoadioJ3Pu3HJAJGe3pxXu1FAHyx4a0iCw0P4eeJYpbp9W/4S1NIW4luZG8uz8yRfJVScBcZ6D+I9jimfEvU9BvvF2sanYafNpPinR9XQTPJ9rmneFJI1F15m8QwR8qoBDZyuCuRX1VRQB86eOR4ZPxR8Tf8AC0TrQuttv/wi/wBg87ft2c/ZtvyeZ5mPv8bvxrcvITe/FDxNDPe6lprTeCYla68ky3UBLfeZIvvOO4TrzgjrXt9FAHzT8Irbw9e6t4g8NaRptlq9heaXJFPqmlvqEKvGDhVninO0SP1BjPy/MASCawtJsPCM/wAAdPM2qjTbi11GR9Vt7u0vZbW6ucMI45jDgx/Jswyn14JzX1nRQB5r8B7+C9+HGyw0ldOsra8lhgeCa4kt7oDBaWHz/wB4qFiw2noQ3fIHpVFMlljgheaeRY4o1LO7nCqByST2FAHPeP8Axha+BfBOoa7d7WaBNtvET/rZm4Rfz6+gBPavJv2Y/C119j1fxvqwZrnVpDDbyOPmdA26R/oz4H/ADXK+MNc1P9oP4mWvhjwvuj8O6dIXa5KnBHR52/DhB79snH05pWl2miaPaaZpsQhtLSJYYUHZVGB+PvQBbooooAKKKKACiiigAooooA8k+MnwXj8eBdc8PyLZeIrZBhs7Vugv3Qx7MOzfgeMEcj8PPj3eeHbxvCnxbiuLW7tG8pdQkjJdfaYDk+zjORgn+9X0TXLeNPhv4Y8fWnleIdOV51XbFeRfJPF9H7j2OR7UAdDYahZ6rYxXumXUN3azDdHNBIHRx7EcVYr5pn+DHxN+HF7Ld/DHxA15aM277MJRG7f78b/u3x0znPsKUfHT4peGP3Xi7wT5oj6zNaSwFv8AgQyh+oFAH0rRXzb/AMNayR/LN4Iw3/YUK/p5NH/DXP8A1JP/AJVv/tNAH0lRXzb/AMNc/wDUk/8AlW/+00f8Nc/9ST/5Vv8A7TQB9JUV82/8Nc/9ST/5Vv8A7TR/w1z/ANST/wCVb/7TQB9JUV82/wDDXP8A1JP/AJVv/tNH/DXP/Uk/+Vb/AO00AfSVFfNv/DXP/Uk/+Vb/AO00f8Nc/wDUk/8AlW/+00AfSVFfNv8Aw1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNAH0lRXzb/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNAH0lRXzb/AMNc/wDUk/8AlW/+00f8Nc/9ST/5Vv8A7TQB9JUV82/8Nc/9ST/5Vv8A7TR/w1z/ANST/wCVb/7TQB9JUV82/wDDXP8A1JP/AJVv/tNH/DXP/Uk/+Vb/AO00AfSVFfNv/DXP/Uk/+Vb/AO00f8Nc/wDUk/8AlW/+00AfSVFfNv8Aw1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNAH0lRXzb/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNAH0lRXzb/AMNc/wDUk/8AlW/+00f8Nc/9ST/5Vv8A7TQB9JUV82/8Nc/9ST/5Vv8A7TR/w1z/ANST/wCVb/7TQB9JUV82/wDDXP8A1JP/AJVv/tNH/DXP/Uk/+Vb/AO00AfSVFfNv/DXP/Uk/+Vb/AO00f8Nc/wDUk/8AlW/+00AfSVFfNv8Aw1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNAH0lRXzb/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNAH0lRXzb/AMNc/wDUk/8AlW/+00f8Nc/9ST/5Vv8A7TQB9JUV82/8Nc/9ST/5Vv8A7TR/w1z/ANST/wCVb/7TQB9JUV82/wDDXP8A1JP/AJVv/tNH/DXP/Uk/+Vb/AO00AfSVFfNv/DXP/Uk/+Vb/AO00f8Nc/wDUk/8AlW/+00AfSVFfNv8Aw1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNAH0lRXzb/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNAH0lRXzb/AMNc/wDUk/8AlW/+00f8Nc/9ST/5Vv8A7TQB9JUV82/8Nc/9ST/5Vv8A7TR/w1z/ANST/wCVb/7TQB9JUV82/wDDXP8A1JP/AJVv/tNH/DXP/Uk/+Vb/AO00AfSVFfNv/DXP/Uk/+Vb/AO00f8Nc/wDUk/8AlW/+00AfSVFfNv8Aw1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNAH0lRXzb/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNAH0lRXzb/AMNc/wDUk/8AlW/+00f8Nc/9ST/5Vv8A7TQB9JUV82/8Nc/9ST/5Vv8A7TR/w1z/ANST/wCVb/7TQB9JUV82/wDDXP8A1JP/AJVv/tNH/DXP/Uk/+Vb/AO00AfSVFfNv/DXP/Uk/+Vb/AO00f8Nc/wDUk/8AlW/+00AfSVFfNv8Aw1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNAH0lRXzb/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNAH0lRXzaf2sLy4G2x8EZc8DOoGTn6CIVG3xM+N/jTMPhnwu2lxOMCdLIr1/6aTHZ+QFAHvvifxdoXg7TDf+JNShsYedgc5eQ+iKOWP0FfOniXxz4t+PfiBvC/gS2msdAUj7RLIdu9c/fmYdF44QZz79tvw/8As5az4g1Yax8V/EE17K2CbaGdpJGH91pW+6PZQfYivd9B8O6R4Y0tNO8P6fBYWqf8s4UxuPqx6sfc5NAGH8OPh1pfw38NjTdNPn3EpD3d46gPO/8ARR2Xt7kknrqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==" /></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version No.: NCDS08 
Date of issue: 4 September 2022


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في أقراص زيزال هي اﻟﻟﻴﭭوسيتيريزين . وتنتمي اﻟﻟﻴﭭوسيتيريزين <strong>&nbsp;</strong>لمجموعة من الأدوية المضادة للحساسية تسمى مضادات الهيستامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">و يُستخدم زيزال لعلاج أعراض العطس، والرشح، وأدماع العينين المصاحبة لحساسية الأنف (بما في ذلك حساسية الأنف المستمرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويستعمل زيزال أيضا لتخفيف الطفح والحكة المصاحبة للحساسية المزمنة الأرتكاريا (الشرى).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل أقراص زيزال:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (فرط الحساسية) لكل من ﻟﻴﭭوسيتيريزين، سيتريزين، هيدروكسيزين، أو أي من مشتقات بيبرازين (أو المواد الفعالة ذات الصلة من الأدوية الأخرى)، أو أي من مكونات زيزال الأخرى (المذكورة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مرض كلوي حاد</strong> (ضعف شديد في وظائف الكلى مع نسبة إزالة للكرياتينين أقل من 10 مل / دقيقة)</p><p dir="RTL">&not;&nbsp;&nbsp; إذا كنت تعتقد أن أيًا من هذه تنطبق عليك ، لا تأخذ <strong>زيزال</strong> حتى تستشير طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذير والإحتياطات</strong></p><p dir="RTL"><strong>تحدث إلي طبيبك أو الصيدلي قبل أخذ زيزال</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تواجه صعوبة في التبول أو تعاني من ظروف تجعلك أكثر عرضة لعدم القدرة على إفراغ المثانة ، مثل إصابة النخاع الشوكي أو تضخم البروستاتا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلى (طبيبك قد يخفض جرعة زيزال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الصرع أو كنت عرضة لخطر التشنجات (نوبات)</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>استشر طبيبك </strong>إذا كنت تعتقد أن أيًا من هذه الحالات قد ينطبق عليك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL"><strong>لا ينصح باستخدام أقراص </strong><strong>زيزال </strong><strong>المغلفة للأطفال دون سن 6 سنوات</strong>، لأن هذه التركيبة لا تسمح بالتكيف المناسب مع الجرعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في أثناء أخذك </strong><strong>زيزال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب الكحول أثناء تناول زيزال (انظر &quot;الطعام والشراب مع زيزال &quot; في القسم 2).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيزال قد يؤثر على نتيجة اختبار الحساسية. إذا كان من المقرر إجراء اختبار الحساسية لك، اسأل طبيبك عما إذا كان يجب عليك التوقف عن تناول زيزال لعدة أيام قبل الاختبار.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحالات التي تحتاج إلى الأنتباه لها</strong></p><p dir="RTL">زيزال يمكن أن يجعل بعض الحالات القائمة أسوأ، أو يسبب <strong>الحساسية الشديدة أو احتباس البول</strong>. قد يكون لدى بعض الأشخاص أفكار انتحارية عند تناول زيزال. يجب أن تنتبه لبعض الأعراض أثناء تناول زيزال ، لتقليل خطورة أي مشاكل. راجع &quot;<strong> </strong>الحالات التي تحتاج إلى الأنتباه لها &quot; في القسم 4.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وأقراص زيزال</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرا، </strong>أو قد تتناول أي أدوية أخرى، ويشمل ذلك الأدوية المشتراة بدون وصفة طبية.</p><p dir="RTL">قد تؤثر بعض الأدوية على كيفية عمل زيزال، أو تزيد من احتمال تعرضك لآثار جانبية. يمكن أن تؤثر زيزال أيضًا على كيفية عمل بعض الأدوية الأخرى. وتشمل هذه:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الثيوفيلين </strong>(يستخدم لعلاج <u>أمراض الجهاز التنفسي</u> مثل <strong>الربو</strong>)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ريتونافير </strong>(يستخدم لعلاج <strong>فيروس نقص المناعة البشرية / الإيدز</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعمل على المخ، على سبيل المثال <strong>مضادات الهيستامين الأخرى</strong> مثل هيدروكسيزين، كليماستين، <strong>والأدوية المستخدمة لعلاج القلق</strong> مثل الديازيبام أو<strong> الحبوب المنومة</strong> مثل الزولبيديم (التعاطي المتزامن مع زيزال مع الأدوية الأخرى التي تعمل على المخ قد تسبب انخفاضات إضافية في اليقظة و ضعف الأداء، أنظر &quot;الطعام والشراب مع زيزال&quot; لاحقًا في القسم 2).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong><strong>أخبر طبيبك أو الصيدلي </strong>إذا كنت تتناول أيًا من هذه الأدوية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أقراص زيزال </strong><strong>مع الطعام والشراب والكحول</strong></p><p dir="RTL">ينصح بالحذر إذا كنت تأخذ زيزال في نفس الوقت مع الكحول. في المرضى الحساسين ، قد يؤدي التناول المتزامن لأقراص زيزال والكحول إلى خفض اليقظة وضعف الأداء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يوجد سوى معلومات محدودة حول أمان إعطاء زيزال في النساء الحوامل<strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لذلك يجب تجنب أعطاء </strong><strong>زيزال</strong> <strong>في النساء الحوامل. </strong>يمكن أعطاء زيزال فقط إذا لزم الأمر وبعد المشورة الطبية.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أخبري طبيبكِ إذا كنتِ حاملا </strong>أو تخططين لتصبحي حاملا<strong>.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا أصبحتِ حاملاً أثناء العلاج </strong>مع زيزال ، أخبري طبيبك<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تنتقل المكونات الموجودة في زيزال إلى حليب الأم. <strong>إذا كنتِ ترضعين طفلك رضاعة طبيعية ، يجب عليكي استشارة طبيبكِ</strong> قبل تناول زيزال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التأثيرات على القدرة على القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يؤثر زيزال بالجرعة الموصى بها على قدرتك على القيادة أو استخدام الآلات. ومع ذلك ، قد يشعر بعض المرضى الذين عولجوا بـزيزال <strong>بالنعاس أو التعب أو الضعف</strong> (انظر &quot;الآثار الجانبية المحتملة&quot; في القسم 4).</p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong><strong>لا تقود السيارة أو تستخدم الآلات </strong>إلا إذا كنت متأكدًا من أنك لست متأثرًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>زيزال</strong> <strong>يحتوي على اللاكتوز</strong></p><p dir="RTL">تحتوي هذه الأقراص على اللاكتوز، فإذاً أخبرك طبيبك أن لديك عدم تحمل لبعض السكريات، فيجب عليك الاتصال بطبيبك قبل تناولها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. يجب عليك مراجعة طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong>أتصل بطبيبك أذا سائت أعراضك أو لم تتحسن في خلال 3 أيام من العلاج.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>البالغين والمراهقين من 12 سنة وما فوق</u></strong></p><p dir="RTL">قرص زيزال المغلف 5 ملجم.</p><p dir="RTL">الجرعة المعتادة من زيزال هي قرص واحد 5 ملجم. تؤخذ مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الأطفال</u></strong></p><p dir="RTL">سيصف طبيبك الشكل الصيدلاني الأنسب لـزيزال وفقًا لعمر طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>الأطفال الذين تتراوح أعمارهم بين 2 إلى 6 سنوات</u></strong></p><p dir="RTL">قرص زيزال المغلف 5 ملجم.</p><p dir="RTL">لا ينصح باستخدام أقراص زيزال المغلفة للأطفال دون سن 6 سنوات ، لأن هذه التركيبة لا تسمح بالتكيف المناسب مع الجرعة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>الأطفال الذين تتراوح أعمارهم بين 6 إلى 12 سنة</u></strong></p><p dir="RTL">قرص زيزال المغلف 5 ملجم.</p><p dir="RTL">الجرعة المعتادة من زيزال هي قرص واحد 5 ملجم. <strong>تؤخذ</strong> مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مرضي القصور الكلوي والكبدي</strong></p><p dir="RTL">سيقرر طبيبك الجرعة الصحيحة من زيزال اعتمادًا على المرض ونتائج اختبارات الدم التي أجريت قبل العلاج. المرضى الذين يعانون من ضعف شديد في وظائف الكلى يجب ألا يأخذوا زيزال (انظر &quot;لا تأخذ زيزال &quot; ، في القسم 2).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيفية استعمال زايزال</strong></p><p dir="RTL">قرص زيزال المغلف 5 ملجم.</p><p dir="RTL">يجب بلع قرص زايزال كامل مع الماءز</p><p dir="RTL">تناول زيزال بجرعة يومية واحدة، مع أو بدون طعام.</p><p dir="RTL">من الأفضل أن تتناول زيزال في وقت النوم كما هو ممكن أن يجعلك تشعر بالنعاس.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أن تأخذ </strong><strong>زيزال</strong></p><p dir="RTL"><strong>لا تأخذ جرعة إضافية لتعويض جرعة منسية</strong>. فقط خذ الجرعة التالية في الوقت المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت </strong><strong>زيزال </strong><strong>أكثر مما يجب</strong></p><p dir="RTL">إذا <strong>أخذت </strong>زيزال أكثر مما يجب <strong>عليك الاتصال بطبيبك أو الصيدلي للحصول على المشورة</strong>. أظهر لهم عبوة زيزال إذا كان ذلك ممكنًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض الجرعة الزائدة قد تشمل <strong>النعاس</strong> عند البالغين. قد يظهر الأطفال في البداية <strong>الهياج والقلق</strong> ، يليه ا<strong>لنعاس</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن أخذ </strong><strong>زيزال</strong></p><p dir="RTL">خذ زيزال طالما يوصي طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادراً ما تحدث الحكة (الحكة الشديدة) إذا توقفت عن تناول زيزال، حتى لو لم تكن تلك الأعراض موجودة قبل بدء العلاج. قد تزول الأعراض تلقائيًا. إذا كانت الأعراض شديدة ، يرجى استشارة طبيبك لأن العلاج قد يحتاج إلى إعادة الأستعمال. يجب أن تكون الأعراض قد زالت عند إعادة استعمال العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong><strong>اسأل طبيبك أو الصيدلي</strong> اذا كانت لديك أي أسئلة في استخدام هذا العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب زيزال آثارًا جانبية ، على الرغم من عدم حدوثها لكل الناس.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>حالات يجب أن تنتبه لها</strong></p><p dir="RTL"><strong>ردود فعل شديدة بالجلد أو الحساسية</strong></p><p dir="RTL">وهذه نادرة جدا في الأفراد الذين يستخدمون أقراص زيزال. وتشمل أعراضها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع حكة بالجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، أحياناً في الوجه أو الفم (أوديما وعائية)، تسبب صعوبة في البلع أو التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهبوط أو فقدان الوعي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أفكار انتحارية</strong>. بعض الناس لديهم أفكار انتحارية عند تناول زيزال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>احتباس البول</strong>. تشمل العلامات:</p><p dir="RTL">&bull; ألم عند التبول أو عدم القدرة على التبول</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>راجع الطبيب فورًا </strong>إذا لاحظت أيًا من هذه الأعراض. <strong>توقف عن تناول أقراص زيزال.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثار جانبية شائعة</strong></p><p dir="RTL">يمكن أن تصيب 1 من 10 من الأفراد:<strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع ، والشعور بالنعاس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف بالفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الطاقة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم والإسهال والإمساك (عند الأطفال)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong></p><p dir="RTL">يمكن أن تصيب 1 من 100 من الأفراد:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء والصداع (عند الأطفال)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية أخرى</strong></p><p dir="RTL">حدثت آثار جانبية أخرى في عدد قليل جدًا من الأشخاص ولكن ترددها الدقيق غير معروف:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (فرط الحساسية) بما في ذلك ردود الفعل التحسسية الشديدة (انظر &quot;الحساسية الشديدة&quot; سابقًا في القسم 4)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن ، زيادة الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوانية، والتهيج، ورؤية أو سماع أشياء ليست موجودة بالفعل، والاكتئاب، وصعوبة النوم، و<strong>الكوابيس</strong>، والأفكار الانتحارية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج (النوبات)، وخز أو خدر في اليدين أو القدمين، والدوخة، والإغماء، والرعشة، واضطراب التذوق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات البصرية، عدم وضوح الرؤية (الزغللة)، تسريب العين (عيون لها حركات دائرية غير منضبطة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دقات قلب سريعة أو غير منتظمة ، ينبض القلب بشكل أسرع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان (الغثيان) والتقيؤ والإسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع صغيرة من تورم واحمرار الجلد ، والتي قد يظهر بها بثور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة والطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحشي (خلايا النحل) (انظر &quot;الحساسية الشديدة&quot; سابقًا في القسم 4)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات والمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم عند التبول، وعدم القدرة على التبول (انظر &quot;احتباس البول&quot; المذكور سابقا في القسم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم ناتج عن السوائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة الشديدة (الحكة) عند التوقف عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية أخرى قد تظهر في اختبارات الدم:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار وظائف الكبد غير طبيعي (زيادة كميات إنزيمات الكبد في الدم)</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&not;&nbsp;&nbsp; إذا حدثت لك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية: </strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong><strong><em> </em></strong></p><p dir="RTL"><strong>-&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية </strong><strong>(</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp; الاتصال بالرقم الموحد : 19999</p><p dir="RTL">&bull;&nbsp;&nbsp; &nbsp;البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp; &nbsp;الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp; </strong><strong>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة. </strong></p><p dir="RTL">&bull;&nbsp;&nbsp; هاتف: 6536666 -12- 966 +</p><p dir="RTL">&bull;&nbsp;&nbsp; جوال:9882-904-56-966 +</p><p dir="RTL">&bull;&nbsp;&nbsp; البريد الإلكتروني: saudi.safety@gsk.com</p><p dir="RTL">&bull;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa//</p><p dir="RTL">&bull;&nbsp;&nbsp; ص.ب 55850، جدة 21544، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify; text-indent:-.25in"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>حافظ على هذا الدواء بعيدًا عن مرأي ومتناول الأطفال.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الكارتون بعد كلمة (EXP).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتخزين الدواء في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي يحتوي عليه </strong><strong>قرص </strong><strong>زيزال </strong><strong>المغلف</strong><strong> </strong><strong>5</strong><strong> </strong><strong>ملجم.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ثنائي هيدروكلوريد اﻟﻟﻴﭭوسيتيريزين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل قرص مغلف يحتوي علي ثنائي هيدروكلوريد اﻟﻟﻴﭭوسيتيريزين 5 ملجم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخري هي الحبيبات الدقيقة من السليلوز، وأحادي هيدرات اللاكتوز، والسيليكا اللامائية الغروية، وستيرات المغنيسيوم، وOpadry Y-1-7000.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل أقراص زيزال ومكونات العبوة</strong></p><p dir="RTL">الأقراص المغلفة هي بيضاء اللون تميل إلي الكريمي وبيضاوية وعلي أحد جوانبها علامة Y.</p><p dir="RTL">يتم تعبئة أقراص زيزال المغلفة في شريط من الألومنيوم وموضوعة في علب كرتون تحتوي الواحدة منها على 20 قرصًا مغلفًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليست كل الأشكال متوفرة في كل بلد.</p><p dir="RTL">أقراص زيزال هي علامة تجارية مسجلة لمجموعة شركات جلاكسو سميث كلاين أس أيه أي</p><p dir="RTL">&copy; جلاكسوسميث كلاين أس أيه أي 2019، جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع: </strong></p><p>&nbsp;Switzerland ،1630 Bulle ،Ch. De Croix Blanche 10 ،UCB Farchim SA</p><p><strong>&nbsp;</strong></p><p><strong>:</strong><strong>تعبئة</strong></p><p>&nbsp; 15 10044 PIANEZZA ،Via Praglia ،Aesica Pharmaceuticals S.r.I،بيانزا ، أيطاليا، تورينو</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك حقوق التسويق</strong><strong>:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL">العنوان: صندوق بريد22617، جدة 21416، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي ، جدة هاتف: 6536666 -12-966 +</p><p dir="RTL">جوال: 9882-904-56-966 +</p><p>gcc.medinfo@gsk.com:البريد الإلكتروني</p><p>https://gskpro.com/en-sa/:الموقع الإلكتروني</p><p dir="RTL">ص.ب: 55850، جدة 21544، المملكة العربية السعودية.</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالرقم الموحد: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة<em>.</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666 -12-966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال:9882-904-56-966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: saudi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/<u> </u></p><p dir="RTL">ص.ب. 55850، جدة 21544، المملكة العربية السعودية.</p></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>هذا المنتج هو دواء</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">- يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفه لك.</p><p dir="RTL">- إن الطبيب والصيدلي هما الخبيران بالدواء وفوائده ومخاطره.</p><p dir="RTL">- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">- لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">- يجب الاحتفاظ بجميع الأدوية بعيدًا عن متناول الأطفال.</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             نسخة رقم: 08 NCDS 
تاريخ الإصدار: 4  سبتمبر 2022

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levocetirizine dihydrochloride, 5 mg, film-coated tablet 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 5 mg levocetirizine dihydrochloride.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off-white, oval, film-coated tablet with a Y logo on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>For the symptomatic treatment of:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic rhinitis (including persistent allergic rhinitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urticaria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The film-coated tablet must be taken orally, swallowed whole with liquid and may be taken with or without food. It is recommended to take the daily dose in one single intake.</p><p><strong><em>Duration of use</em></strong><!--[if supportFields]><b><i style='mso-bidi-font-style:
normal'><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2d6f2c2f-0dde-40bf-90f8-d5df4d325d56 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>Intermittent allergic rhinitis (symptoms &lt; 4 days/week or for less than 4 weeks a year) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear.</p><p>In case of persistent allergic rhinitis (symptoms &gt; 4 days/week or for more than 4 weeks a year), continuous therapy can be proposed to the patient during the period of exposure to allergens.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>There is clinical experience with the use of levocetirizine for treatment periods of at least 6 months. In chronic urticaria and chronic allergic rhinitis, there is clinical experience of use of cetirizine (racemate) for up to one year.</p><p>&nbsp;</p><p><strong>Route of Administration</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_c8221fd0-556c-4392-83c8-1ff4da150643 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>For oral use.</p><p>&nbsp;</p><p><strong>Adults and adolescents 12 years and above:</strong></p><p><strong>&nbsp;</strong></p><p>The daily recommended dose is 5 mg (1 film-coated tablet).</p><p>&nbsp;</p><p><strong>Children</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Children aged less than 2 years</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9baca5f0-cefe-47a7-930a-232cc0cd8d52 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>The administration of levocetirizine to infants and toddlers aged less than 2 years <strong>is not recommended <em>(see Section Warnings and Precautions)</em>.</strong></p><p><strong>&nbsp;</strong></p><p><strong><em><u>Children aged 2 to 6 years</u></em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><u style='text-underline:thick'><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f9cf8154-ac79-4e4a-b1f7-3068c145f713 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u></i></b><![endif]--><strong><em><u>&nbsp;</u></em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><u style='text-underline:thick'><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></u></i></b><![endif]--></p><p><strong><em>&nbsp;</em></strong></p><p><em>Levocetirizine dihydrochloride, 5 mg, film-coated tablet</em></p><p>For children aged 2 to 6 years no adjusted dosage is possible with the film-coated tablet formulation. It is recommended to use a paediatric formulation of levocetirizine <em>(see Section Warnings and Precautions)</em>.</p><p>&nbsp;</p><p><strong><em><u>Children aged 6 to 12 years</u></em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><u style='text-underline:thick'><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3efffd25-843e-4516-a3b5-612f39a10879 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u></i></b><![endif]--><strong><em><u>&nbsp;</u></em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><u style='text-underline:thick'><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></u></i></b><![endif]--></p><p>The daily recommended dose is 5 mg (1 film-coated tablet).</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p><strong>&nbsp;</strong></p><p>Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment <em>(see Renal impairment).</em></p><p><strong>Renal impairment</strong></p><p><strong>&nbsp;</strong></p><p>The dosing intervals must be individualised according to renal function <strong>(eGFR &ndash; estimated Glomerular Filtration Rate)</strong>. Refer to the following table and adjust the dose as indicated.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>CLcr=</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="image2.png" o:spid="_x0000_i1025" type="#_x0000_t75"
   alt="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=19877&amp;key=SPC.19877.4_FILES/IMAGE002.GIF"
   style='width:245pt;height:31.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title="IMAGE002"/>
  </v:shape><![endif]--><img width="327" height="42" alt="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=19877&amp;key=SPC.19877.4_FILES/IMAGE002.GIF" src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></p></td></tr></tbody></table><p>&nbsp;</p><p><u>Dosing Adjustments for Patients with Impaired Renal Function:</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Group</strong></p></td><td style="vertical-align:top"><p><strong>eGFR</strong><strong>(ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Dosage and frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Normal renal function</p></td><td style="vertical-align:top"><p>&ge; 90</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Mildly decreased renal function</p></td><td style="vertical-align:top"><p>60 &ndash; &lt;90</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p><s>&nbsp;</s>Moderately decreased renal function</p></td><td style="vertical-align:top"><p>30 - &lt;60</p></td><td style="vertical-align:top"><p>5 mg once every 2 days</p></td></tr><tr><td style="vertical-align:top"><p>Severely decreased renal function</p></td><td style="vertical-align:top"><p>15 &ndash; &lt; 30 (not requiring dialysis)</p></td><td style="vertical-align:top"><p>5 mg once every 3 days</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease (ESRD) &ndash;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 15</p><p>(requiring dialysis treatment)</p></td><td style="vertical-align:top"><p>Contraindicated</p></td></tr></tbody></table><p>In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight.</p><p>There are no specific data for children with renal impairment.</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p><strong>&nbsp;</strong></p><p>No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended <em>(see Renal impairment)</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levocetirizine is contraindicated in:

•	hypersensitivity to levocetirizine, to cetirizine, to hydroxyzine, to any piperazine derivatives or to any of the excipients,
•	Patients with end stage renal disease with estimated Glomerular Filtration Rate (eGFR) below 15 ml/min (requiring dialysis treatment).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Alcohol</em></p><p>Precaution is recommended with concurrent intake of alcohol <em>(see Section Interactions).</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><strong><em>Risk of urinary retention</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b628f38a-83b8-4013-a76a-28a01cc77b27 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as levocetirizine may increase the risk of urinary retention.</p><p>&nbsp;</p><p><strong><em>Risk of seizure aggravation</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c92e587b-bb9c-4d4d-859d-36ffa332b8b6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>Caution should be taken in patients with epilepsy and patients at risk of convulsion as levocetirizine may cause seizure aggravation.</p><p>&nbsp;</p><p><strong><em>Allergy skin tests</em></strong><!--[if supportFields]><b><i style='mso-bidi-font-style:
normal'><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7e32025f-56ae-48d1-ba9a-aa65d4dbd2e4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>Response to allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them.</p><p>&nbsp;</p><p><strong><em>Withdrawal syndrome</em></strong><!--[if supportFields]><b><i style='mso-bidi-font-style:
normal'><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_96a39e8d-29c6-4dce-b6cb-3131bdfed608 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>Pruritus may occur when levocetirizine is stopped even if those symptoms were not present before treatment initiation <em>(see Section Adverse Reactions)</em>. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted.</p><p>&nbsp;</p><p><strong><em>Infants and children under 2 years</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_e1e4abc6-df8a-4c2f-98bf-70a95b4a56c0
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>Even if some clinical data are available in children aged 6 months to 12 years (<em>see <strong>Section </strong>Adverse Reactions</em>), these data are not sufficient to support the administration of levocetirizine to infants and toddlers aged less than 2 years. Therefore, the administration of levocetirizine to infants and toddlers aged less than 2 years is not recommended.</p><p>&nbsp;</p><p><strong>Tablets</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Children aged less than 6 years</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_baced2ad-6f31-4d67-a1a6-26de18cecb4c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>The use of the film-coated tablet formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation. It is recommended to use a paediatric formulation of levocetirizine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Excipients</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_04a69a16-26cd-4cd6-86a6-daa7582b0657 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong><em>Lactose</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ba6c3759-e8ff-4cde-86e8-dfcff7d65b3a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p><strong><em>&nbsp;</em></strong></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, glipizide and diazepam).</p><p>&nbsp;</p><p><em>Theophylline</em></p><p>A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration.</p><p>&nbsp;</p><p><em>Ritonavir</em></p><p>In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.</p><p>&nbsp;</p><p><em>Food</em></p><p>The extent of absorption of levocetirizine is not reduced with food, although the rate of absorption is decreased.</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>In sensitive patients the concurrent administration of cetirizine or levocetirizine and alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1. </strong><strong>Fertility</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:194%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5325e455-c839-4b5a-840c-dc2ee64445ae \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:194%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>There are no relevant data available.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_61f57063-f79e-43ab-93c8-50a3b2dc1532 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The use of levocetirizine may be considered during pregnancy, if necessary.There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of levocetirizine in pregnant women. However, for cetirizine, the racemate of levocetirizine, a large amount of data (more than 1000 pregnancy outcomes) on pregnant women indicate no malformative or feto/neonatal toxicity.Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.</p><p>&nbsp;</p><p><strong>Lactation</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_742355bf-6a53-48a9-b005-3baa3ae2f423 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Caution should be exercised when prescribing to lactating women. Cetirizine, the racemate of levocetirizine has been shown excreted in human. Therefore, the excretion of levocetirizine in human milk is likely. Adverse reactions associated with levocetirizine may be observed in breastfed infants.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Comparative clinical trials have revealed no evidence that levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive and use machines.</p><p>Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy with levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trial Data</p><p><strong><em>Adults and adolescents above 12 years of age</em></strong></p><p>In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate.</p><p>In therapeutic trials, the dropout rate due to adverse events was 1.0% (9/935) with levocetirizine 5 mg and 1.8% (14/771) with placebo. Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the drug at the recommended dose of 5 mg daily.</p><p>Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency.</p><p>&nbsp;</p><p>Very common &ge;1/10</p><p>Common &ge;1/100 to &lt;1/10</p><p>Uncommon &ge;1/1000 to &lt;1/100</p><p>Rare &ge;1/10000 to &lt;1/1000</p><p>Very rare &lt;1/10000</p><p>Not known (cannot be estimated from the available data).</p><p><em>Nervous system disorders</em></p><p><em>Common: </em>headache, somnolence</p><p><em>Gastrointestinal disorders</em></p><p><em>Common: </em>dry mouth</p><p><em>Uncommon:</em> abdominal pain</p><p><em>General disorders and administration site conditions</em></p><p><em>Common</em>: fatigue</p><p><em>Uncommon: </em>asthenia</p><p>The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1 %) under levocetirizine 5 mg than under placebo (3.1%).</p><p>Oral drops, oral solution</p><p><strong><em>Paediatric Patients </em></strong></p><p>In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to less than 6 years, 159 subjects were exposed to levocetirizine at the dose of 1.25 mg daily for 2 weeks and 1.25 mg twice daily respectively. The following incidence of adverse drug reactions was reported under levocetirizine.</p><p><em>Psychiatric disorders</em></p><p><em>Common: </em>sleep disorders</p><p><em>Nervous system disorders</em></p><p><em>Common:</em> somnolence</p><p><em>Gastrointestinal disorders</em></p><p><em>Common: </em>diarrhoea, constipation</p><p><em>Uncommon: </em>vomiting</p><p>In children aged 6-12 years double blind placebo controlled studies were performed where 243 children were exposed to 5 mg levocetirizine daily for variable periods ranging from less than 1 week to 13 weeks. The following incidence of adverse drug reactions was reported.</p><p><em>Nervous system disorders</em></p><p><em>Common: </em>somnolence</p><p><em>Uncommon:</em> headache</p><p>Please note that even if clinical data presented in this section are available in children aged 6 months to 12 years, we do not have sufficient data to support the administration of the product to infants and toddlers aged less than 2 years.</p><p>Post Marketing Data</p><p><em>Immune system disorders</em></p><p><em>Not known: </em>hypersensitivity including anaphylaxis</p><p><em>Metabolism and nutrition disorders</em></p><p><em>Not known</em>: increased weight, &nbsp;increased appetite</p><p><em>Psychiatric disorders</em></p><p><em>Not known: </em>aggression, agitation, hallucination, depression, insomnia, suicidal ideation, nightmares</p><p><em>Nervous system disorders</em></p><p><em>Not known: </em>convulsions, paraesthesia, dizziness, syncope, tremor, dysgeusia</p><p><em>Eye disorders</em></p><p><em>Not known: </em>visual disturbances, blurred vision, oculogyration</p><p><em>Ear and labyrinth disorders</em></p><p><em>Not known:</em> vertigo</p><p><em>Cardiac disorders</em></p><p><em>Not known: </em>palpitations, tachycardia</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p><em>Not known: </em>dyspnoea</p><p><em>Gastrointestinal disorders</em></p><p><em>Not known: </em>nausea, vomiting, diarrhoea</p><p><em>Hepatobiliary disorders</em></p><p><em>Not known: </em>hepatitis, abnormal liver function test</p><p><em>Skin and subcutaneous tissue disorders</em></p><p><em>Not known: </em>angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p><em>Not known: </em>myalgia, arthralgia</p><p><em>Renal and urinary disorders</em></p><p><em>Not known: </em>dysuria, urinary retention</p><p><em>General disorders and administration site conditions</em></p><p><em>Not known: </em>oedema</p><p><em><u>Skin reactions occuring after discontinuation of levocetirizine</u></em></p><p>After levocetirizine discontinuation, pruritus has been reported <em>(see Section Warnings and Precautions)</em>.</p><p><strong>To report any side effect(s):</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_083d469b-e710-4dfb-a1ba-9c064fe7d4dd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa<u> </u></p><p><strong>&nbsp;</strong></p><p><strong>-GSK - Head Office, Jeddah</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_73905e9e-b48d-420f-b38f-1d86a317754a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com &nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O Box 55850, Jeddah 21544, Saudi Arabia.</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1. </strong><strong>Symptoms and signs</strong><!--[if supportFields]><b><span lang=EN-US
style='font-size:12.0pt;line-height:192%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";letter-spacing:-.15pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_64968901-e692-4073-aa16-b2a70ba4aaca \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:192%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";letter-spacing:-.15pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Symptoms of overdose may include drowsiness in adults. In children, agitation and</p><p>restlessness may initially occur, followed by drowsiness.</p><p>&nbsp;</p><p><strong>Treatment</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_73085005-88ce-4dff-bcba-e025a68ff0a4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>There is no known specific antidote to levocetirizine. Should overdose occur, symptomatic or supportive treatment is recommended. Levocetirizine is not effectively removed by haemodialysis.</p><p>&nbsp;</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.&nbsp;&nbsp;&nbsp; </strong><strong>Pharmacotherapeutic group</strong></p><p>Antihistamine for systemic use, piperazine derivative.</p><p>&nbsp;</p><p><strong>ATC Code</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_66619152-2f70-41e0-919e-7c8598cbf83e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>R06A E09</p><p>&nbsp;</p><p><strong>Mechanism of Action/Pharmacodynamic effects</strong><!--[if supportFields]><b><span lang=EN-US style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5fb03578-5d9c-4701-80c8-984b1b48b22c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.</p><p>Binding studies revealed that levocetirizine has high affinity for human H1- receptors (Ki = 3.2 nmol/l). Levocetirizine has an affinity 2-fold higher than that of cetirizine (Ki = 6.3 nmol/l). Levocetirizine dissociates from H1- receptors with a half-life of 115 &plusmn; 38 min.</p><p>After single administration, levocetirizine shows a receptor occupancy of 90% at 4 hours and 57% at 24 hours.</p><p>Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.</p><p>The pharmacodynamic activity of levocetirizine has been studied in randomised, controlled trials:</p><p>In a study comparing the effects of levocetirizine 5 mg, desloratadine 5 mg, and placebo on histamine-induced wheal and flare, levocetirizine treatment resulted in significantly decreased wheal and flare formation which was highest in the first 12 hours and lasted for 24 hours, (p&lt;0.001) compared with placebo and desloratadine.</p><p>The onset of action of levocetirizine 5 mg in controlling pollen-induced symptoms has been observed at 1 hour post drug intake in placebo controlled trials in the model of the allergen challenge chamber.</p><p>&nbsp;</p><p><em>In vitro </em>studies (Boyden chambers and cell layers techniques) show that levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A pharmacodynamic experimental study <em>in vivo </em>(skin chamber technique) showed three main inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced reaction, compared with placebo in 14 adult patients: inhibition of VCAM-1 release, modulation of vascular permeability and a decrease in eosinophil recruitment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of levocetirizine are linear with dose - and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when given as cetirizine. No chiral inversion occurs during the process of absorption and elimination.</p><p><strong>Absorption</strong></p><p><strong>&nbsp;</strong></p><p>Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two days. Peak concentrations are typically 270 ng/ml and 308 ng/ml following a single and a repeated 5 mg once daily dose, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed.</p><p><strong>Distribution</strong></p><p><strong>&nbsp;</strong></p><p>No tissue distribution data are available in humans, neither concerning the passage of levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment. In humans, levocetirizine is 90% bound to plasma proteins. The distribution of levocetirizine is restrictive, as the volume of distribution is 0.4 l/kg.</p><p><strong>Metabolism</strong></p><p><strong>&nbsp;</strong></p><p>The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose.</p><p>&nbsp;</p><p>Due to its low metabolism and absence of metabolic inhibition potential, the interaction of levocetirizine with other substances, or vice-versa, is unlikely.</p><p><strong>Elimination</strong></p><p><strong>&nbsp;</strong></p><p>The plasma half-life in adults is 7.9 &plusmn; 1.9 hours. The half-life is shorter in small children. The mean apparent total body clearance in adults is 0.63 ml/min/kg. The major route of</p><p>excretion of levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.</p><p>&nbsp;</p><p><strong>Special patient populations</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Children</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that Cmax and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean Cmax was 450 ng/mL, occurring at a mean time of 1.2 hours, weight-normalised, total body clearance was 30% greater, and the elimination half-life 24% shorter in this paediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 323 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age is expected to result in plasma concentrations similar to those of adults receiving 5 mg once daily.</p><p>&nbsp;</p><p><strong>Elderly</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_058da84c-c0c8-490c-8282-2d8c2acc6e11 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65&ndash;74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dose should be adjusted in accordance with renal function in elderly patients.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Renal impairment</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The apparent body clearance of levocetirizine is correlated to the creatinine clearance. It is therefore recommended to adjust the dosing intervals of levocetirizine, based on creatinine</p><p>clearance in patients with moderate and severe renal impairment. In anuric end stage renal disease subjects, the total body clearance is decreased by approximately 80% when compared to normal subjects. The amount of levocetirizine removed during a standard 4- hour hemodialysis procedure was &lt; 10%.</p><p>&nbsp;</p><p><strong><em>Hepatic impairment</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The pharmacokinetics of levocetirizine in hepatically impaired subjects have not been tested. Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half life along with a 40% decrease in clearance compared to healthy subjects.</p><p>&nbsp;</p><p><strong><em>Other patient characteristics</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em><u>Gender</u></em></p><p>Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 &plusmn; 1.72 hr) than in men (8.62 &plusmn; 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 &plusmn; 0.16 mL/min/kg) appears to be comparable to that in men (0.59 &plusmn; 0.12 mL/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.</p><p>&nbsp;</p><p><em><u>Race</u></em></p><p>The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.</p><p>&nbsp;</p><p><strong>Clinical Studies</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d5d53788-28f6-4210-83ce-441d9d31c21b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The efficacy and safety of levocetirizine has been demonstrated in several double-blind, placebo controlled, clinical trials performed in adult patients suffering from seasonal allergic rhinitis, perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some studies.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>A 6-month clinical study in 551 adult patients (including 276 levocetirizine-treated patients) suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4 consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on the relief from the total symptom score of allergic rhinitis throughout the whole duration of the study, without any tachyphylaxis. During the whole duration of the study, levocetirizine significantly improved the quality of life of the patients.</p><p>In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic urticaria, 85 patients were treated with placebo and 81 patients with levocetirizine 5mg once daily over six weeks. Treatment with levocetirizine resulted in significant decrease in pruritus severity over the first week and over the total treatment period as compared to placebo. Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed by the Dermatology Life Quality Index as compared to placebo.</p><p>Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histamine release is a causal factor in urticarial diseases, levocetirizine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria.</p><p>ECGs did not show relevant effects of levocetirizine on QT interval.</p><p>&nbsp;</p><p>Pharmacokinetic / pharmacodynamic relationship:</p><p>The action on histamine-induced skin reactions is out of phase with the plasma concentrations.</p><p><strong>Paediatric population</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_19eac089-4f9b-4a36-a81f-f38ca73027a3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The paediatric safety and efficacy of levocetirizine tablets has been studied in two placebo controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and perennial allergic rhinitis, respectively. In both trials, levocetirizine significantly improved symptoms and increased health-related quality of life.</p><p>In children below the age of 6 years, clinical safety has been established from several short- or long -term therapeutic studies:</p><p>-&nbsp; one clinical trial in which 29 children 2 to 6 years of age with allergic rhinitis were treated with levocetirizine 1.25 mg twice daily for 4 weeks</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp; one clinical trial in which 114 children 1 to 5 years of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg twice daily for 2 weeks</p><p>-&nbsp; one clinical trial in which 45 children 6 to 11 months of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg once daily for 2 weeks</p><p>-&nbsp; one long-term (18 months) clinical trial in 255 levocetirizine - treated atopic subjects aged 12 to 24 months at inclusion.</p><p>The safety profile was similar to that seen in the short-term studies conducted in children 1 to 5 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, Lactose monohydrate, Colloidal anhydrous silica, Magnesium stearate, Hypromellose, Titanium dioxide, Macrogol 400&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no relevant data available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:7.05pt">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xyzal film-coated tablets are packed in aluminium blisters placed into cardboard boxes containing 20 film-coated tablets.</p><p>Not all presentations are available in every country.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no special requirements for use or handling of this product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xyzal is a registered trademark of the GlaxoSmithKline group of companies
© 2022 GlaxoSmithKline group of companies. All rights reserved.

Manufactured by: 
UCB Farchim SA
Z.I. de Planchy 10, Chemin de Croix blanche 1630 Bulle, Switzerland
Packed by: 
Aesica Pharmaceuticals S.r.l.
Via Praglia, 15 10044 PIANEZZA, Torino, Italy, Pianezza, Italy
Marketing Authorization Holder: 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companies

Z.I. de Planchy 10, Chemin de Croix blanche 1630 Bulle, Switzerland
Packed by:
Aesica Pharmaceuticals S.r.l.
Via Praglia, 15 10044 PIANEZZA, Torino, Italy, Pianezza, Italy
Marketing Authorization Holder:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA 
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia 
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: NCDS v08 Version date: 4 September 2022 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>